<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/61EA6E05-55C5-4A83-8A3B-FFF2B3B8D1E4"><gtr:id>61EA6E05-55C5-4A83-8A3B-FFF2B3B8D1E4</gtr:id><gtr:name>Basildon and Thurrock University Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EB43CBC1-0824-493C-A9FC-7597DBB0EBB8"><gtr:id>EB43CBC1-0824-493C-A9FC-7597DBB0EBB8</gtr:id><gtr:name>North Cumbria University Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B5750C27-7358-4FF2-842C-1C5A1E937D3D"><gtr:id>B5750C27-7358-4FF2-842C-1C5A1E937D3D</gtr:id><gtr:name>Chalmers University of Technology</gtr:name><gtr:address><gtr:line1>Chalmers University of Technology</gtr:line1><gtr:line4>Gothenburg</gtr:line4><gtr:postCode>SE-41296</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/111C9142-8B0E-4FFE-8DAE-D2D4E23EFC63"><gtr:id>111C9142-8B0E-4FFE-8DAE-D2D4E23EFC63</gtr:id><gtr:name>Alderley Imaging Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9154D7A2-6DDE-43CF-AE50-0BA86A7BD2AD"><gtr:id>9154D7A2-6DDE-43CF-AE50-0BA86A7BD2AD</gtr:id><gtr:name>Intensive Care Society</gtr:name><gtr:address><gtr:line1>Churcill House</gtr:line1><gtr:line2>38 Red Lion Square</gtr:line2><gtr:postCode>WC1R 4PN</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9205BEB5-9BF3-4CE2-9F9C-A82EB79BD3EE"><gtr:id>9205BEB5-9BF3-4CE2-9F9C-A82EB79BD3EE</gtr:id><gtr:name>Northumbria Healthcare NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>c/o School of Life Science
University of Warwick
Gibbet Hill Road</gtr:line1><gtr:city>Coventry</gtr:city><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1BD4A556-B16E-4335-AE9D-9DD36A9FEF33"><gtr:id>1BD4A556-B16E-4335-AE9D-9DD36A9FEF33</gtr:id><gtr:name>University Hospitals of Morecambe Bay NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99348D67-9BCC-4A55-B2AE-B1A01CEFAEDB"><gtr:id>99348D67-9BCC-4A55-B2AE-B1A01CEFAEDB</gtr:id><gtr:name>South Warwickshire NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8120C767-AC30-4B55-B463-168258FD6C31"><gtr:id>8120C767-AC30-4B55-B463-168258FD6C31</gtr:id><gtr:name>Western Health and Social Care Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/84AF7908-6B18-4717-9A12-1D01E5C6E188"><gtr:id>84AF7908-6B18-4717-9A12-1D01E5C6E188</gtr:id><gtr:name>NHS Oldham CCG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/337901E4-D9A7-438B-B275-0631F5F384A3"><gtr:id>337901E4-D9A7-438B-B275-0631F5F384A3</gtr:id><gtr:name>Royal Liverpool and Broadgreen University Hospital NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/85A635C4-582C-44CC-AC53-59E444FC3DC2"><gtr:id>85A635C4-582C-44CC-AC53-59E444FC3DC2</gtr:id><gtr:name>Betsi Cadwaladr University Health Board</gtr:name><gtr:address><gtr:line1>Betsi Cadwaladr University Health Board</gtr:line1><gtr:line2>Ysbyty Gwynedd</gtr:line2><gtr:line3>Penrhosgarnedd</gtr:line3><gtr:postCode>LL57 2PW</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4822D555-BD0C-4560-9E9B-4FA59A8ECD57"><gtr:id>4822D555-BD0C-4560-9E9B-4FA59A8ECD57</gtr:id><gtr:name>St Antonius Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BEC4474-9121-447D-9FE8-0B24B3AD9318"><gtr:id>7BEC4474-9121-447D-9FE8-0B24B3AD9318</gtr:id><gtr:name>Haywood Hospital</gtr:name><gtr:address><gtr:line1>Haywood Hospital</gtr:line1><gtr:line2>High Lane</gtr:line2><gtr:line3>Burslem</gtr:line3><gtr:postCode>ST6 7BA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4507E2B5-D15B-4A7E-AC54-983A8E8CC26F"><gtr:id>4507E2B5-D15B-4A7E-AC54-983A8E8CC26F</gtr:id><gtr:name>NHS Salford CCG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B5102CAA-7DEB-4D4F-9BC3-EF0303EDD544"><gtr:id>B5102CAA-7DEB-4D4F-9BC3-EF0303EDD544</gtr:id><gtr:name>Bio.logis Genetic Information Management GMBH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B9BB4EF0-4405-4A96-A361-289BB1928078"><gtr:id>B9BB4EF0-4405-4A96-A361-289BB1928078</gtr:id><gtr:name>University of Ljubljana</gtr:name><gtr:address><gtr:line1>University of Ljubljana</gtr:line1><gtr:line4>Ljubljana</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Slovenia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0B25E60A-3D5D-43BE-84C3-BDE0FE8F5E67"><gtr:id>0B25E60A-3D5D-43BE-84C3-BDE0FE8F5E67</gtr:id><gtr:name>The Federal Institute for Drugs and Medical Devices</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1AF5F6BE-7C00-4B82-9E89-38545CE86CB4"><gtr:id>1AF5F6BE-7C00-4B82-9E89-38545CE86CB4</gtr:id><gtr:name>Pennine Acute Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Bury General Hospital</gtr:line1><gtr:line2>Walmersley Road</gtr:line2><gtr:postCode>BL9 6PG</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE7A2CDE-C041-4244-A92D-C4DC327E14B7"><gtr:id>BE7A2CDE-C041-4244-A92D-C4DC327E14B7</gtr:id><gtr:name>Cambridge University Hospitals</gtr:name><gtr:address><gtr:line1>Addenbrooke's Hospital
Hills Road</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB2 0QQ</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F2969CD7-0AFD-457D-BDD3-237B6B31B405"><gtr:id>F2969CD7-0AFD-457D-BDD3-237B6B31B405</gtr:id><gtr:name>Sanquin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ACC47021-1C8C-4370-9827-0D233BE08BD3"><gtr:id>ACC47021-1C8C-4370-9827-0D233BE08BD3</gtr:id><gtr:name>York Teaching Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4275040C-FFF8-42A4-B7ED-3A013E2BD4BC"><gtr:id>4275040C-FFF8-42A4-B7ED-3A013E2BD4BC</gtr:id><gtr:name>ICON</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E13D6CC-F47B-47F5-9B84-E30FDD9B9DCB"><gtr:id>4E13D6CC-F47B-47F5-9B84-E30FDD9B9DCB</gtr:id><gtr:name>Blackpool Teaching Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EE899202-565F-43EB-B462-A98C6C72EC5A"><gtr:id>EE899202-565F-43EB-B462-A98C6C72EC5A</gtr:id><gtr:name>Oncological Referral Centre (Centro di Riferimento Oncologico)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AC141207-8DF3-421F-A604-1500E71BAF1C"><gtr:id>AC141207-8DF3-421F-A604-1500E71BAF1C</gtr:id><gtr:name>The Golden Helix Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F3F5883D-A54E-4ACD-9913-10CDADFD78D1"><gtr:id>F3F5883D-A54E-4ACD-9913-10CDADFD78D1</gtr:id><gtr:name>Brighton and Sussex University Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/276CCBAB-1433-4E39-BEA5-E8327D170815"><gtr:id>276CCBAB-1433-4E39-BEA5-E8327D170815</gtr:id><gtr:name>Servicio C?ntabro de Salud</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C20DA85F-7E12-4BA7-A5A6-4C14EBDC0014"><gtr:id>C20DA85F-7E12-4BA7-A5A6-4C14EBDC0014</gtr:id><gtr:name>Maidstone and Tunbridge Wells NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A67F0D66-6EB6-4F78-8AD7-2116C54EF353"><gtr:id>A67F0D66-6EB6-4F78-8AD7-2116C54EF353</gtr:id><gtr:name>Arthritis Research UK</gtr:name><gtr:address><gtr:line1>Copeman House</gtr:line1><gtr:line2>St Marys Court</gtr:line2><gtr:line3>St Marys Gate</gtr:line3><gtr:postCode>S41 7TD</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F65D0759-F366-436C-B138-1903E5C56DF1"><gtr:id>F65D0759-F366-436C-B138-1903E5C56DF1</gtr:id><gtr:name>Derby Teaching Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF4393D0-F67D-48F9-B944-1498ABC3FDEA"><gtr:id>BF4393D0-F67D-48F9-B944-1498ABC3FDEA</gtr:id><gtr:name>Northern Devon Healthcare NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/40C11C1F-15E5-4C6D-9C90-C224B738A6CE"><gtr:id>40C11C1F-15E5-4C6D-9C90-C224B738A6CE</gtr:id><gtr:name>Pennine MSK Partnership Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055E428B-EF35-46E3-83A6-4D4004294C32"><gtr:id>055E428B-EF35-46E3-83A6-4D4004294C32</gtr:id><gtr:name>University of Utah</gtr:name><gtr:address><gtr:line1>201 South Presidents Circle</gtr:line1><gtr:line2>Salt Lake City</gtr:line2><gtr:line4>Utah</gtr:line4><gtr:postCode>UT 84112</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5382568-3EB8-401D-9279-BBE34BB27CA6"><gtr:id>D5382568-3EB8-401D-9279-BBE34BB27CA6</gtr:id><gtr:name>Barnsley Hospital NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>NHS Trust</gtr:line1><gtr:line2>Gawber Road</gtr:line2><gtr:line4>Barnsley</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S75 2EP</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BC9B36BB-6459-4D83-9C99-35616FB7E2C3"><gtr:id>BC9B36BB-6459-4D83-9C99-35616FB7E2C3</gtr:id><gtr:name>University of Burgundy</gtr:name><gtr:address><gtr:line1>ICB, UMR CNRS No 5027</gtr:line1><gtr:line2>University of Burgundy</gtr:line2><gtr:line3>BP: 47 870, Ave. A. Savary</gtr:line3><gtr:postCode>21078</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37DF3344-DD88-410F-B325-60ACA04B958B"><gtr:id>37DF3344-DD88-410F-B325-60ACA04B958B</gtr:id><gtr:name>City Hospitals Sunderland NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/856A7EAA-C834-4DBE-8764-98C315C40614"><gtr:id>856A7EAA-C834-4DBE-8764-98C315C40614</gtr:id><gtr:name>Mario Negri Institute for Pharmacological Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7"><gtr:id>D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7</gtr:id><gtr:name>Birmingham Heartlands Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5"><gtr:id>8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5</gtr:id><gtr:name>North Manchester General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB"><gtr:id>60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB</gtr:id><gtr:name>Brigham and Women's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/41434B79-7F01-4924-85CB-95E8C52DD7EA"><gtr:id>41434B79-7F01-4924-85CB-95E8C52DD7EA</gtr:id><gtr:name>Aintree University Hospitals</gtr:name><gtr:address><gtr:line1>Longmoor Lane</gtr:line1><gtr:postCode>L9 7AL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31A74B90-3EBC-45FC-83E2-515B95245315"><gtr:id>31A74B90-3EBC-45FC-83E2-515B95245315</gtr:id><gtr:name>Sengenics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/983472DD-9E51-452B-B77C-B140EA0BA4D5"><gtr:id>983472DD-9E51-452B-B77C-B140EA0BA4D5</gtr:id><gtr:name>Wrightington, Wigan and Leigh NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/064A41A2-AC2E-4ACC-A55B-D38D3434BD6A"><gtr:id>064A41A2-AC2E-4ACC-A55B-D38D3434BD6A</gtr:id><gtr:name>Queen's Medical Centre</gtr:name><gtr:address><gtr:line1>Queen's Medical Centre</gtr:line1><gtr:line2>Derby Rd</gtr:line2><gtr:postCode>NG7 2UH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/13DABD91-2872-4018-B377-DD813F21C894"><gtr:id>13DABD91-2872-4018-B377-DD813F21C894</gtr:id><gtr:name>University of Patras</gtr:name><gtr:address><gtr:line1>Rion-Patras</gtr:line1><gtr:postCode>GR - 265-0</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Greece</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/56FEE91B-DEFF-45BD-B566-0411B9D729D5"><gtr:id>56FEE91B-DEFF-45BD-B566-0411B9D729D5</gtr:id><gtr:name>NHS Lanarkshire</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/45CC3960-CEEF-4392-A4EF-42FABB08FAB7"><gtr:id>45CC3960-CEEF-4392-A4EF-42FABB08FAB7</gtr:id><gtr:name>East Cheshire NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9AC02505-66B0-496C-91E4-109B02CD6F04"><gtr:id>9AC02505-66B0-496C-91E4-109B02CD6F04</gtr:id><gtr:name>Children's Mercy Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E8E15A6C-B983-40C3-9EA5-64ABDD6EB216"><gtr:id>E8E15A6C-B983-40C3-9EA5-64ABDD6EB216</gtr:id><gtr:name>King's Mill Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF06ABFB-9547-484C-84F9-4110ED8759B7"><gtr:id>BF06ABFB-9547-484C-84F9-4110ED8759B7</gtr:id><gtr:name>Manchester University NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Central Manchester University Hospitals NHS Foundation Trust,Manchester Royal Infirmary,Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1B0161A9-9EC7-4A57-AC51-97057219C9DC"><gtr:id>1B0161A9-9EC7-4A57-AC51-97057219C9DC</gtr:id><gtr:name>Plymouth Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A806762-0AE0-45A9-8FCF-1BFD41FB7B5F"><gtr:id>8A806762-0AE0-45A9-8FCF-1BFD41FB7B5F</gtr:id><gtr:name>Lancashire Care NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C69B3D64-ED3B-44D7-81C5-482074E1B82E"><gtr:id>C69B3D64-ED3B-44D7-81C5-482074E1B82E</gtr:id><gtr:name>NHS Manchester</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89E93EBE-6563-4E33-A4F2-9AC7482A5AD0"><gtr:id>89E93EBE-6563-4E33-A4F2-9AC7482A5AD0</gtr:id><gtr:name>Ipswich Hospital NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3545CDC8-076D-4BD8-B370-8E558F9D46EE"><gtr:id>3545CDC8-076D-4BD8-B370-8E558F9D46EE</gtr:id><gtr:name>Leeds Teaching Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Beckett Street</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS9 7TF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B5A30E5C-A84D-4A68-9DBE-18DD3F2DC88B"><gtr:id>B5A30E5C-A84D-4A68-9DBE-18DD3F2DC88B</gtr:id><gtr:name>Hampshire Hospitals Charity</gtr:name><gtr:address><gtr:line1>Brintons Terrace</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO14 0YG</gtr:postCode><gtr:region>South East</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9"><gtr:id>67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9</gtr:id><gtr:name>NHS Lothian</gtr:name><gtr:address><gtr:line1>Royal Victoria Hospital</gtr:line1><gtr:line2>13 Craigleith Road</gtr:line2><gtr:postCode>EH4 2DN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70190FBA-17F4-410B-99F0-8883DA732818"><gtr:id>70190FBA-17F4-410B-99F0-8883DA732818</gtr:id><gtr:name>Royal Victoria Infirmary</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A96DFBC-864F-4499-B7FE-257903C927F0"><gtr:id>4A96DFBC-864F-4499-B7FE-257903C927F0</gtr:id><gtr:name>Royal National Hospital for Rheumatic Diseases</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF96472C-C9CC-4D84-A2E5-C304A7501580"><gtr:id>EF96472C-C9CC-4D84-A2E5-C304A7501580</gtr:id><gtr:name>Robert Bosch Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/145473C4-55E7-4C51-ABB4-D93855BAEA4D"><gtr:id>145473C4-55E7-4C51-ABB4-D93855BAEA4D</gtr:id><gtr:name>Gateshead Health NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Aidan House</gtr:line1><gtr:line2>Sunderland Road</gtr:line2><gtr:postCode>NE8 3EP</gtr:postCode><gtr:region>North East</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BC62F3B4-8F22-4AD0-8F9F-57966529DE73"><gtr:id>BC62F3B4-8F22-4AD0-8F9F-57966529DE73</gtr:id><gtr:name>The Dudley Group NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DC78695-EE95-4528-8ACC-E01C3B06B605"><gtr:id>9DC78695-EE95-4528-8ACC-E01C3B06B605</gtr:id><gtr:name>KNMP Holding B.V.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD"><gtr:id>BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD</gtr:id><gtr:name>Salford Royal NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Cleveland House
Salford</gtr:line1><gtr:city>Greater Manchester</gtr:city><gtr:postCode>M6 8AL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A21478EA-E506-4B64-A8A9-42CD8D97C635"><gtr:id>A21478EA-E506-4B64-A8A9-42CD8D97C635</gtr:id><gtr:name>University College London Hospital (UCLH) NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/231A826B-DDAF-48DF-A388-9BB8AD1FB653"><gtr:id>231A826B-DDAF-48DF-A388-9BB8AD1FB653</gtr:id><gtr:name>University of Toulouse III Paul Sabatier</gtr:name><gtr:address><gtr:line1>UMR 5215</gtr:line1><gtr:line2>University Paul Sabatier</gtr:line2><gtr:line3>177, Avenue de Rangueil</gtr:line3><gtr:postCode>31077</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/55B08AB5-DB58-4FCE-9037-1D4179E0F4E3"><gtr:id>55B08AB5-DB58-4FCE-9037-1D4179E0F4E3</gtr:id><gtr:name>The Walton Centre NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Lower Lane</gtr:line1><gtr:city>Fazakerley</gtr:city><gtr:postCode>L9 7LJ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0FC4443F-A83C-4ABF-A52B-3739AB2BA1E6"><gtr:id>0FC4443F-A83C-4ABF-A52B-3739AB2BA1E6</gtr:id><gtr:name>Bioxydn</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F4FA74B3-7DF5-44E3-A340-2B12E0931569"><gtr:id>F4FA74B3-7DF5-44E3-A340-2B12E0931569</gtr:id><gtr:name>Tampere University of Technology</gtr:name><gtr:address><gtr:line1>PO Box 527</gtr:line1><gtr:line4>Tampere</gtr:line4><gtr:postCode>FIN 33101</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE"><gtr:id>70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE</gtr:id><gtr:name>North Middlesex University Hospital NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2B52BF73-9693-465D-95F7-034883753E63"><gtr:id>2B52BF73-9693-465D-95F7-034883753E63</gtr:id><gtr:name>Staffordshire and Stoke On Trent Partnership NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/76119A17-D4F8-4258-80F0-C8B307FFFA52"><gtr:id>76119A17-D4F8-4258-80F0-C8B307FFFA52</gtr:id><gtr:name>Radboud University Nijmegen</gtr:name><gtr:address><gtr:line1>Radboud University Nijmegen</gtr:line1><gtr:line2>PO Box 9102</gtr:line2><gtr:line4>Nijmegen</gtr:line4><gtr:postCode>6500 HC</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8D411442-C4F0-4EE4-B77D-C4C98BFD666D"><gtr:id>8D411442-C4F0-4EE4-B77D-C4C98BFD666D</gtr:id><gtr:name>Truly Labs AB</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Biomedical Sciences</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/61EA6E05-55C5-4A83-8A3B-FFF2B3B8D1E4"><gtr:id>61EA6E05-55C5-4A83-8A3B-FFF2B3B8D1E4</gtr:id><gtr:name>Basildon and Thurrock University Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EB43CBC1-0824-493C-A9FC-7597DBB0EBB8"><gtr:id>EB43CBC1-0824-493C-A9FC-7597DBB0EBB8</gtr:id><gtr:name>North Cumbria University Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B5750C27-7358-4FF2-842C-1C5A1E937D3D"><gtr:id>B5750C27-7358-4FF2-842C-1C5A1E937D3D</gtr:id><gtr:name>Chalmers University of Technology</gtr:name><gtr:address><gtr:line1>Chalmers University of Technology</gtr:line1><gtr:line4>Gothenburg</gtr:line4><gtr:postCode>SE-41296</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/111C9142-8B0E-4FFE-8DAE-D2D4E23EFC63"><gtr:id>111C9142-8B0E-4FFE-8DAE-D2D4E23EFC63</gtr:id><gtr:name>Alderley Imaging Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9154D7A2-6DDE-43CF-AE50-0BA86A7BD2AD"><gtr:id>9154D7A2-6DDE-43CF-AE50-0BA86A7BD2AD</gtr:id><gtr:name>Intensive Care Society</gtr:name><gtr:address><gtr:line1>Churcill House</gtr:line1><gtr:line2>38 Red Lion Square</gtr:line2><gtr:postCode>WC1R 4PN</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9205BEB5-9BF3-4CE2-9F9C-A82EB79BD3EE"><gtr:id>9205BEB5-9BF3-4CE2-9F9C-A82EB79BD3EE</gtr:id><gtr:name>Northumbria Healthcare NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>c/o School of Life Science
University of Warwick
Gibbet Hill Road</gtr:line1><gtr:city>Coventry</gtr:city><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1BD4A556-B16E-4335-AE9D-9DD36A9FEF33"><gtr:id>1BD4A556-B16E-4335-AE9D-9DD36A9FEF33</gtr:id><gtr:name>University Hospitals of Morecambe Bay NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99348D67-9BCC-4A55-B2AE-B1A01CEFAEDB"><gtr:id>99348D67-9BCC-4A55-B2AE-B1A01CEFAEDB</gtr:id><gtr:name>South Warwickshire NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8120C767-AC30-4B55-B463-168258FD6C31"><gtr:id>8120C767-AC30-4B55-B463-168258FD6C31</gtr:id><gtr:name>Western Health and Social Care Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/84AF7908-6B18-4717-9A12-1D01E5C6E188"><gtr:id>84AF7908-6B18-4717-9A12-1D01E5C6E188</gtr:id><gtr:name>NHS Oldham CCG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/337901E4-D9A7-438B-B275-0631F5F384A3"><gtr:id>337901E4-D9A7-438B-B275-0631F5F384A3</gtr:id><gtr:name>Royal Liverpool and Broadgreen University Hospital NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/85A635C4-582C-44CC-AC53-59E444FC3DC2"><gtr:id>85A635C4-582C-44CC-AC53-59E444FC3DC2</gtr:id><gtr:name>Betsi Cadwaladr University Health Board</gtr:name><gtr:address><gtr:line1>Betsi Cadwaladr University Health Board</gtr:line1><gtr:line2>Ysbyty Gwynedd</gtr:line2><gtr:line3>Penrhosgarnedd</gtr:line3><gtr:postCode>LL57 2PW</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4822D555-BD0C-4560-9E9B-4FA59A8ECD57"><gtr:id>4822D555-BD0C-4560-9E9B-4FA59A8ECD57</gtr:id><gtr:name>St Antonius Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BEC4474-9121-447D-9FE8-0B24B3AD9318"><gtr:id>7BEC4474-9121-447D-9FE8-0B24B3AD9318</gtr:id><gtr:name>Haywood Hospital</gtr:name><gtr:address><gtr:line1>Haywood Hospital</gtr:line1><gtr:line2>High Lane</gtr:line2><gtr:line3>Burslem</gtr:line3><gtr:postCode>ST6 7BA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4507E2B5-D15B-4A7E-AC54-983A8E8CC26F"><gtr:id>4507E2B5-D15B-4A7E-AC54-983A8E8CC26F</gtr:id><gtr:name>NHS Salford CCG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B5102CAA-7DEB-4D4F-9BC3-EF0303EDD544"><gtr:id>B5102CAA-7DEB-4D4F-9BC3-EF0303EDD544</gtr:id><gtr:name>Bio.logis Genetic Information Management GMBH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B9BB4EF0-4405-4A96-A361-289BB1928078"><gtr:id>B9BB4EF0-4405-4A96-A361-289BB1928078</gtr:id><gtr:name>University of Ljubljana</gtr:name><gtr:address><gtr:line1>University of Ljubljana</gtr:line1><gtr:line4>Ljubljana</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Slovenia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0B25E60A-3D5D-43BE-84C3-BDE0FE8F5E67"><gtr:id>0B25E60A-3D5D-43BE-84C3-BDE0FE8F5E67</gtr:id><gtr:name>The Federal Institute for Drugs and Medical Devices</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1AF5F6BE-7C00-4B82-9E89-38545CE86CB4"><gtr:id>1AF5F6BE-7C00-4B82-9E89-38545CE86CB4</gtr:id><gtr:name>Pennine Acute Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Bury General Hospital</gtr:line1><gtr:line2>Walmersley Road</gtr:line2><gtr:postCode>BL9 6PG</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE7A2CDE-C041-4244-A92D-C4DC327E14B7"><gtr:id>BE7A2CDE-C041-4244-A92D-C4DC327E14B7</gtr:id><gtr:name>Cambridge University Hospitals</gtr:name><gtr:address><gtr:line1>Addenbrooke's Hospital
Hills Road</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB2 0QQ</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F2969CD7-0AFD-457D-BDD3-237B6B31B405"><gtr:id>F2969CD7-0AFD-457D-BDD3-237B6B31B405</gtr:id><gtr:name>Sanquin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACC47021-1C8C-4370-9827-0D233BE08BD3"><gtr:id>ACC47021-1C8C-4370-9827-0D233BE08BD3</gtr:id><gtr:name>York Teaching Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4275040C-FFF8-42A4-B7ED-3A013E2BD4BC"><gtr:id>4275040C-FFF8-42A4-B7ED-3A013E2BD4BC</gtr:id><gtr:name>ICON</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E13D6CC-F47B-47F5-9B84-E30FDD9B9DCB"><gtr:id>4E13D6CC-F47B-47F5-9B84-E30FDD9B9DCB</gtr:id><gtr:name>Blackpool Teaching Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE899202-565F-43EB-B462-A98C6C72EC5A"><gtr:id>EE899202-565F-43EB-B462-A98C6C72EC5A</gtr:id><gtr:name>Oncological Referral Centre (Centro di Riferimento Oncologico)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AC141207-8DF3-421F-A604-1500E71BAF1C"><gtr:id>AC141207-8DF3-421F-A604-1500E71BAF1C</gtr:id><gtr:name>The Golden Helix Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F3F5883D-A54E-4ACD-9913-10CDADFD78D1"><gtr:id>F3F5883D-A54E-4ACD-9913-10CDADFD78D1</gtr:id><gtr:name>Brighton and Sussex University Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/276CCBAB-1433-4E39-BEA5-E8327D170815"><gtr:id>276CCBAB-1433-4E39-BEA5-E8327D170815</gtr:id><gtr:name>Servicio C?ntabro de Salud</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C20DA85F-7E12-4BA7-A5A6-4C14EBDC0014"><gtr:id>C20DA85F-7E12-4BA7-A5A6-4C14EBDC0014</gtr:id><gtr:name>Maidstone and Tunbridge Wells NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A67F0D66-6EB6-4F78-8AD7-2116C54EF353"><gtr:id>A67F0D66-6EB6-4F78-8AD7-2116C54EF353</gtr:id><gtr:name>Arthritis Research UK</gtr:name><gtr:address><gtr:line1>Copeman House</gtr:line1><gtr:line2>St Marys Court</gtr:line2><gtr:line3>St Marys Gate</gtr:line3><gtr:postCode>S41 7TD</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F65D0759-F366-436C-B138-1903E5C56DF1"><gtr:id>F65D0759-F366-436C-B138-1903E5C56DF1</gtr:id><gtr:name>Derby Teaching Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF4393D0-F67D-48F9-B944-1498ABC3FDEA"><gtr:id>BF4393D0-F67D-48F9-B944-1498ABC3FDEA</gtr:id><gtr:name>Northern Devon Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/40C11C1F-15E5-4C6D-9C90-C224B738A6CE"><gtr:id>40C11C1F-15E5-4C6D-9C90-C224B738A6CE</gtr:id><gtr:name>Pennine MSK Partnership Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055E428B-EF35-46E3-83A6-4D4004294C32"><gtr:id>055E428B-EF35-46E3-83A6-4D4004294C32</gtr:id><gtr:name>University of Utah</gtr:name><gtr:address><gtr:line1>201 South Presidents Circle</gtr:line1><gtr:line2>Salt Lake City</gtr:line2><gtr:line4>Utah</gtr:line4><gtr:postCode>UT 84112</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5382568-3EB8-401D-9279-BBE34BB27CA6"><gtr:id>D5382568-3EB8-401D-9279-BBE34BB27CA6</gtr:id><gtr:name>Barnsley Hospital NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>NHS Trust</gtr:line1><gtr:line2>Gawber Road</gtr:line2><gtr:line4>Barnsley</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S75 2EP</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BC9B36BB-6459-4D83-9C99-35616FB7E2C3"><gtr:id>BC9B36BB-6459-4D83-9C99-35616FB7E2C3</gtr:id><gtr:name>University of Burgundy</gtr:name><gtr:address><gtr:line1>ICB, UMR CNRS No 5027</gtr:line1><gtr:line2>University of Burgundy</gtr:line2><gtr:line3>BP: 47 870, Ave. A. Savary</gtr:line3><gtr:postCode>21078</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37DF3344-DD88-410F-B325-60ACA04B958B"><gtr:id>37DF3344-DD88-410F-B325-60ACA04B958B</gtr:id><gtr:name>City Hospitals Sunderland NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/856A7EAA-C834-4DBE-8764-98C315C40614"><gtr:id>856A7EAA-C834-4DBE-8764-98C315C40614</gtr:id><gtr:name>Mario Negri Institute for Pharmacological Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7"><gtr:id>D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7</gtr:id><gtr:name>Birmingham Heartlands Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5"><gtr:id>8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5</gtr:id><gtr:name>North Manchester General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB"><gtr:id>60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB</gtr:id><gtr:name>Brigham and Women's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/41434B79-7F01-4924-85CB-95E8C52DD7EA"><gtr:id>41434B79-7F01-4924-85CB-95E8C52DD7EA</gtr:id><gtr:name>Aintree University Hospitals</gtr:name><gtr:address><gtr:line1>Longmoor Lane</gtr:line1><gtr:postCode>L9 7AL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31A74B90-3EBC-45FC-83E2-515B95245315"><gtr:id>31A74B90-3EBC-45FC-83E2-515B95245315</gtr:id><gtr:name>Sengenics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/983472DD-9E51-452B-B77C-B140EA0BA4D5"><gtr:id>983472DD-9E51-452B-B77C-B140EA0BA4D5</gtr:id><gtr:name>Wrightington, Wigan and Leigh NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/064A41A2-AC2E-4ACC-A55B-D38D3434BD6A"><gtr:id>064A41A2-AC2E-4ACC-A55B-D38D3434BD6A</gtr:id><gtr:name>Queen's Medical Centre</gtr:name><gtr:address><gtr:line1>Queen's Medical Centre</gtr:line1><gtr:line2>Derby Rd</gtr:line2><gtr:postCode>NG7 2UH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/13DABD91-2872-4018-B377-DD813F21C894"><gtr:id>13DABD91-2872-4018-B377-DD813F21C894</gtr:id><gtr:name>University of Patras</gtr:name><gtr:address><gtr:line1>Rion-Patras</gtr:line1><gtr:postCode>GR - 265-0</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Greece</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/56FEE91B-DEFF-45BD-B566-0411B9D729D5"><gtr:id>56FEE91B-DEFF-45BD-B566-0411B9D729D5</gtr:id><gtr:name>NHS Lanarkshire</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/45CC3960-CEEF-4392-A4EF-42FABB08FAB7"><gtr:id>45CC3960-CEEF-4392-A4EF-42FABB08FAB7</gtr:id><gtr:name>East Cheshire NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9AC02505-66B0-496C-91E4-109B02CD6F04"><gtr:id>9AC02505-66B0-496C-91E4-109B02CD6F04</gtr:id><gtr:name>Children's Mercy Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E8E15A6C-B983-40C3-9EA5-64ABDD6EB216"><gtr:id>E8E15A6C-B983-40C3-9EA5-64ABDD6EB216</gtr:id><gtr:name>King's Mill Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF06ABFB-9547-484C-84F9-4110ED8759B7"><gtr:id>BF06ABFB-9547-484C-84F9-4110ED8759B7</gtr:id><gtr:name>Manchester University NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Central Manchester University Hospitals NHS Foundation Trust,Manchester Royal Infirmary,Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1B0161A9-9EC7-4A57-AC51-97057219C9DC"><gtr:id>1B0161A9-9EC7-4A57-AC51-97057219C9DC</gtr:id><gtr:name>Plymouth Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A806762-0AE0-45A9-8FCF-1BFD41FB7B5F"><gtr:id>8A806762-0AE0-45A9-8FCF-1BFD41FB7B5F</gtr:id><gtr:name>Lancashire Care NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C69B3D64-ED3B-44D7-81C5-482074E1B82E"><gtr:id>C69B3D64-ED3B-44D7-81C5-482074E1B82E</gtr:id><gtr:name>NHS Manchester</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89E93EBE-6563-4E33-A4F2-9AC7482A5AD0"><gtr:id>89E93EBE-6563-4E33-A4F2-9AC7482A5AD0</gtr:id><gtr:name>Ipswich Hospital NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3545CDC8-076D-4BD8-B370-8E558F9D46EE"><gtr:id>3545CDC8-076D-4BD8-B370-8E558F9D46EE</gtr:id><gtr:name>Leeds Teaching Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Beckett Street</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS9 7TF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B5A30E5C-A84D-4A68-9DBE-18DD3F2DC88B"><gtr:id>B5A30E5C-A84D-4A68-9DBE-18DD3F2DC88B</gtr:id><gtr:name>Hampshire Hospitals Charity</gtr:name><gtr:address><gtr:line1>Brintons Terrace</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO14 0YG</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9"><gtr:id>67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9</gtr:id><gtr:name>NHS Lothian</gtr:name><gtr:address><gtr:line1>Royal Victoria Hospital</gtr:line1><gtr:line2>13 Craigleith Road</gtr:line2><gtr:postCode>EH4 2DN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70190FBA-17F4-410B-99F0-8883DA732818"><gtr:id>70190FBA-17F4-410B-99F0-8883DA732818</gtr:id><gtr:name>Royal Victoria Infirmary</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A96DFBC-864F-4499-B7FE-257903C927F0"><gtr:id>4A96DFBC-864F-4499-B7FE-257903C927F0</gtr:id><gtr:name>Royal National Hospital for Rheumatic Diseases</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF96472C-C9CC-4D84-A2E5-C304A7501580"><gtr:id>EF96472C-C9CC-4D84-A2E5-C304A7501580</gtr:id><gtr:name>Robert Bosch Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/145473C4-55E7-4C51-ABB4-D93855BAEA4D"><gtr:id>145473C4-55E7-4C51-ABB4-D93855BAEA4D</gtr:id><gtr:name>Gateshead Health NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Aidan House</gtr:line1><gtr:line2>Sunderland Road</gtr:line2><gtr:postCode>NE8 3EP</gtr:postCode><gtr:region>North East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BC62F3B4-8F22-4AD0-8F9F-57966529DE73"><gtr:id>BC62F3B4-8F22-4AD0-8F9F-57966529DE73</gtr:id><gtr:name>The Dudley Group NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DC78695-EE95-4528-8ACC-E01C3B06B605"><gtr:id>9DC78695-EE95-4528-8ACC-E01C3B06B605</gtr:id><gtr:name>KNMP Holding B.V.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD"><gtr:id>BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD</gtr:id><gtr:name>Salford Royal NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Cleveland House
Salford</gtr:line1><gtr:city>Greater Manchester</gtr:city><gtr:postCode>M6 8AL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A21478EA-E506-4B64-A8A9-42CD8D97C635"><gtr:id>A21478EA-E506-4B64-A8A9-42CD8D97C635</gtr:id><gtr:name>University College London Hospital (UCLH) NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/231A826B-DDAF-48DF-A388-9BB8AD1FB653"><gtr:id>231A826B-DDAF-48DF-A388-9BB8AD1FB653</gtr:id><gtr:name>University of Toulouse III Paul Sabatier</gtr:name><gtr:address><gtr:line1>UMR 5215</gtr:line1><gtr:line2>University Paul Sabatier</gtr:line2><gtr:line3>177, Avenue de Rangueil</gtr:line3><gtr:postCode>31077</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/55B08AB5-DB58-4FCE-9037-1D4179E0F4E3"><gtr:id>55B08AB5-DB58-4FCE-9037-1D4179E0F4E3</gtr:id><gtr:name>The Walton Centre NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Lower Lane</gtr:line1><gtr:city>Fazakerley</gtr:city><gtr:postCode>L9 7LJ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0FC4443F-A83C-4ABF-A52B-3739AB2BA1E6"><gtr:id>0FC4443F-A83C-4ABF-A52B-3739AB2BA1E6</gtr:id><gtr:name>Bioxydn</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F4FA74B3-7DF5-44E3-A340-2B12E0931569"><gtr:id>F4FA74B3-7DF5-44E3-A340-2B12E0931569</gtr:id><gtr:name>Tampere University of Technology</gtr:name><gtr:address><gtr:line1>PO Box 527</gtr:line1><gtr:line4>Tampere</gtr:line4><gtr:postCode>FIN 33101</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE"><gtr:id>70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE</gtr:id><gtr:name>North Middlesex University Hospital NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2B52BF73-9693-465D-95F7-034883753E63"><gtr:id>2B52BF73-9693-465D-95F7-034883753E63</gtr:id><gtr:name>Staffordshire and Stoke On Trent Partnership NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/76119A17-D4F8-4258-80F0-C8B307FFFA52"><gtr:id>76119A17-D4F8-4258-80F0-C8B307FFFA52</gtr:id><gtr:name>Radboud University Nijmegen</gtr:name><gtr:address><gtr:line1>Radboud University Nijmegen</gtr:line1><gtr:line2>PO Box 9102</gtr:line2><gtr:line4>Nijmegen</gtr:line4><gtr:postCode>6500 HC</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D411442-C4F0-4EE4-B77D-C4C98BFD666D"><gtr:id>8D411442-C4F0-4EE4-B77D-C4C98BFD666D</gtr:id><gtr:name>Truly Labs AB</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/77F021F2-CB59-421B-9A71-664FE2218FBD"><gtr:id>77F021F2-CB59-421B-9A71-664FE2218FBD</gtr:id><gtr:firstName>Munir</gtr:firstName><gtr:surname>Pirmohamed</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000417"><gtr:id>6CFA1DEB-FB05-483C-B5F0-2F10F464E0ED</gtr:id><gtr:title>North West England MRC Fellowships in Clinical Pharmacology and Therapeutics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1000417</gtr:grantReference><gtr:abstractText>In a recent report from the Office for Life Sciences, Clinical Pharmacology was highlighted as
a specialty vital for healthcare and industry in the UK. Our proposed scheme builds upon a
highly successful training programme in Clinical Pharmacology, based at the University of
Liverpool. Our unique selling point is the collaboration between the Universities of Liverpool
and Manchester based on the existing MRC Centre for Drug Safety Science, and with 2
pharmaceutical companies (AstraZeneca and GlaxoSmithKline) and 2 contract research
organisations (ICON and Medicines Evaluation Unit). We focus on important subject areas,
including paediatrics, where there is a fundamental need to improve drugs for children. The
scheme is designed to identify the best students, provide them with ?without walls? training
through attachments with our industry partners, together with excellent supervision and
mentoring arrangements, all of which enhance the student learning experience. Over 4
years, we will train 12 clinical fellows to undertake PhDs; each project will be tailored to the
individual and their clinical training. The Clinical Pharmacology skills base in the UK will be
enhanced by the scheme with benefit to healthcare, academia, industry, regulation and
ultimately undergraduate training.</gtr:abstractText><gtr:technicalSummary>The North West Clinical Pharmacology Training programme utilises the complementary
expertise of:
the Universities of Liverpool and Manchester building upon strengths in translational
research and;
Two major pharmaceutical companies (AstraZeneca and GlaxoSmithKline) and 2
contract research organisations (ICON and Medicines Evaluation Unit) to provide a
highly integrated !?without walls!? training scheme.
The programme is based on an established Liverpool-Manchester collaboration, the MRC
Centre for Drug Safety Science, which provides the management framework. It is based
around the successful training programme which has been the hallmark of the Department of
Pharmacology and Therapeutics in Liverpool, where there is a seamless working relationship
between clinical and basic pharmacologists. The focus of the scheme will be on Stratified
Medicines and Drug Safety in the clinical areas of Paediatrics, Infectious Diseases and
Inflammation and Repair. Over a period of 4 years, we aim to train 12 clinical research
training fellows to undertake a doctoral thesis. The fellows. specific skills training will be
supplemented with generic and transferable skills training. We will implement a taught clinical
pharmacology programme in keeping with the curriculum approved by JRCPTB. Trainees will
interact closely with our industrial partners. Industrial placements will be developed in a
bespoke manner to suit the individual needs of the trainee and their project aims. The key to
the programme is its flexibility which will enhance the student experience. A two-stage
interview procedure will be implemented to ensure the selection of the best students and the
best projects consistent with the recruitment procedures utilised with the MRC. Academic
clinical fellows will form the main source for recruits. All trainees will be comprehensively
monitored, being supported by their supervisors, an advisory panel and mentor. Annual
showcase events will allow fellows to present their work, and interact with other students,
and key players from both Universities and external academics. We envisage, and will
actively promote, that on completion of the PhD, the trainees will move to lecturer posts. Our
partners have contributed 46% of the total cost of the programme which represents
significant added value. Our aim is to develop high-calibre clinician scientists of the future
with the ability to link bi-directionally between clinical and basic science, from molecule to
man, and from bench to bedside. Such individuals will have benefited from research
experience in the settings of academia and industry, and could thus function as future
research leaders in either sector.</gtr:technicalSummary><gtr:fund><gtr:end>2017-08-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1684480</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Western Health and Social Care Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>73E8D9A2-4D1E-4D53-ACE7-595CF3C5BAC2</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-15</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>7945AFF2-EFB3-4760-A4E9-C50FBB8E6616</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-1</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Burgundy</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>CBAE363F-D331-47F6-91B7-28E98E7499D1</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-4</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brighton and Sussex University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Royal Sussex County Hospital (Sam Nightingale)</gtr:description><gtr:id>3C7459EE-8318-4D82-BB72-433DE83720BE</gtr:id><gtr:impact>31 patients were recruited to Study A of PARTITION and 11 patients were recruited to study B of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>EvXR97xuyPc-1</gtr:outcomeId><gtr:partnerContribution>31 patients were recruited to Study A of PARTITION and 11 patients were recruited to study B of PARTITION.</gtr:partnerContribution><gtr:piContribution>Participant in 2 multi-site study lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team :
1) CNS Penetration of Antiretrovirals
2) The CNS as a Sanctuary Site for HIV</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Federal Institute for Drugs and Medical Devices</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>EA94B5BE-15FF-46A1-B986-5A52E4007D99</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-2</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Staffordshire and Stoke On Trent Partnership NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>98D3F17C-FD49-45E8-8AD0-12F370B8F7E1</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-16</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>66527C03-3A8F-4B35-BBF0-DD818FFA05BB</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-10</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Walton Centre NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The Walton Centre (Sam Nightingale)</gtr:description><gtr:id>E9183086-AA62-45DF-8474-86A217C9DAF4</gtr:id><gtr:impact>3 patients were recruited to Study A of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>qMS76hZfEjN-1</gtr:outcomeId><gtr:partnerContribution>3 patients were recruited to Study A of PARTITION.</gtr:partnerContribution><gtr:piContribution>Participant in a multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team:
1) CNS Penetration of Antiretrovirals</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hampshire Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>8B68823C-8A4F-43D6-B717-9D608E6B0FE1</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-24</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pennine MSK Partnership Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>785AECB4-F695-406B-8761-9E0FE583D35A</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-19</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Patras</gtr:collaboratingOrganisation><gtr:country>Greece, Hellenic Republic</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>B1CB5776-BC4F-473C-9C08-282DB74895DA</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-13</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PSORT Psoriasis Stratification to Optimise Relevant Therapy (Amy Foulkes)</gtr:description><gtr:id>8CEBADEC-AE11-4039-B634-6AD1D42A8C2B</gtr:id><gtr:impact>No outputs yet, Amy Foulke's data is likely to be published as the first output next year</gtr:impact><gtr:outcomeId>cxB7wX7fWvL-3</gtr:outcomeId><gtr:partnerContribution>The University of Manchester is coordinating this whole study, there are 2 work streams &amp;amp; Amy Foulke's data was pilot data for one of them. 

GSK and Newcastle are processing samples.

QMUL are completing the data analysis 

Funding</gtr:partnerContribution><gtr:piContribution>Major collaborative succsessful MRC bid with Amy Foulkes supervisors Dr Richard Warren and Professor Chris Griffiths.

Amy Foulkes:-
?Fellowship data formed pilot data for one of the two work streams of the successful bid.
? Regularly attended GSK Stevenage site. Samples from her Fellowship have been processed there. She has also presented to GSK staff on behalf of the PSORT consortium prior to the successful bid.
?Regularly attended QMUL London where data analysis is being completed with the Bioinformatics team. 
?Spent &amp;gt;4 weeks working with our collaborators at Newcastle University on laboratory sample processing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tampere University of Technology</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:department>Inpatient Telemetry Unit/Clinical Trials</gtr:department><gtr:description>Tampere (PPS Study) (Lauren Walker)</gtr:description><gtr:id>3A6B3060-7FE3-4CD6-850F-5CE3582FE88C</gtr:id><gtr:impact>The samples have been analysed and the results will be incorporated into a scientific paper (in preparation)</gtr:impact><gtr:outcomeId>WXtajjXeTr4-1</gtr:outcomeId><gtr:partnerContribution>50 post-seizure serum samples to to be contributed to PPS study.</gtr:partnerContribution><gtr:piContribution>None</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>A482F4DD-F19F-4D8C-9033-623219CE0940</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-9</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanquin</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Detection of drug antibodies (Meghna Jani)</gtr:description><gtr:id>9D0A7F15-0882-458C-9F78-5A9001ED0370</gtr:id><gtr:impact>Outcomes of collaboration being evaluated at present</gtr:impact><gtr:outcomeId>rkdUTKkfSJF-1</gtr:outcomeId><gtr:partnerContribution>Partners provided service of measurement of drug antibodies using radioimmunoassay</gtr:partnerContribution><gtr:piContribution>Contacting scientific team in The Netherlands, establishing collaboration, negotiating a feasible price for detection of drug antibodies.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Barnsley Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>849C0E1A-98AD-4492-8222-E43B5D59EE7A</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-8</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birmingham Heartlands Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Birmingham Heartlands Hospital (Sam Nightingale)</gtr:description><gtr:id>B271C680-A1F3-44B2-BC6A-AF09CDAE4819</gtr:id><gtr:impact>19 patients were recruited to Study A of PARTITION and 5 patients were recruited to study B of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>VgJVy3e57Mq-1</gtr:outcomeId><gtr:partnerContribution>19 patients were recruited to Study A of PARTITION and 5 patients were recruited to study B of PARTITION.</gtr:partnerContribution><gtr:piContribution>Participants in a multi site study lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team :
A) CNS Penetration of Antiretrovirals
B) The CNS as a sanctuary site for HIV</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Servicio C?ntabro de Salud</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>A61FF685-8E15-4071-A0A8-B168D2C60F39</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-12</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lancashire Care NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>B0337588-22FF-4BA9-874F-B6F71D71FB78</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-10</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>South Warwickshire NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>C40A7FAA-5843-4C35-BB64-2269F1F98168</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-26</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>E828E302-F36D-4B55-BFD3-91BA3BE84DC2</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-21</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Measurement of Methotrexate and 7-OH-methotrexate levels in patients with rheumatoid arthritis.(James Bluett)</gtr:description><gtr:id>280E3027-80D7-446B-9030-E57BC4C99DBB</gtr:id><gtr:impact>Measurement of methotrexate levels</gtr:impact><gtr:outcomeId>J5Q6aiFQNt6-1</gtr:outcomeId><gtr:partnerContribution>Samples were provided from patients with rheumatoid arthritis</gtr:partnerContribution><gtr:piContribution>Measurement of MTX/7-OH-MTX levels in patients with rheumatoid arthritis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>MRC CDSS-AZ collaboration (Richard Kia)</gtr:description><gtr:id>C297E9BE-0E41-45C6-BE34-1524E489D1C2</gtr:id><gtr:impact>Publication of a review paper with a listed co-author from AZ</gtr:impact><gtr:outcomeId>pFY1kRHKdpA-1</gtr:outcomeId><gtr:partnerContribution>Experimental data from attempts to derive induced pluripotent stem cells using different methodology to ours and also technical expertise in stem cell culture techniques</gtr:partnerContribution><gtr:piContribution>Experimental data from attempts to derive induced pluripotent stem cells using different methodology.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Middlesex University Hospital NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>North Middlesex Hospital (Sam Nightingale)</gtr:description><gtr:id>41B92F4A-BD4C-490F-9E7E-1ACC2E25E4F8</gtr:id><gtr:impact>8 patients were recruited to Study A of PARTITION and 2 patients were recruited to study B of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>s1keC7bjxgQ-1</gtr:outcomeId><gtr:partnerContribution>8 patients were recruited to Study A of PARTITION and 2 patients were recruited to study B of PARTITION.</gtr:partnerContribution><gtr:piContribution>Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team:
A) CNS Penetration of Antiretrovirals
B) The CNS as a sanctuary site for HIV</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Manchester Musculoskeletal Biomedical Research Unit</gtr:department><gtr:description>Manchester MSK BRU (Sarah Skeoch)</gtr:description><gtr:id>AFB14E6F-2893-4685-B400-BD4ED95EF03B</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>SzPaQ6toqW4-1</gtr:outcomeId><gtr:partnerContribution>Part of the research project is funded by the BRU approx. &amp;pound;50,000</gtr:partnerContribution><gtr:piContribution>None</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi centre study suported by the CLRN (Sarah Skeoch)</gtr:description><gtr:id>DF4AA0C4-8F90-4784-8686-C6927F4028D9</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Ub5WGejS72R-10</gtr:outcomeId><gtr:partnerContribution>Patient Recruitment</gtr:partnerContribution><gtr:piContribution>We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aintree University Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Hepatobiliary Surgical Department</gtr:department><gtr:description>MRC CDSS-University Hospital Aintree collaboration (Richard Kia)</gtr:description><gtr:id>6B18693D-B124-411D-94C7-4B5640EA6004</gtr:id><gtr:impact>None Yet</gtr:impact><gtr:outcomeId>Mz8bHutVrKy-1</gtr:outcomeId><gtr:partnerContribution>Provision of liver resections and potentially other clinical material</gtr:partnerContribution><gtr:piContribution>Not directly by Richard Kia but potential data by other members of his team that could inform clinical practice</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PSORT Psoriasis Stratification to Optimise Relevant Therapy (Amy Foulkes)</gtr:description><gtr:id>83E51346-26B9-4141-99F2-A2500EFA441F</gtr:id><gtr:impact>No outputs yet, Amy Foulke's data is likely to be published as the first output next year</gtr:impact><gtr:outcomeId>cxB7wX7fWvL-4</gtr:outcomeId><gtr:partnerContribution>The University of Manchester is coordinating this whole study, there are 2 work streams &amp;amp; Amy Foulke's data was pilot data for one of them. 

GSK and Newcastle are processing samples.

QMUL are completing the data analysis 

Funding</gtr:partnerContribution><gtr:piContribution>Major collaborative succsessful MRC bid with Amy Foulkes supervisors Dr Richard Warren and Professor Chris Griffiths.

Amy Foulkes:-
?Fellowship data formed pilot data for one of the two work streams of the successful bid.
? Regularly attended GSK Stevenage site. Samples from her Fellowship have been processed there. She has also presented to GSK staff on behalf of the PSORT consortium prior to the successful bid.
?Regularly attended QMUL London where data analysis is being completed with the Bioinformatics team. 
?Spent &amp;gt;4 weeks working with our collaborators at Newcastle University on laboratory sample processing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Plymouth Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>D15D0FFD-26B9-4C06-8502-FA039BB685ED</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-23</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Liverpool and Broadgreen University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal Liverpool Clinical Research Unit (CRU)</gtr:department><gtr:description>PICME Study (Vincent Yip)</gtr:description><gtr:id>B4FEA4E6-F1A3-47D5-A589-52D7A3EEC2F4</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>E3YDjqNPFhA-1</gtr:outcomeId><gtr:partnerContribution>Review of clinical protocol, co-sponsorship, facilities, pharmacy</gtr:partnerContribution><gtr:piContribution>Vincent Yip developed the clinical protocol, ethics and CTA application.
Clinical trial has now commenced with 7 out of 8 volunteers completing the study (2013).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aintree University Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>79B87178-F207-48E7-8F7A-8AA1525C06B6</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-1</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>York Teaching Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>03A6E50C-9158-452E-AE3E-58C1E6EA9FC8</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-29</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Gronigen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>11BBD43C-1DF2-43FA-AFCA-CFFB2DAE11AB</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-6</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northern Devon Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>North Devon Hospital</gtr:department><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>7561217F-138A-4B06-ACBD-81C7AFA2C3C4</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-6</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Alderley Imaging Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>1150E7E5-CB7C-431A-9F2E-C032EA18D128</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-2</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>FAB45D57-35DC-4B36-A5F9-3F93DB4EAC21</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-3</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Toxicology Unit</gtr:department><gtr:description>MRC CDSS-MRC Toxicology Unit, Leicester (Richard Kia)</gtr:description><gtr:id>B6F10724-0371-4966-9F88-1B4DEF75D36E</gtr:id><gtr:impact>It is hoped that the MRC CDSS will share experimental data that will inform the development of a better in vitro liver model for drug screening.</gtr:impact><gtr:outcomeId>HDhHpFstfkB-1</gtr:outcomeId><gtr:partnerContribution>MRC Toxicology Unit will provide technical expertise and bear the costs of the analyses.</gtr:partnerContribution><gtr:piContribution>MRC CDSS team will provide experimental samples for analysis of microRNA profiles using the Agilent microRNA microarray platform in MRC Toxicology Unit.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Salford CCG</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi centre study suported by the CLRN (Sarah Skeoch)</gtr:description><gtr:id>5B1A3FB3-4DF3-40EB-838B-A6661DADC11F</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Ub5WGejS72R-9</gtr:outcomeId><gtr:partnerContribution>Patient Recruitment</gtr:partnerContribution><gtr:piContribution>We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals of Morecambe Bay NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>FA696F91-4EC7-4BFC-94DF-2138C7ACB369</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-27</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>City Hospitals Sunderland NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>1AEAFC2A-B214-4D28-A037-AA51AD9A417D</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-12</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>National Institute of Arthritis and Musculoskeletal and Skin Diseases</gtr:department><gtr:description>Collaboration with National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Health (John Reynolds)</gtr:description><gtr:id>34A113CB-D294-48A4-9844-1FFB98FBDD82</gtr:id><gtr:impact>Training in animal models received, access to facilities at NIH</gtr:impact><gtr:outcomeId>53a2bcdd7f6dd5.61527527-1</gtr:outcomeId><gtr:partnerContribution>Training in Using Animal Models of SLE to Test Novel Agents</gtr:partnerContribution><gtr:piContribution>None - training collaboration for the benefit of John Reynolds</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Trust Clinical Research Facility</gtr:department><gtr:description>Wellcome Trust CRF (Sarah Skeoch)</gtr:description><gtr:id>75176452-BB57-4CB3-A3A9-AFC4E36C99C6</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>BgRDgp56oT1-1</gtr:outcomeId><gtr:partnerContribution>The CRF provide administrative and nursing support in addition to ultrasonography and laboratory services.</gtr:partnerContribution><gtr:piContribution>We applied to use the CRF for clinical visits during the research study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Robert Bosch Foundation</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Robert Bosch Foundation for Medical Research (RBMF)</gtr:department><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>B29ECF26-7361-4931-975A-DD69E8BB2D40</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-15</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>East Cheshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi centre study suported by the CLRN (Sarah Skeoch)</gtr:description><gtr:id>8D9B33B1-1F4F-4936-A055-2C8BD88E8717</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Ub5WGejS72R-6</gtr:outcomeId><gtr:partnerContribution>Patient Recruitment</gtr:partnerContribution><gtr:piContribution>We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salford Royal NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>285E7538-9F4A-4EDA-8BBF-D5C351C0921C</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-5</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Victoria Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Royal Victoria Infirmary (Sam Nightingale)</gtr:description><gtr:id>57D68A3D-8E5F-4B3F-B131-E26BED604723</gtr:id><gtr:impact>3 patients were recruited to Study A of PARTITION. Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>o3ag21baSjD-1</gtr:outcomeId><gtr:partnerContribution>3 patients were recruited to Study A of PARTITION</gtr:partnerContribution><gtr:piContribution>Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team:
1) CNS Penetration of Antiretrovirals</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Manchester General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi centre study suported by the CLRN (Sarah Skeoch)</gtr:description><gtr:id>CE63BBA3-6222-4575-8284-DE3369EB669B</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Ub5WGejS72R-2</gtr:outcomeId><gtr:partnerContribution>Patient Recruitment</gtr:partnerContribution><gtr:piContribution>We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leeds Teaching Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Experimental Medicine Cancer Centre</gtr:department><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>68A5958F-413E-4A9E-95B1-373C167D3BF5</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-4</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>St Mary's Hospital London (Sam Nightingale)</gtr:description><gtr:id>586F684D-A472-4870-8B4C-20673B717F71</gtr:id><gtr:impact>17 patients were recruited to Study A of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>eFPPkfT2zEK-1</gtr:outcomeId><gtr:partnerContribution>17 patients were recruited to Study A of PARTITION</gtr:partnerContribution><gtr:piContribution>Participant in multi-site study lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team:
CNS Penetration of Antiretrovirals</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Bioinformatics</gtr:department><gtr:description>University of Manchester Bioinformatics Group (Amy Foulkes)</gtr:description><gtr:id>AF9F593B-DC3D-4638-B1BA-A5D5734F7BE1</gtr:id><gtr:impact>Currently discussing preliminary data, likely for combination publication</gtr:impact><gtr:outcomeId>ArtqGq87SCk-1</gtr:outcomeId><gtr:partnerContribution>All laboratory work was paid for by the partner.
Amy Foulkes worked with them in the processing of clinical samples. Future collaboration planned</gtr:partnerContribution><gtr:piContribution>Patient samples collected by Amy Foulkes for her Fellowship research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Utah</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Preclinical Research Resource (PRR)</gtr:department><gtr:description>AED development programme (Lauren Walker)</gtr:description><gtr:id>F6E30903-4D0F-4BE7-9A07-401DF6007196</gtr:id><gtr:impact>The samples have been analysed and this will be incorporated into a scientific paper (in preparation).</gtr:impact><gtr:outcomeId>Jno3xBUJz3Y-1</gtr:outcomeId><gtr:partnerContribution>The AED DDP screen all new anti-convulsants through an established maximum electro-shock mouse model of seizures. They collected serum and brain samples at time points following seizure. They met the cost of the rodents.</gtr:partnerContribution><gtr:piContribution>Lauren Walker designed the sample collection time frame. Samples were analyzed at the university of Liverpool.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Lanarkshire</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>38410EE9-FA1B-4114-83DC-ACB053BB8C7C</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-31</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Lothian</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Western General Hospital (Edinburgh) (Sam Nightingale)</gtr:description><gtr:id>035621F4-E02C-4AF4-838F-159A7F39BCEC</gtr:id><gtr:impact>6 patients were recruited to Study A of PARTITION and 4 patients were recruited to study B of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>gSjHt3op1sK-1</gtr:outcomeId><gtr:partnerContribution>6 patients were recruited to Study A of PARTITION and 4 patients were recruited to study B of PARTITION.</gtr:partnerContribution><gtr:piContribution>Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team :
1) CNS Penetration of Antiretrovirals
2) The CNS as a sanctuary site for HIV</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UCB Pharma Pilocarpine animal epilepsy model study (Lauren Walker)</gtr:description><gtr:id>77A04093-5D73-4E50-8E30-D584CF1D826A</gtr:id><gtr:impact>Samples have been analysed and results will be incorporated in a scientific paper (in preparation.)</gtr:impact><gtr:outcomeId>SNA98i2bvZ5-1</gtr:outcomeId><gtr:partnerContribution>A collaboration has been established with Rafal Kaminski at UCB Pharma to undertake brain and blood sample collection from their established validated pilocarpine murine epilepsy model. UCB will meet the costs of this study.</gtr:partnerContribution><gtr:piContribution>UCB will follow the protocol designed by Lauren Walker to collect brain tissue (half for western blotting and half for IHC) and serum at time points 12 weeks after pilocarpine induced status epilepticus.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pennine Acute Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>North Manchester Hospital (Sam Nightingale)</gtr:description><gtr:id>6312CD6E-D091-4B4F-874E-A970E7B56B55</gtr:id><gtr:impact>25 patients were recruited to Study A of PARTITION and 5 patients were recruited to study B of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>FccV5gHP96i-1</gtr:outcomeId><gtr:partnerContribution>25 patients were recruited to Study A of PARTITION and 5 patients were recruited to study B of PARTITION.</gtr:partnerContribution><gtr:piContribution>Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team :
A) CNS Penetration of Antiretrovirals
B) The CNS as a sanctuary site for HIV</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>72157A68-C42D-4CA2-A67C-AD007E111975</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-11</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Health Economics</gtr:department><gtr:description>Detection of drug antibodies/Centre for Health Economics , University of Manchester (Meghna Jani)</gtr:description><gtr:id>FC326B87-52B8-431A-80E9-AE195D2AF673</gtr:id><gtr:impact>Outcomes of collaboration being evaluated at present</gtr:impact><gtr:outcomeId>53aae37a0edf00.62237336-1</gtr:outcomeId><gtr:partnerContribution>Health economics modelling of immunogenicity testing in the UK</gtr:partnerContribution><gtr:piContribution>Non-clinical PhD student and Meghna Jani to collaborate to establish to health economic feasibility of immunogenicity testing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brigham and Women's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Bonventre Lab Collaboration (Stephen McWilliam)</gtr:description><gtr:id>49B1630B-280C-40D7-AE7F-D02FD22BD78D</gtr:id><gtr:impact>- McWilliam SJ, Antoine DJ, Sabbisetti V, Pearce RE, Jorgensen AL, Lin Y, Leeder JS, Bonventre JV, Smyth RL, Pirmohamed M. Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomark Med. 2014, 8(10):1189-1197

- McWilliam SJ, Antoine DJ, Sabbisetti V, Turner MA, Farragher T, Bonventre JV, Park BK, Smyth RL, Pirmohamed M. Mechanism-Based Urinary Biomarkers to Identify the Potential for Aminoglycoside-Induced Nephrotoxicity in Premature Neonates: A Proof-of-Concept Study. PLoS ONE 7(8): e43809, 2012. doi:10.1371/journal.pone.0043809 PMID: 22937100

-D.J. Antoine, S. McWilliam, V. Sabbisetti, M. Turner, R. Smyth, M. Pirmohamed, J.V. Bonventre, B.K. Park. Measurement of the urinary biomarker KIM-1 identifies the potential for aminoglycoside-induced nephrotoxicity in premature neonates. Toxicology 290(2-3):107, 2011. doi:10.1016/j.tox.2011.09.015. Abstract

-McWilliam, S.J.; Antoine, D.J.; Turner, M.; Sabbisetti, V.; Bonventre, J.V.; Park, B.K.; Smyth, R.L.; Pirmohamed, M. Urinary Kim-1 As A Biomarker of Aminoglycoside-Induced Nephrotoxicity in Premature Neonates. Pediatric Research. 70(5supplement):107, 2011. doi:10.1203/01.pdr.0000403893.61640.b6. Abstract &amp;amp; oral presentation at European Society for Paediatric Research, October 2011</gtr:impact><gtr:outcomeId>kGkeaBoAQeF-1</gtr:outcomeId><gtr:partnerContribution>The collaborators have contributed through sample analysis and co-authoring a research paper and abstracts</gtr:partnerContribution><gtr:piContribution>Stephen McWilliam and his research team have provided the collaborator with samples for analysis from studies they are conducting</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Washington</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Vascular Imaging Laboratory, Department of Radiology</gtr:department><gtr:description>University of Washington (Sarah Skeoch)</gtr:description><gtr:id>2FC152FF-C59E-4C55-A2B6-D9E287C7CC04</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>CVFB99cYk6X-1</gtr:outcomeId><gtr:partnerContribution>We are working with the team at UW on a clinical study using carotid MRI techniques which they developed. We hope to build on existing protocols to improve some imaging sequences and analysis techniques in conjunction with their team and are conducting the clinical study.
The UW team have provided their imaging protocols, expertise and are training myself up to analysis the MRI scans.</gtr:partnerContribution><gtr:piContribution>We are working with the team at UW on a clinical study using carotid MRI techniques which they developed. We hope to build on existing protocols to improve some imaging sequences and analysis techniques in conjunction with their team and are conducting the clinical study.
The UW team have provided their imaging protocols, expertise and are training myself up to analysis the MRI scans.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals of Morecambe Bay NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal Lancaster Infirmary</gtr:department><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>E38F1697-0126-46AD-AC54-26586AE9E435</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-10</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>D0F3AD40-BF50-42AB-8090-447F96BC7F74</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-2</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>C6EA4E14-0A9E-41BB-9FB0-68B2233DB80A</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-8</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mario Negri Institute for Pharmacological Research</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Consorzio Mario Negri Sud (CMNS)</gtr:department><gtr:description>Kindling rat model of epilepsy with pharmacological intervention (Lauren Walker)</gtr:description><gtr:id>C37787F3-6A51-4720-A1DB-3DC0AA3A6F22</gtr:id><gtr:impact>The data is being incorporated into a paper, combining multiple animal studies with human data and intervention animal studies, for submission to Nature Medicine</gtr:impact><gtr:outcomeId>5666b3468259e8.10975416-1</gtr:outcomeId><gtr:partnerContribution>Annamaria Vezzani (Mario Negri) provided brain and blood samples for analysis of rats with epilepsy taken 7, 15 and 90 days after the onset of disease. Three experimental groups were included; controls, epileptic rats and epileptic rats treated with novel immunomodulatory drugs.</gtr:partnerContribution><gtr:piContribution>The samples were analysed by liquid chromatography tandem mass spectrometry at the University of Liverpool by Dr Dan Antoine. Lauren Walker (supervised by Dr Dan Antoine) undertook the interpretation of the LCMS/MS data from the samples</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Haywood Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>C82200FF-F824-4557-BBEC-A73480211B25</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-12</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Liverpool and Broadgreen University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Royal Liverpool and Broadgreen University Hospital Trust (Amy Foulkes)</gtr:description><gtr:id>4851A985-E561-475C-A04B-54DD0478140B</gtr:id><gtr:impact>Clinical collaboration for the recruitment of patients. Patients recruited. Samples under analysis.</gtr:impact><gtr:outcomeId>XPnj4SgdXN4-1</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Clinical collaboration for the collection of research patients. Sample analysis.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Derby Teaching Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>231F737A-B4A9-4D71-BFEC-848BE44F6F6B</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-11</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>E0E6C9B0-AE35-43D7-82E1-04C57D8EB93C</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-4</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pennine MSK Partnership Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi centre study suported by the CLRN (Sarah Skeoch)</gtr:description><gtr:id>74813D8B-DED3-4396-9F8C-C52A50A00C3F</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Ub5WGejS72R-7</gtr:outcomeId><gtr:partnerContribution>Patient Recruitment</gtr:partnerContribution><gtr:piContribution>We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Dudley Group NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>8423A9AE-DF42-4180-8667-582EA5C213C5</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-30</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GSK PKPD modelling collaboration (Stephen McWilliam)</gtr:description><gtr:id>293EC635-ABB4-488D-910F-65035117CC6E</gtr:id><gtr:impact>No outcomes as yet. Plan is to produce a publication.</gtr:impact><gtr:outcomeId>Er8jb8uGF92-1</gtr:outcomeId><gtr:partnerContribution>GSK provided modelling software, training and support.</gtr:partnerContribution><gtr:piContribution>Stephen McWilliam provided data and time.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's Medical Centre</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>6D654A71-436A-44AE-82E1-EE3EDF6BAA9F</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-8</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR CLAHRC for Greater Manchester</gtr:department><gtr:description>Multi centre study suported by the CLRN (Sarah Skeoch)</gtr:description><gtr:id>3F75D051-5087-4B98-9D62-4A94711A0C41</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Ub5WGejS72R-1</gtr:outcomeId><gtr:partnerContribution>Patient Recruitment</gtr:partnerContribution><gtr:piContribution>We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PSORT Psoriasis Stratification to Optimise Relevant Therapy (Amy Foulkes)</gtr:description><gtr:id>99DA2201-8A14-4D40-82C2-E44121C3F42C</gtr:id><gtr:impact>No outputs yet, Amy Foulke's data is likely to be published as the first output next year</gtr:impact><gtr:outcomeId>cxB7wX7fWvL-2</gtr:outcomeId><gtr:partnerContribution>The University of Manchester is coordinating this whole study, there are 2 work streams &amp;amp; Amy Foulke's data was pilot data for one of them. 

GSK and Newcastle are processing samples.

QMUL are completing the data analysis 

Funding</gtr:partnerContribution><gtr:piContribution>Major collaborative succsessful MRC bid with Amy Foulkes supervisors Dr Richard Warren and Professor Chris Griffiths.

Amy Foulkes:-
?Fellowship data formed pilot data for one of the two work streams of the successful bid.
? Regularly attended GSK Stevenage site. Samples from her Fellowship have been processed there. She has also presented to GSK staff on behalf of the PSORT consortium prior to the successful bid.
?Regularly attended QMUL London where data analysis is being completed with the Bioinformatics team. 
?Spent &amp;gt;4 weeks working with our collaborators at Newcastle University on laboratory sample processing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salford Royal NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi centre study suported by the CLRN (Sarah Skeoch)</gtr:description><gtr:id>92EFCE9B-B834-4EA1-82B1-EFC3346925B5</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Ub5WGejS72R-4</gtr:outcomeId><gtr:partnerContribution>Patient Recruitment</gtr:partnerContribution><gtr:piContribution>We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Cumbria University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>F849E494-F2D8-4A1E-A021-13DB7685AAA7</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-25</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Walton Centre NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Biomarkers in brain and blood Study (Lauren Walker)</gtr:description><gtr:id>7A6DAAA6-F4A0-4EEE-8038-648B92B742E8</gtr:id><gtr:impact>The samples have been analysed and will be compared to a second set of collected samples (yet to be analysed) and this will be incorporated into a scientific paper.</gtr:impact><gtr:outcomeId>AiyMY3MEDph-1</gtr:outcomeId><gtr:partnerContribution>Active support from the centre in patient recruitment</gtr:partnerContribution><gtr:piContribution>Lauren Walker designed the study, put together the protocol, patient leaflet and consent forms etc and did the ethics application and attended the meeting. Lauren Walker collected all the CSF and serum samples and recruited all the patients</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>St Stephen's AIDS Trust</gtr:department><gtr:description>Chelsea and Westminster (Sam Nightingale)</gtr:description><gtr:id>930348D4-1837-4E08-AC70-B16CD50EFA90</gtr:id><gtr:impact>31 patients were recruited to Study A of PARTITION and 3 patients were recruited to study B of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>U3DsE4yAYn1-1</gtr:outcomeId><gtr:partnerContribution>31 patients were recruited to study A and 3 patient have been recruited to study B</gtr:partnerContribution><gtr:piContribution>Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team:
A) CNS Penetration of Antiretrovirals
B) The CNS as a sanctuary site for HIV</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ICON</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Data Analysis Discussion (James McCaffrey)</gtr:description><gtr:id>3F242DAC-4FFA-406C-BF4D-B302B489994F</gtr:id><gtr:impact>Submission of paper for publication in June 2014</gtr:impact><gtr:outcomeId>53a2c7c1477cd3.82290903-1</gtr:outcomeId><gtr:partnerContribution>Discussion with Cyril Clarke (ICON) helped in the initial stages of data analysis for the AKI paper that has been submitted for publication in October 2014.</gtr:partnerContribution><gtr:piContribution>Data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's Mill Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>B32D16BE-AB5A-438B-AA98-9B8608A9D5BB</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-22</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>08952261-1E1D-45CE-AFC7-1BD5BDD9541D</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-28</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pennine Acute Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Fairfield Hospital</gtr:department><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>C4DE622B-A20A-429E-9111-E2472CF35322</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-9</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Advanced Discovery and Experimental Therapeutics</gtr:department><gtr:description>Measurement of Methotrexate and 7-OH-methotrexate levels in patients with rheumatoid arthritis.(James Bluett)</gtr:description><gtr:id>33F569FF-C5C3-4205-8CCD-2904E5B7D9D9</gtr:id><gtr:impact>Measurement of methotrexate levels</gtr:impact><gtr:outcomeId>J5Q6aiFQNt6-2</gtr:outcomeId><gtr:partnerContribution>Samples were provided from patients with rheumatoid arthritis</gtr:partnerContribution><gtr:piContribution>Measurement of MTX/7-OH-MTX levels in patients with rheumatoid arthritis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gateshead Health NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>2243867E-A48F-4F8C-A92E-21116E368746</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-7</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salford Royal NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>25BB26E8-E3F7-457E-A36A-7D0E99681AB2</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-3</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>PSORT Psoriasis Stratification to Optimise Relevant Therapy (Amy Foulkes)</gtr:description><gtr:id>39069062-2937-43A2-AEAB-1DFD8F42BE55</gtr:id><gtr:impact>No outputs yet, Amy Foulke's data is likely to be published as the first output next year</gtr:impact><gtr:outcomeId>cxB7wX7fWvL-1</gtr:outcomeId><gtr:partnerContribution>The University of Manchester is coordinating this whole study, there are 2 work streams &amp;amp; Amy Foulke's data was pilot data for one of them. 

GSK and Newcastle are processing samples.

QMUL are completing the data analysis 

Funding</gtr:partnerContribution><gtr:piContribution>Major collaborative succsessful MRC bid with Amy Foulkes supervisors Dr Richard Warren and Professor Chris Griffiths.

Amy Foulkes:-
?Fellowship data formed pilot data for one of the two work streams of the successful bid.
? Regularly attended GSK Stevenage site. Samples from her Fellowship have been processed there. She has also presented to GSK staff on behalf of the PSORT consortium prior to the successful bid.
?Regularly attended QMUL London where data analysis is being completed with the Bioinformatics team. 
?Spent &amp;gt;4 weeks working with our collaborators at Newcastle University on laboratory sample processing</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Arthritis Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Arthritis Research UK Epidemiology Unit</gtr:department><gtr:description>Arthritis Research UK EU (Sarah Skeoch)</gtr:description><gtr:id>D380FB12-34DE-46FA-B0C2-78A0BF99439E</gtr:id><gtr:impact>Abstract at EULAR 2012 Conference</gtr:impact><gtr:outcomeId>UYQ5wAiX2As-1</gtr:outcomeId><gtr:partnerContribution>Sarah Skeoch is based within this unit where she participates in teaching and research activities. She is provided with teaching, pastoral and IT support and desk space.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch is based within this unit where she participates in teaching and research activities.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Vienna</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>E8ED32D5-DD6B-4F53-B857-02BC90EF75DB</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-8</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Maidstone and Tunbridge Wells NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>5DE0244B-91CB-4136-8620-B208F9FDB16D</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-20</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chalmers University of Technology</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>11947CD3-7F36-4EBA-B3D6-CC9A53A32960</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-5</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PSORT Psoriasis Stratification to Optimise Relevant Therapy (Amy Foulkes)</gtr:description><gtr:id>24BD2DF5-8DDA-46E3-935D-AECD99AE4226</gtr:id><gtr:impact>No outputs yet, Amy Foulke's data is likely to be published as the first output next year</gtr:impact><gtr:outcomeId>cxB7wX7fWvL-5</gtr:outcomeId><gtr:partnerContribution>The University of Manchester is coordinating this whole study, there are 2 work streams &amp;amp; Amy Foulke's data was pilot data for one of them. 

GSK and Newcastle are processing samples.

QMUL are completing the data analysis 

Funding</gtr:partnerContribution><gtr:piContribution>Major collaborative succsessful MRC bid with Amy Foulkes supervisors Dr Richard Warren and Professor Chris Griffiths.

Amy Foulkes:-
?Fellowship data formed pilot data for one of the two work streams of the successful bid.
? Regularly attended GSK Stevenage site. Samples from her Fellowship have been processed there. She has also presented to GSK staff on behalf of the PSORT consortium prior to the successful bid.
?Regularly attended QMUL London where data analysis is being completed with the Bioinformatics team. 
?Spent &amp;gt;4 weeks working with our collaborators at Newcastle University on laboratory sample processing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Antonius Hospital</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>St. Antonius Hospital Foundation</gtr:department><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>9B127672-6CA7-4571-8D50-6C4DD1BCB2DF</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-7</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Proteomics &amp;amp; Pharmacokinetics Collaboration [Richard Myles Turner]</gtr:description><gtr:id>8DA6F867-8192-479E-A4B6-DE7CF7C8FCDD</gtr:id><gtr:impact>Research results presented as a poster at the British Pharmacological Society Annual Winter meeting, 2016</gtr:impact><gtr:outcomeId>56683fce7302c0.98580283-1</gtr:outcomeId><gtr:partnerContribution>Provision of relevant samples from wild-type and knock out murine models for the proteomics experiments</gtr:partnerContribution><gtr:piContribution>i) Undertaking iTRAQ proteomics experiments on samples provided from the University of Dundee, and sharing the generated data with our collaborators. ii) In vivo murine pharmacokinetics study carried out using novel dried blood spot sampling.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Basildon and Thurrock University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>FED2C863-7B39-4F9D-9E7B-76615BD3EBC8</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-11</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ipswich Hospital NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>A52807F0-154B-4711-A259-C7E31F206922</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-5</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>East Cheshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>9C0E0BA3-390D-4DC2-B44F-CA148E49331E</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-14</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sengenics</gtr:collaboratingOrganisation><gtr:country>Singapore, Republic of</gtr:country><gtr:description>Immunome Protein Array for Autoantibody detection in the circumstance of oncology immunotherapy toxicity (Munir Pirmohamed/ Anna Olsson-Brown)</gtr:description><gtr:id>20F78363-CA7E-49B6-9F68-D3E2DE850AF7</gtr:id><gtr:impact>pending</gtr:impact><gtr:outcomeId>589c3d8bcb84e2.44634891-1</gtr:outcomeId><gtr:partnerContribution>provision of specific test for pilot study</gtr:partnerContribution><gtr:piContribution>Study design and sample provision for pilot study</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ICON</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>ICON observation (Amy Foulkes)</gtr:description><gtr:id>4FEC2FE2-7C06-42A5-939D-4B6B6C6BA0A3</gtr:id><gtr:impact>Personal learning for Fellow</gtr:impact><gtr:outcomeId>oCwRufXKBU2-1</gtr:outcomeId><gtr:partnerContribution>Opportunity to attend meetings of pre-clinical trial design/discussion and follow up with observation of Phase I clinical trial in dermatology</gtr:partnerContribution><gtr:piContribution>None</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Walton Centre NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PPS Study (Lauren Walker)</gtr:description><gtr:id>166F8D53-45B5-4FC0-873C-7D5088176472</gtr:id><gtr:impact>Once collection of the samples is complete, they will be analysed and this will be incorporated into a scientific paper.</gtr:impact><gtr:outcomeId>hmZZ85ryZGJ-1</gtr:outcomeId><gtr:partnerContribution>Active support from Walton Centre and CLRN nurse in recruiting patients</gtr:partnerContribution><gtr:piContribution>Lauren Walker designed the study, put together the protocol, patient leaflet and consent forms etc. and did the ethics application and attended the meeting. As a portfolio study Lauren Walker is assisted by a research nurse to recruit patients and collect samples.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ljubljana</gtr:collaboratingOrganisation><gtr:country>Slovenia, Republic of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>BEC7D7BA-1EB3-4CE8-8581-5240B056FE8B</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-14</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>BA27667E-4D25-4803-B72E-810D1090301A</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-1</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Betsi Cadwaladr University Health Board</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>57C8F14F-859B-43C9-885A-B28C099A0B77</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-18</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi centre study suported by the CLRN (Sarah Skeoch)</gtr:description><gtr:id>CCA9A4FB-6615-463C-9328-C7BE0C4FE98E</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Ub5WGejS72R-3</gtr:outcomeId><gtr:partnerContribution>Patient Recruitment</gtr:partnerContribution><gtr:piContribution>We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Betsi Cadwaladr University Health Board</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>7A45F31D-2E4A-40DF-9173-4453C0419C36</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-1</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University College London Hospital (Sam Nightingale)</gtr:description><gtr:id>5E865CAF-B930-4096-A54F-7D11041E25DF</gtr:id><gtr:impact>15 patients were recruited to Study A of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>F7LdZHsuY6L-1</gtr:outcomeId><gtr:partnerContribution>15 patients were recruited to Study A of PARTITION.</gtr:partnerContribution><gtr:piContribution>Participants in a multi site study lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team :
A) CNS Penetration of Antiretrovirals</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Children's Mercy Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Leeder collaboration (Stephen McWilliam)</gtr:description><gtr:id>68C05DBC-AD17-4FFA-9A2D-EA4CD14A8065</gtr:id><gtr:impact>- McWilliam SJ, Antoine DJ, Sabbisetti V, Pearce RE, Jorgensen AL, Lin Y, Leeder JS, Bonventre JV, Smyth RL, Pirmohamed M. Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomark Med. 2014, 8(10):1189-1197</gtr:impact><gtr:outcomeId>GsZDsxqrMf8-1</gtr:outcomeId><gtr:partnerContribution>The collaborators will contribute through co-authoring research papers and analysis of results</gtr:partnerContribution><gtr:piContribution>The collaborator has provided us with samples for analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Blackpool Teaching Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>C158D639-D8A3-4C49-9E0A-E19F26E24EC2</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-17</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi centre study suported by the CLRN (Sarah Skeoch)</gtr:description><gtr:id>2F8B1C72-3B1C-4DCA-851C-CEB4BFF2C09B</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Ub5WGejS72R-5</gtr:outcomeId><gtr:partnerContribution>Patient Recruitment</gtr:partnerContribution><gtr:piContribution>We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Truly Labs AB</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>EFD00AE8-C6CC-40D2-B97E-5C3A6C87514E</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-12</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal National Hospital for Rheumatic Diseases</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>B9E64165-7C3F-4910-B41F-9A571E1FBE6C</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-2</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KNMP Holding B.V.</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>986E396D-ED67-48E2-8E0A-8E5D71B40EDA</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-5</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bio.logis Genetic Information Management GMBH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>BF50F099-0CD4-48BD-B854-9E25B6A657C8</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-6</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oncological Referral Centre (Centro di Riferimento Oncologico)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>0558E56F-CE46-44FD-A378-067D0CFA2B30</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-11</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>62303A7D-CFD0-4C1F-8FD2-4B1FFF8D0218</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-10</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pennine Acute Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>B84EEC1D-D39F-422A-954E-4267FB9D9CF8</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-6</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Liverpool University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Royal Liverpool University Hospital (Sam Nightingale)</gtr:description><gtr:id>D201CF5B-A665-44B9-8599-0E7E21FACBFC</gtr:id><gtr:impact>R&amp;amp;D support in the set up of further sites involved in this study.
25 patients were recruited to Study A of PARTITION and 11 patients were recruited to study B of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>DvBzvvMb5ns-1</gtr:outcomeId><gtr:partnerContribution>Co-sponsor and recruitment of patients to these studies.
25 patients were recruited to Study A of PARTITION and 11 patients were recruited to study B of PARTITION.</gtr:partnerContribution><gtr:piContribution>Co-Sponsor and participating site in two multi site studies conducted by Dr Sam Nightingale (Clinical Fellow) who works directly with the clinical team to recruit patients.
1) CNS Penetration of Antiretrovirals
2) The CNS as a Sanctuary Site for HIV</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cambridge University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>083B5CA4-6D13-4ED5-ADDC-B39843BA998D</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-9</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northumbria Healthcare NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett)</gtr:description><gtr:id>A1EFA6F1-7FC6-4C89-B969-274EBD065A24</gtr:id><gtr:impact>Testing of samples ongoing</gtr:impact><gtr:outcomeId>LhxiNkwCsYH-13</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients</gtr:partnerContribution><gtr:piContribution>Multi-centred study with multiple NHS sites.
Genetic testing of samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>F21D6391-D68D-4F69-99D3-0F225094632F</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-13</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>2222B303-8EA6-4303-8FAF-94B6143E308F</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-7</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Paul Sabatier University (University of Toulouse III)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>9F08F8B1-E72F-423D-B078-2A6899E72909</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-9</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Golden Helix Foundation</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>07553AA2-50C2-42DA-8778-E725FA17FA0D</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-4</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bioxydn</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch)</gtr:description><gtr:id>7ECBE7CD-E2A9-48EF-BB6F-F461495E89F3</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>58c032fa5033a1.64507892-3</gtr:outcomeId><gtr:partnerContribution>Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Oldham CCG</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi centre study suported by the CLRN (Sarah Skeoch)</gtr:description><gtr:id>7028ADFC-226D-4E4A-BFD2-9F17996604A8</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Ub5WGejS72R-8</gtr:outcomeId><gtr:partnerContribution>Patient Recruitment</gtr:partnerContribution><gtr:piContribution>We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Intensive Care Society</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Biomarker-guided duration of antibiotic treatment Group (Tim Felton)</gtr:description><gtr:id>B3F5084D-7D11-4EF0-8D65-D8382E2967FC</gtr:id><gtr:impact>Application to NIHR for a Health Technology Appraisal Grant of &amp;pound;1,590,629</gtr:impact><gtr:outcomeId>569fb1d811ca21.45577953-1</gtr:outcomeId><gtr:partnerContribution>Tim Felton has been Invited to join collaborative group studying the use of biomarkers to guide duration of antibiotics. Clinicians and clinical trialist from across the UK involved with the support of the Intensive Care Society. This has led to submission of an NIHR Health Technology Appraisal grant &amp;quot;Biomarker-guided duration of antibiotic treatment&amp;quot;. The proposed trial is a three-arm randomised control trial of 2760 patients. (&amp;pound;1,590629).</gtr:partnerContribution><gtr:piContribution>Tim Felton has been Invited to join collaborative group studying the use of biomarkers to guide duration of antibiotics. Clinicians and clinical trialist from across the UK involved with the support of the Intensive Care Society. Has led to successful submission of an NIHR Health Technology Appraisal grant &amp;quot;Biomarker-guided duration of antibiotic treatment&amp;quot;. The proposed trial will be a three-arm randomised control trial of 2760 patients. (&amp;pound;1,590629).</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wrightington, Wigan and Leigh NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Multi-centre observational study (Meghna Jani)</gtr:description><gtr:id>24B631F0-B47B-4FF6-8B78-7FD615185F7B</gtr:id><gtr:impact>Recruiting patients to a multi-centre national study. Results awaited after completion</gtr:impact><gtr:outcomeId>FrZTtaBZGFC-7</gtr:outcomeId><gtr:partnerContribution>Patient recruitment</gtr:partnerContribution><gtr:piContribution>Approached sites for recruitment, completed R&amp;amp;D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ICON</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Clinical Pharmacology Unit</gtr:department><gtr:description>24hr biomarker profile in healthy volunteers (Lauren Walker)</gtr:description><gtr:id>E236AAB5-E175-4AD3-9A5C-1A2D19AFCE99</gtr:id><gtr:impact>Samples analysed for circadian variability, combined with a panel of other liver-related biomarkers, results incorporated into a scientific paper (in preparation).</gtr:impact><gtr:outcomeId>Bdn8A81XdUT-1</gtr:outcomeId><gtr:partnerContribution>ICON (USA Site) undertook the screening, recruitment and inpatient stay, including collection of the samples, for which they covered all of the costs.</gtr:partnerContribution><gtr:piContribution>Lauren Walker designed the study in collaboration with ICON, she designed the protocol, patient leaflet and consent forms etc. together with support from ICON particularly the medical director and she did the ethics application and attended the meeting with the medical director.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital NHS Foundation Trust (NCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>King's College Hospital London (Sam Nightingale)</gtr:description><gtr:id>0F9B8179-4FCD-40E1-858F-2C535E023C8D</gtr:id><gtr:impact>8 patients were recruited to Study A of PARTITION and 2 patients were recruited to study B of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>pw9bGpfsosx-1</gtr:outcomeId><gtr:partnerContribution>8 patients were recruited to Study A of PARTITION and 2 patients were recruited to study B of PARTITION.</gtr:partnerContribution><gtr:piContribution>Participants in a multi site study lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team :
A) CNS Penetration of Antiretrovirals
B) The CNS as a sanctuary site for HIV</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leeds Teaching Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Leeds General Infirmary (Sam Nightingale)</gtr:description><gtr:id>864EFD05-5189-44AE-AC7C-35B67DDDC496</gtr:id><gtr:impact>14 patients were recruited to Study A of PARTITION and 3 patients were recruited to study B of PARTITION.
Analysis of samples is ongoing.</gtr:impact><gtr:outcomeId>G4qiFPEcSpT-1</gtr:outcomeId><gtr:partnerContribution>14 patients were recruited to Study A of PARTITION and 3 patients were recruited to study B of PARTITION.</gtr:partnerContribution><gtr:piContribution>Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team:
A) CNS Penetration of Antiretrovirals
B) The CNS as a sanctuary site for HIV</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ICON</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Population PK of carbamazepine therapy (Vincent Yip)</gtr:description><gtr:id>4CA31494-15A0-4E24-83B9-DF524643B0BB</gtr:id><gtr:impact>Data collection is now complete and a model being developed.</gtr:impact><gtr:outcomeId>ZGMUhtwhWqr-1</gtr:outcomeId><gtr:partnerContribution>ICON supported Vincent Yip with study/trial design and provided the licence for the NONMEM software in order to carry out a population PK of carbamazepine therapy.</gtr:partnerContribution><gtr:piContribution>Study data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AZ-UOM Strategic Alliance Fund (Sarah Skeoch)</gtr:description><gtr:id>8C707483-55EB-477B-9624-B0A5282823A6</gtr:id><gtr:impact>Abstracts published</gtr:impact><gtr:outcomeId>VouqypPYyXc-1</gtr:outcomeId><gtr:partnerContribution>Sarah Skeoch and her research team applied for funding to the alliance and were granted funding for equipment, training and imaging costs.</gtr:partnerContribution><gtr:piContribution>Sarah Skeoch and her research team have included members of Astra Zeneca in discussions of study set up and will report our findings in the 1st 12 patients involved in the study to the alliance.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Blizard Institute</gtr:department><gtr:description>Serum neurofilament analysis (Sam Nightingale)</gtr:description><gtr:id>1AEA6177-149B-4839-953D-90780FBCB004</gtr:id><gtr:impact>Work ongoing</gtr:impact><gtr:outcomeId>EkEymVraiPz-1</gtr:outcomeId><gtr:partnerContribution>Sam Nightingale is providing samples and they will perform the analysis using their unique assay.</gtr:partnerContribution><gtr:piContribution>Samples Sam Nightingale has collected from the MRC funded PARTITION study will be analysed by the BLIZZARD institute using a novel assay for neurofilament detection in serum.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Walton Centre NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PICME II Study (Vincent Yip)</gtr:description><gtr:id>EAB75384-E8ED-429D-857E-17F8E54B3E65</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>ZVXSVJg2Xws-1</gtr:outcomeId><gtr:partnerContribution>Walton Centre will review protocol, provide co-sponsorship and will provide facilities for study to be undertaken.</gtr:partnerContribution><gtr:piContribution>Vincent Yip developed clinical protocol, ethics and CTA application.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>U-PGx Collaboration (Richard Turner)</gtr:description><gtr:id>AC1169D0-D192-45E5-B576-86DC57F2FE9B</gtr:id><gtr:impact>No Impact yet</gtr:impact><gtr:outcomeId>566841ce24afe4.23428474-3</gtr:outcomeId><gtr:partnerContribution>The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.</gtr:partnerContribution><gtr:piContribution>Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>North West Coast Academic Health Science Network Atrial Fibrillation Symposium Day (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9288FF51-DD21-40EF-A565-56054874DC56</gtr:id><gtr:impact>Richard Turner gave an oral presentation entitled, 'Genotype-Guided Warfarin Dosing' regarding the current state-of-the art of warfarin pharmacogenomics in the context of Personalised Medicine at the North West Coast Academic Health and Science Network Atrial Fibrillation symposium day. This sparked subsequent discussion with requests for copies of the presentation slides and led to a separate meeting with Dr Tom Dawson, founder of Rescon Technologies (a mobile healthcare technology private enterprise). This may lead to a new collaboration.
Presentation available on YouTube: https://www.youtube.com/watch?v=MvEKkd8FV74</gtr:impact><gtr:outcomeId>56a89116527041.32484590</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.eventbrite.co.uk/e/innovation-in-identifying-and-managing-atrial-fibrillation-symposium-tickets-16747593503?aff=erellivorg</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British society for rheumatology annual conference 2013 (Meghna Jani)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>93E9D8C0-121A-49CB-BDC1-5ED4B19327FE</gtr:id><gtr:impact>Scientific oral presentation.
Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines


Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines</gtr:impact><gtr:outcomeId>ETFdm9LDu5G</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference for Retrovirology and Opportunistic infection (CROI) 2014, Boston Massachusetts (Sam Nightingale)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2BB651E9-354C-4F4B-8229-CFFA50939533</gtr:id><gtr:impact>Sam Nightingale presented his research data at an international conference - Conference for Retrovirology and Opportunistic infection. Nightingale S, on behalf of the PARTITION investigators. HIV-1 RNA Detection in CSF in ART Treated Subjects with Incomplete Viral Suppression in Plasma.

This is the major US HIV conference. Sam Nightingale spoke to approx 600 people. He met leaders in the field and discussed potential collaborations.</gtr:impact><gtr:outcomeId>53d8d5d4591807.40404834</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.croi2014.org/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American College of Rheumatology Conference Washington DC November 2012 (John Reynolds)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9D7FEA85-15F3-4DCE-8232-7014A171ACD9</gtr:id><gtr:impact>Poster Presentation of Research</gtr:impact><gtr:outcomeId>Uh5S8M5hquN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC CDSS International Workshop (Richard Kia)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>805CBA2C-50B1-4816-BEEF-3E34E1E8ECC8</gtr:id><gtr:impact>Poster presented at International Workshop entitled, &amp;quot;In vitro endpoints and markers of hepatotoxicity&amp;quot; organised by MRC CDSS at the University of Liverpool on 17 September 2013

None yet.</gtr:impact><gtr:outcomeId>rzKVATxG6Yd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Translational Medicine and Therapeutics Research Showcase 2013 (Edinburgh)(All NWE MRC CPT Fellows)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>41F032DF-76AA-4597-AAD9-627A15B89FE1</gtr:id><gtr:impact>NWE MRC Research Fellows joined with Research Fellows from similar schemes in Glasgow and Edinburgh. Research in the form of presentations and posters was shared between fellows and approx. 60 academics and industry researchers.

An opportunity for Fellows to network and share research experience.</gtr:impact><gtr:outcomeId>keMxgNWzWWq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The European league against rheumatism (EULAR ) (James Bluett)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>50684836-1145-44EA-983E-8894CA2E54C2</gtr:id><gtr:impact>James Bluett presented his reasearch in a talk entitled: LONG-TERM PERSISTENCE WITH ORAL METHOTREXATE IN PATIENTS WITH EARLY INFLAMMATORY ARTHRITIS

None yet</gtr:impact><gtr:outcomeId>53a1ab6529ab77.20947962</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2006,2009,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Digestive Diseases Week (Richard Kia)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2BEC4DFD-1A0F-46A7-8FEA-54474018A21F</gtr:id><gtr:impact>Oral presentation of research at the annual premier gastroenterology conference DDW entitled, &amp;quot; Phenotypic Comparison of Hepatocyte-Like Cells Differentiated From Human Induced Pluripotent Stem Cells Derived by Cellular Reprogramming of Primary Hepatocytes and Dermal Fibroblasts Obtained From the Same Donor&amp;quot; organised jointly by a few societies including American Association for the Study of Liver Diseases, in Chicago, May 5, 2014.

Publicity of research and dissemination of preliminary findings</gtr:impact><gtr:outcomeId>53ad78b797a8e1.54908416</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NOWGEN: A-Level Visit Day 25/1/13 (John Reynolds)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9FDCBD23-171E-4B25-A62B-C91455C495B2</gtr:id><gtr:impact>Around 50 A-level students attended NOWGEN at the NIHR Wellcome Trust Clinical Research facility in Manchester. Students attended in small groups to receive demonstrations of current research techniques. This was to encourage an interest in pursuing science beyond A-level.

Students gave good feedback and took an active part in the demonstrations and discussions.</gtr:impact><gtr:outcomeId>QLAiox2XQbQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interviewed for online profile (Amy Foulkes)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1471CFC1-DF56-4802-9475-AC2DDD1EF755</gtr:id><gtr:impact>Amy foulkes was interviewed by Kath Nightingale (MRC Press Officer) for the creation of a scientist profile for the MRC website. 
http://www.mrc.ac.uk/Achievementsimpact/Profiles/AmyFoulkes/index.htm

No impact yet.</gtr:impact><gtr:outcomeId>hm8QzNd29VW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Manchester Children's Hospital Grand Round (James McCaffrey)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C69CC273-4AFF-442C-8765-A3699DF6243C</gtr:id><gtr:impact>Talk resulted in discussion about how best to detect Acute Kidney Injury (AKI) in patients at Royal Manchester Children's Hospital (RMCH). This talk showcased work from our AKI biomarker paper..one of the biomarkers in this trial is now in routine use at RMCH.</gtr:impact><gtr:outcomeId>56a63aa6b7ef58.99062235</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American College of Rheumatology annual Conference, Boston 2014 (Meghna Jani)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A616B56C-3753-45AE-AA7F-250215C624F6</gtr:id><gtr:impact>Scientific oral presentation

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines.</gtr:impact><gtr:outcomeId>545b9c55254244.06936162</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society for Rheumatology meeting, April 2015 (Meghna Jani)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D0F357E7-AF8C-4AA3-BF53-94C9AD901CD6</gtr:id><gtr:impact>Scientific oral presentation X1

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines</gtr:impact><gtr:outcomeId>5666f80f4f01f4.89276139</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society for Rheumatology meeting, April 2015 (Meghna Jani)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>295B7060-B17A-48CC-A85F-0ADC7BE05667</gtr:id><gtr:impact>Disseminated findings to a clinical and research audience, to improve patient safety and impact future guidelines

None Yet</gtr:impact><gtr:outcomeId>5666f763d1ea12.92534218</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Immunoconvention, Berlin (31st October- 1st November 2014) (Meghna Jani)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5E5776C9-0230-42A9-A5AF-AB7C124E505C</gtr:id><gtr:impact>Talks: (1) Using treatment algorithms in inflammatory disease (rheumatology) (2) Clinical relevance of immunogenicity- case studies from daily practice: rheumatology

Invited speaker for 2 talks as outlined above. Each talk 30-45 minutes followed by workshop/discussion.
Possible new collaboration</gtr:impact><gtr:outcomeId>545b9dacedea20.04350613</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Skin Research' Newsletter (Amy Foulkes)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>386137AC-14D5-4B08-B6E2-EB0B51436EE2</gtr:id><gtr:impact>An article about her PhD research by Amy Foulkes appeared in the November 2011 edition of a regular newsletter, 'Skin research', published by the University of Manchester and the Salford Royal Foundation Trust aimed at dermatology patients and the general public.

Continued engagement with patient group.</gtr:impact><gtr:outcomeId>iZqtXigoRaR</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Society of Paediatric Infectious Diseases conference (Dublin 2014) (Tim Felton)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F960F21B-CF59-446C-81CD-1EACA376A039</gtr:id><gtr:impact>Tim Felton presented a poster:
Ramos-Mart&amp;iacute;n V, Paulus S, Siner S, Scott E, Padmore K, Newland P, Drew RJ, Felton TW, Docobo- P&amp;eacute;rez F, Pizer B, Pea F, Peak M, Turner MA, Beresford MW, Hope WW. LIPSTIC: Liverpool pharmacokinetic study of teicoplanin in children. European Society of Paediatric Infectious Diseases. Dublin 2014. (Poster presentation, international meeting).

The poster presentation provided an opportunity for Tim Felton to meet with conference delegates and talk about his work:
Ramos-Mart&amp;iacute;n V, Paulus S, Siner S, Scott E, Padmore K, Newland P, Drew RJ, Felton TW, Docobo- P&amp;eacute;rez F, Pizer B, Pea F, Peak M, Turner MA, Beresford MW, Hope WW. LIPSTIC: Liverpool pharmacokinetic study of teicoplanin in children. European Society of Paediatric Infectious Diseases. Dublin 2014. (Poster presentation, international meeting).</gtr:impact><gtr:outcomeId>54477a7bb80988.58178210</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Video about what it's like to be a PhD Student at the University of Manchester (Amy Foulkes)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AAA31ED6-4E4C-403D-8D25-6F2A392A6767</gtr:id><gtr:impact>http://www.mhs.manchester.ac.uk/postgraduate/videochangingfacePhD/
Amy foulkes featured in a video entitled the 'changing face of the PhD encouraging students to consider PhD research

Video available on University of Manchester website to be viewed by future generations of phD students.</gtr:impact><gtr:outcomeId>cEaHRTdH4LA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American College of Rheumatology Annual Conference, November 2015 (Meghna Jani) (1)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>32A06AC5-9F7D-4560-9470-6577DA94D47D</gtr:id><gtr:impact>Scientific Oral presentation. Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines.</gtr:impact><gtr:outcomeId>56a5ece2885b25.77867825</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) - 3rd Poster (Tim Felton)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FFCEA8AF-76B1-4F9C-8494-E5456D74ED4C</gtr:id><gtr:impact>Tim Felton Presented a poster about his research work:
Ramos-Mart&amp;iacute;n V, Paulus S, Siner S, Scott E, Padmore K, Newland P, Drew RJ, Felton TW, Docobo- P&amp;eacute;rez F, Pizer B, Pea F, Peak M, Turner MA, Beresford MW, Hope WW. Population Pharmacokinetics of Teicoplanin in Children and Neonates. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington 2014. (Poster presentation, international meeting).

Poster presentation provided the opportunity to talk to international delegates about research work.
Ramos-Mart&amp;iacute;n V, Paulus S, Siner S, Scott E, Padmore K, Newland P, Drew RJ, Felton TW, Docobo- P&amp;eacute;rez F, Pizer B, Pea F, Peak M, Turner MA, Beresford MW, Hope WW. Population Pharmacokinetics of Teicoplanin in Children and Neonates. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington 2014. (Poster presentation, international meeting).</gtr:impact><gtr:outcomeId>544779572f6a11.04246007</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Festival (Manchester) (Several NWE MRC CPT Research Fellows)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EAB5BB0D-0207-4F20-B1DB-0B98F3FF079C</gtr:id><gtr:impact>9 NWE MRC Fellows ran a table top activity entitled 'Marvellouse Medicine' at the University of Manchester Science Spectacular event (Part of the Manchester Science Festival). Approximately 2000 people visited the event with approximately 75 children (under 10) and their families taking part in the activity.

The activity was popular with visitors and the research Fellows are keen to take part in the event again next year. Several GCSE and A Level students also spoke to the Fellows about careers in medeicine, pharmacology and scientific research.</gtr:impact><gtr:outcomeId>U89YtSkTDh9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference: Health is Wealth (Dr Anna Olsson-Brown)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>86962FEA-2C32-4FE7-927C-1CF5599B93F2</gtr:id><gtr:impact>To share information. Stimulated panel debate within the session.</gtr:impact><gtr:outcomeId>58c6c6e7081988.29946325</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.liverpoollep.org/events/health-wealth-2017-conference/</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Women in Science Edit-a-Thon (Liverpool)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6BAE70BF-B118-44A7-B2AC-628EBA919DE1</gtr:id><gtr:impact>21 people attended an edit-a-thon focussed on Women in Science. This began with a training session from three wikimedia volunteers about how to edit the website wikipedia. This was then followed by an editing session lasting approximately 4 hours in which the editing group (made up of University staff, students and members of the public created and/or improved 12 wikipedia pages dedicated to female scientists.

The editing session was then followed by a Key note talk about women in Science from Dame Julia Higgins and a panel discussion Charied by Executive Pro-Vice Chancellor, Prof Fiona Beveridge, featuring three University of Liverpool Professors (Prof Susan Wray, Prof Tara Shears and Prof Jude Robinson) and MRC Clinical Research Fellows (Dr Lauren Walker and Dr Sarah Skeoch). The key note talk was attended by approx. 60 people (a combination of University staff, students and members of the public). Approximately 80 people attended this panel session.

- The creation of 12 wikipedia pages about women in science.
- 21 people trained as Wikipedia editors
- Potential for further wikipedia editing projects (e.g. improving information about drugs and pharmacology on Wikipedia)</gtr:impact><gtr:outcomeId>5375ce55512446.38859203</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://en.wikipedia.org/wiki/Wikipedia:WikiProject_Women_scientists/Editathon_13_May_2014_-_University_of_Liverpool</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>An oral lecture for University of Liverpool year 2 medical students entitled, 'Biologics and Biosimilars' (2016) (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CBB9CE3B-29A8-4E19-9143-B0F80725385D</gtr:id><gtr:impact>I gave a lecture to year 2 medical students on behalf of the Clinical Pharmacology department as part of delivering the new University of Liverpool undergraduate medical curriculum (2016). 

This activity helped educate undergraduate medical students about the development and pharmacology of biologics and biosimilars.</gtr:impact><gtr:outcomeId>58a32b27086c67.81532143</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2008,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2015 (Tim Felton)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9962AA0D-A72C-48D6-BD6A-E9F9DEE5D641</gtr:id><gtr:impact>Poster Presentation: Piperacillin Time Above MIC Correlates with Improved Outcomes (O'Donnell JN, Rhodes NJ, Day JZ, Jett RS, Felton TW, Neely MN, Scheetz MH)</gtr:impact><gtr:outcomeId>56a0c283ded677.67217991</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Manchester Widening Participation video to encourage school students into taking science degrees (Amy Foulkes)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>851BF3D7-2628-4985-8B5F-97838E96A4FF</gtr:id><gtr:impact>http://www.youtube.com/watch?v=g66ad_1pqPE&amp;amp;feature=youtu.be Video viewed 103 times on You tube.

Encouraging school students to think about taking degrees in bioscience.</gtr:impact><gtr:outcomeId>dYGssBfqYp8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=g66ad_1pqPE</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Organisation of Seminar from External Speakers - Sengenics (Dr Anna Olsson-Brown; Dr Neil French)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>856F1E09-9891-409D-8185-34ACC656C986</gtr:id><gtr:impact>To share information. Stimulated debate and questions within the attendees.</gtr:impact><gtr:outcomeId>58c6c7ba810b01.75841596</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Pharmacological Society annual flagship meeting (2015) (Richard Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9708988A-F647-4A25-9888-A605504BAB7F</gtr:id><gtr:impact>This was a presentation, entitled 'Investigating the prevalence, predictors and prognosis of suboptimal statin therapy early after a non-ST elevation acute coronary syndrome' concerning the the research Richard Turner has been conducting as part of his Fellowship on the North West England MRC Scheme in Clinical Pharmacology &amp;amp; Therapeutics. The presentation was well received and led to a thought-provoking discussion.

Richard was awarded the GlaxoSmithKline Prize for clinical oral communications as a result of this presentation at the British Pharmacological Society flagship annual meeting.</gtr:impact><gtr:outcomeId>56a8e36e5de837.72515623</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.bps.ac.uk/news-events/future-scientific-meetings/2015/pharmacology-2015#</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Play on Personalised Medicine</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EA8763F6-C26C-43C2-B1BF-3F194E5FC805</gtr:id><gtr:impact>This involved a number of activities - (a) an initial workshop with 14-16 year olds and a presentation on personalised medicine to these students, and to a playwright; (b) helping the playwright to develop a play on personalised medicine; (c) commenting on the script; (d) meeting actors who acted in the play and undertaking a general Q&amp;amp;A session; (e) attending the play and taking part in a debate session with members of the general public. All these activities were undertaken with the Y-touring theatre company. Further details available on the website: http://www.theatreofdebate.com/Projects/Dayglo/Story.html

The play was performed in many schools throughout the UK. it also ran for 1 week at the Royal Albert Hall. A DVD of the play which is called &amp;quot;Dayglo&amp;quot; has been made and was shown at the Edinburgh Science Festival, and will also be shown to medical students initially at Liverpool and eventually nationally.</gtr:impact><gtr:outcomeId>gRXG4WeogG8</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BSR Annual Conference (Sarah Skeoch)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2E4C5853-FDB0-48AD-88D0-89D0F5F0A72D</gtr:id><gtr:impact>Poster Tour presentation &amp;quot;Investigation of the prevalence and phenotype of atherosclerosis in patients with rheumatoid arthritis&amp;quot;
S. Skeoch, P. Cristinacce, H. Williams, D. Xu, S. Jie, N. Balu, J. James, C. Yuan, T. Hatsukami, P. Hockings, Y. Alexander, J. Waterton, I. Bruce.


None yet</gtr:impact><gtr:outcomeId>5668486a4e2b36.75339538</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Personalised Medicine Workshop Presentation (2013) (Stephen McWilliam)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5DD9E20D-9BED-4F49-AB1A-D9DC786AE405</gtr:id><gtr:impact>Presentation at a Workshop at the University of Liverpool Institute of Translational Medicine. Stephen McWilliam presented his MRC research and outcomes to date.

None yet</gtr:impact><gtr:outcomeId>CXE9wM2QTwL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Psoriasis Awareness Day - Salford Royal NHS Foundation Trust (Amy Foulkes)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>78E823AF-BFC5-4114-A99A-B761B1CC3CA9</gtr:id><gtr:impact>Well publicised and well attended event.

none</gtr:impact><gtr:outcomeId>FuNsrkAmF8a</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academic Paediatric Association Conference (2014) (Stephen McWilliam)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>40B3BC7D-A94E-4C0F-8B32-6C370AE20F00</gtr:id><gtr:impact>This event took place in Winchester , and was organised by the Academic Paediatric Association. There were aproximately 50 people there. The presentation was entitled: 'Association of Urinary Kidney Injury Molecule-1 with Aminoglycoside Exposure in Children with Cystic Fibrosis'

None yet</gtr:impact><gtr:outcomeId>53b6a94ecbb948.55567234</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EACPT Summer School Edinburgh July 2013 (Lauren Walker)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>725DABE8-F61F-45C2-86F5-8EAB574BBA23</gtr:id><gtr:impact>Lauren Walker submitted and abstract and gave a poster presentation of research results to date.

None yet.</gtr:impact><gtr:outcomeId>hc37rgodYLW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK CF Clinical Trials Meeting, Bristol (2015) (Stephen McWilliam)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3AD3977B-25DC-495F-B453-38E268AB30A0</gtr:id><gtr:impact>This event took place in Bristol. There were probably around 100 people present. I presented 'The PROteKT study' to a group of clinicians and researchers involved in CF clinical care and trial. Promoted wider awareness of the trial and generated interest</gtr:impact><gtr:outcomeId>56a64ff2eb8571.20864722</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival 7th July 2014 (BPS PERSONALISED MEDICINE )</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>21A6540B-3539-4E16-8E60-15B3E38CAE90</gtr:id><gtr:impact>Present a broad range of science and scientific issues in an exciting and engaging environment.

To present a broad range of science and scientific issues in an exciting and engaging environment t encourge people to pursue careers in science and bring to life</gtr:impact><gtr:outcomeId>54535536d28b79.93423798</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>98492BEE-5AB8-431D-9E09-EF93567F40FC</gtr:id><gtr:impact>Poster presentation: 16s rRNA Gene Sequencing Applied to Bronchoalveolar Lavage Fluid of Critically Ill Patients is Able to Detect Pathogens and May Influence Antibiotic Therapy. (Thomas S, Logan JMJ, Hassan I, Barker J, Ashworth A, Barnes A, Feddy L, Hayes T, Malagon I, Stirling S, Szentgyorgi L, Chand MA, Mutton K, Felton TW)</gtr:impact><gtr:outcomeId>56a0bddda34577.70603309</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2015(Invited speaker 2) (Tim Felton)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2564FED8-E300-45A1-AFD8-6BB7BDCF6250</gtr:id><gtr:impact>Tim Felton was invited to give a presentaiton at this conference, &amp;quot;Application of Pharmacokinetic/Pharmacodynamic (PK/PD) Models&amp;quot;</gtr:impact><gtr:outcomeId>56a0c0acd6be09.91616312</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academy of Medical Sciences Spring Meeting for Clinical Scientists in Training (Sarah Skeoch)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>38014FD5-B4F3-43F4-AA23-EFFBB80D3706</gtr:id><gtr:impact>Poster Presentation: Evaluation of carotid plaque inflammation in patients with rheumatoid arthritis using 18F-fluorodeoxyglucose PET-MRI: a pilot study. Sarah Skeoch, Heather Williams, Penny Cristinacce, Paul Hockings, Jacqueline James, Yvonne Alexander, John Waterton, Ian Bruce.


Networking and discussion of ideas with other researchers</gtr:impact><gtr:outcomeId>566848d3c5bf79.30011359</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American College of Rheumatology Conference 2014:  Boston 2014 (John Reynolds)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C18A78DB-883A-4131-AEF0-51D7CA6DE0ED</gtr:id><gtr:impact>Presentation on John Reynolds' research in an oral abstract session

None yet</gtr:impact><gtr:outcomeId>5666b1d663f714.19896124</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AMS/MRS/RCP Meeting for Clinician Scientists in Training.  London. February 2013 (John Reynolds)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B422C561-F44C-4C60-B2BF-39CCAE0F7613</gtr:id><gtr:impact>Poster Presentation of Research</gtr:impact><gtr:outcomeId>pNtZft92qVE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>12th European Congress on Epileptology - Novel predictive biomarkers of epileptogenesis and therapy response: bedside to bench-and back  (Lauren Walker)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5B43EBA2-B384-4514-89CC-DD2BCBDC5B1D</gtr:id><gtr:impact>Lauren Walker was invited to give a platform presentation in a forum on biomarkers in epilepsy .</gtr:impact><gtr:outcomeId>58ad81f265be18.87384564</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Warfarin Pharmacogenomics,' given at the 1st Ubiquitous Pharmacogenomics Medicine Day in Granada, Spain (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>99418886-630E-4C43-A4E3-C4B59EA73125</gtr:id><gtr:impact>The oral presentation gave an overview of anticoagulant pharmacogenomics, and stimulated interest and discussion. The talk provided publicity for the department's ongoing work.</gtr:impact><gtr:outcomeId>58be8607661a30.31810056</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.goldenhelix.org/index.php/education/golden-helix-conferences/pharmacogenomics-days/previous-conferences/246-upcomingconferencestobeannounced</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Showcase Presentation (Vincent Yip)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1A86B0B4-7359-435E-8D6A-5C2788BD6951</gtr:id><gtr:impact>MRC Centenary Showcase Presentation to patients and public. Overview of personalised medicine and applications in the future as part of the University of Liverpool's contribution to the MRC's Centenary celebrations.

None yet</gtr:impact><gtr:outcomeId>53ad5a6438d888.95605839</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference on Retroviruses &amp; Opportunistic Infections, Seattle, Mar 5-9, 2012</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>521E1C7D-78D0-40C2-9FD3-3A1990E2E1B8</gtr:id><gtr:impact>Presented the study background for TAILoR at this International HIV conference.

Presentation was well appreciated</gtr:impact><gtr:outcomeId>fH8QmptUv4H</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.retroviruses.org</gtr:url><gtr:year>2010,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society of Rheumatology (BSR) 2014 (James Bluett)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EA6C0601-363E-4ADB-ADEF-04D17A1B1A68</gtr:id><gtr:impact>Poster presentation 'North west regional audit: Management of polymyalgia rheumatica' at a national conference. North west regional audit: Management of polymyalgia rheumatica

None yet</gtr:impact><gtr:outcomeId>54526a68112d94.03211739</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society of Rheumatology (BSR) 2013 (James Bluett 1st entry)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9B7171E3-85B2-49E0-A57C-3718F4EE5492</gtr:id><gtr:impact>James Bluett presented a poster entitled, 'Using encode data to identify potential functional genetic variants at the 5q31 psoriatic arthritis susceptibility locus'

None Yet</gtr:impact><gtr:outcomeId>53a1b3a8087f42.04103399</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Transplant Association/Renal association conference 2013 (James McCaffrey)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>857972A7-6808-4668-930A-A4AEF54D62F0</gtr:id><gtr:impact>Scientific meeting/National conference. Moderated poster presentation consisting of 5 min talk followed by questions.

None yet</gtr:impact><gtr:outcomeId>TFfsUYrBMCQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EULAR annual Conference, Paris 2014 (Meghna Jani)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2993F51-F3C9-4481-A69F-C5344C0B28C8</gtr:id><gtr:impact>Scientific oral presentation

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines</gtr:impact><gtr:outcomeId>53aad969e09b23.70537727</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paediatric Intensive Care Society 2013 (James McCaffrey)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BE7456AD-F9DA-4EA7-B017-584D27D374EE</gtr:id><gtr:impact>National Conference/Scientific meeting

Discussion helped refine data analysis of acute kidney injury (AKI) biomarker trial we have run in the paediatric intensive care unit (PICU) at the Royal Manchester Children's Hospital (RMCH). This article has been submitted for review for publication on 16 June 2014. This trial has contributed to one of the biomarkers in the project becoming routinely available for RMCH PICU patients.</gtr:impact><gtr:outcomeId>Biqt8Y2gePT</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academic Paediatricians in Training Meeting 2013 (James McCaffrey)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E9271952-1964-4FDD-AE08-E4A3DBC06A71</gtr:id><gtr:impact>Scientific meeting increasing awareness of research being performed by junior paediatricians across the country.

None yet</gtr:impact><gtr:outcomeId>cc9epueiy5d</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EULAR Congress 2013 (2) (Sarah Skeoch)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C1448062-5F48-4EFC-9B50-E30F7D1B3F79</gtr:id><gtr:impact>Poster presentation: Antibody positivity is associated with increased arterial stiffness in rheumatoid arthritis patients: results from the Norfolk Arthritis Register 
S. Skeoch, S. Verstappen, J. Chipping, T. Marshall, D.P. Symmons, I.Bruce
Presented at the EULAR congress, Madrid 2013

None yet</gtr:impact><gtr:outcomeId>tD8Gt9Q7j87</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Joint Drug Metabolism Discussion Group and Groupe de Metabolisme et Pharmacocinetique Meeting 2014 (Vincent Yip)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AAAC4648-5091-40DB-A64A-3218240DFE5A</gtr:id><gtr:impact>Vincent Yip gave a poster presentation of his MRC research work

Discussion with fellow clinical academics and industry regarding current work and future work.</gtr:impact><gtr:outcomeId>54526580d25981.95016997</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EULAR annual conference 2014 (2) (Meghna Jani)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FC619F8F-1584-4D83-8736-2176F0D3F6FE</gtr:id><gtr:impact>Poster presentation of research to scientific audience/Healthcare professionals.

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines</gtr:impact><gtr:outcomeId>53aadc4b306fd0.14395462</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Thoracic Society Winter Meeting. 2015. (Time Felton)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C0D0A83E-78AE-4ACD-8B6A-0F583CDEB167</gtr:id><gtr:impact>Poster presentation: Survival in patients with chronic type 2 respiratory failure: a comparison of obesity hypoventilation syndrome, COPD and overlap syndrome. ( Jothieswaran A, Mascareno M, Bokhari S, Chaudhry N, Felton TW, Bentley AM)</gtr:impact><gtr:outcomeId>56a0bd07a119c6.40728942</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NOWGEN: A Level Visit (Sarah Skeoch)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3E59782D-81B6-438F-957A-8C0F8D1A0E96</gtr:id><gtr:impact>Sarah Skeoch arranged a session for A level students visiting the University of Manchester at the NIHR/Wellcome Trust Clinical Research Facility. The session included discussion and demonstrations of musculoskeletal imaging (MRI and ultrasound)

Positive feedback was received and further &amp;quot;meet the scientist &amp;quot; days are being planned for January 2014</gtr:impact><gtr:outcomeId>a5pgu8ucBSe</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American College of Rheumatology Conference San Diego November 2013 (John Reynolds)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A4C027DD-7161-41EC-BC68-1A9CEEAA70CB</gtr:id><gtr:impact>Poster Presentation of Research</gtr:impact><gtr:outcomeId>53a2ba901c5c89.69193456</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2009,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Contributed article to &quot;Young Persons' University blog&quot; (James McCaffrey)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2FCA5D11-A83E-478F-B0BB-85253E6745DF</gtr:id><gtr:impact>This Blog has been developed for secondary school and college students and is used to showcase research that PhD students are doing at the Univeristy of Manchester. 
James McCaffrey Explained in lay-terms the basis of his PhD research question

Increased awareness of local population to research activities ongoing at University of Manchester, and encouraging young people to apply for University and post-graduate education.</gtr:impact><gtr:outcomeId>53a2c543007b61.19096799</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.ypu.manchester.ac.uk/blog/pondering-podocytes</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Ubiquitous Pharmacogenomics,' given to the North Locality Liverpool Clinical Commissioning Group (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D942D479-AE1C-42E2-A5F2-92128AB6F244</gtr:id><gtr:impact>Purpose: to improve understanding of others thinking. The oral presentation was given to general practitioners (GPs) and provided an overview of pharmacogenomics and an introduction to the prospective pharmacogenomics clinical implementation study (PREPARE) that is commencing locally. Asked to give two more talks at other Clinical Commissioning Group (CCG) meetings.</gtr:impact><gtr:outcomeId>58bd913c593c12.04880999</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Community Open day- Faculty of Medicine and Human Sciences (28th June 2014) (Meghna Jani)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>16E035A4-C661-4592-92EC-10D3C8871603</gtr:id><gtr:impact>Use of ultrasound in musculoskeletal research

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines</gtr:impact><gtr:outcomeId>53aadf212a1ae6.23639306</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EULAR annual conference 2013 (Meghna Jani)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>234C2932-8026-4C32-B9E2-D820DB42D997</gtr:id><gtr:impact>Poster presentation of research to scientific audience/Healthcare professionals.

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines</gtr:impact><gtr:outcomeId>TzYfMtV6LLN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BAD meeting (Amy Foulkes)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>34851CAE-8607-449F-B5BE-78628453BED0</gtr:id><gtr:impact>British Association of Dermatologists meeting 2012 Poster presentation 'Patient satisfaction in a specialist combined dermatology and rheumatology clinic'

None</gtr:impact><gtr:outcomeId>aisTYR7zQPB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AMS/MRS/RCP Meeting for Clinician Scientists in Training.  London. February 2012 (John Reynolds)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F0402A05-6ED6-4FD1-A5CE-E854978774B7</gtr:id><gtr:impact>Poster Presentation of Research</gtr:impact><gtr:outcomeId>Wb4VLHr9oeA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Women in Science Edit-a-Thon (Manchester)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D8A6D3A4-1A5C-40B4-BED8-7D4A6F0AB644</gtr:id><gtr:impact>The Wiki edit-a-thon was held in the Main Library at The University of Manchester providing access to a rich collection of printed and electronic works about women in science. The workshop was attended by 17 individuals working and studying across the University who wanted to make a difference to this important gender agenda. During the workshop participants learnt how to edit, create and improve Wikipedia articles. 

The Women in Science Panel Discussion was held in the Manchester Museum at The University of Manchester and attracted over 50 academics, researchers, students, and teachers from both inside and outside the University. The event offered the opportunity to listen to panellists who each spoke openly about their role and their progression at the University, and shared their own experiences as a woman in science. The panellists each offered hints and tips, as well as discussing the challenges they faced. Our panellists were Professor Dame Nancy Rothwell (President and Vice Chancellor of the University, Professor of Physiology), Professor Dame Tina Lavendar (Professor of Midwifery), Professor Dame Nicky Cullum (Professor of Nursing) and Professor Helen Gleeson (Professor of Physics). The panel was facilitated by Professor Chris Griffiths (Professor of Dermatology). An informal networking session followed the discussion.

In response to the editing session participants reported &amp;quot;feeling inspired&amp;quot; and requested &amp;quot;follow-up sessions&amp;quot; the University is now looking to host monthly Edit-a-thon sessions to ensure the editing skills learnt will not be forgotten! An advanced workshop for our 'experienced' Wiki editors is planned for later in the year.</gtr:impact><gtr:outcomeId>543f7def264919.25346713</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://wikimedia.org.uk/wiki/Women_in_Science_Wikipedia_Edit-a-thon_at_the_University_of_Manchester_2014</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EULAR annual conference, June 2015 (Meghna Jani)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>01C2D591-CC65-4734-8EF7-4998E933E9EE</gtr:id><gtr:impact>Poster presentations X2

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines</gtr:impact><gtr:outcomeId>5666f8b83f51c3.16995234</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Advances against Aspergillus, 2012, Istanbul, Turkey (Tim Felton)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4A92C804-5765-4A4F-A061-8D59DC676232</gtr:id><gtr:impact>Tim Felton was present at the posters during poster rounds. 

http://www.advancesagainstaspergillosis.org/2012/index.htm

Chrdle A, Mustakim S, Bright-Thomas R, Baxter CG, Felton TW, Denning DW. Aspergillus bronchitis in non-immunocompromised patients - case series, response to treatment and criteria for diagnosis. Advances against aspergillosis. Istanbul. 2012. - POSTER PRESENTATION

Tim felton was involved in many discussions around the topic with delegates.</gtr:impact><gtr:outcomeId>UeEwt6Jz1m6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Expression of Unique and Diverse HIV Variants in Cerebrospinal Fluid during ART</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7ED9FED8-6DC9-450F-AF25-E4AD83FBEA74</gtr:id><gtr:impact>Poster presentation to physicians and allied health professional at Conference for retrovirology and Opportunistic infections (CROI).</gtr:impact><gtr:outcomeId>58bec9565a3c76.27813833</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academy of Medical Science meeting (Amy Foulkes)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A449E759-996A-4120-8919-069FEFB16C88</gtr:id><gtr:impact>Amy spoke about industry collaboration at an Academy of Medical Science event in May 2012

As a result Amy Foulkes was interviewed by Kath Nightingale (MRC Press Officer) for the creation of a scientist profile for the MRC website</gtr:impact><gtr:outcomeId>caSFjyNiY5N</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Liverpool University Hospital medical Grand Round (2015) (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BF630A75-AF37-4D8A-B232-7292187498D4</gtr:id><gtr:impact>Richard Turner gave an oral presentation entitled 'Warfarin Pharmacogenetics', as part of a programme of presentations given at a Royal Liverpool University Hospital medical Grand Round. The aim was to highlight to clinicians the current research into personalised medicine being carried out at the Wolfson Centre for Personalised Medicine (University of Liverpool). The talks helped to engender interest in the subject and we received positive feedback about the usefulness of the event. 
This activity helped educate clinicians about the current research base for personalised medicine and brought to their attention the ongoing initiatives to implement pharmacogenetic testing into specific clinics at the Royal Liverpool hospital.</gtr:impact><gtr:outcomeId>56a897003e91b5.19660874</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Pharmacological Society Winter Meeting Dec 2013 (Lauren Walker)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>52C302B1-7FEA-4693-BB6B-F05410BC7A2D</gtr:id><gtr:impact>Lauren Walker submitted and abstract and gave a poster presentation of research results to date

None Yet</gtr:impact><gtr:outcomeId>53a2abd60e7064.12336631</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 1st poster (Tim Felton)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EB226062-491E-43D7-9BB3-35943DA2EDF8</gtr:id><gtr:impact>Presentation of a Poster: 
Felton TW, Livermore J, Goodwin J, Sharp AD, Gregson L, Hope WW. Pharmacodynamic rationale for intermittent dosing of micafungin in immunocompetent patients. Washington 2014. (Poster presentation, international meeting).

Meeting with other Delegates to share research work:
Felton TW, Livermore J, Goodwin J, Sharp AD, Gregson L, Hope WW. Pharmacodynamic rationale for intermittent dosing of micafungin in immunocompetent patients. Washington 2014. (Poster presentation, international meeting).</gtr:impact><gtr:outcomeId>544777d4ab7018.84067680</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STEM Ambassador Training (Sarah Skeoch)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>597BDC50-50C3-4E09-8125-16F575CEBDC8</gtr:id><gtr:impact>Sarah Skeoch attended the Science Technology, Engineering and Mathematics Ambassador training programme which aims to promote and explain STEM subjects to children of all ages. She is now a member of the STEM network and school visits have been arranged in forthcoming months.

Ongoing promotion of STEM subjects.</gtr:impact><gtr:outcomeId>mZURQxBG9uY</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.stemnet.org.uk/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>An oral lecture for University of Liverpool year 3 medical students entitled, 'Cardiac Arrhythmias &amp; Antiarrhythmics (2015) (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D1A62AD2-A111-48EB-8125-EBF756A00F3E</gtr:id><gtr:impact>Richard Turner gave a lecture to year 3 medical students as part of the Clinical Pharmacology curriculum (2015). This activity helped educate undergraduate medical students about arrhythmia pharmacology.</gtr:impact><gtr:outcomeId>56a89767bf9ec5.25801317</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Podocyte International Conference, Freiburg, Germany, 2014 (James McCaffrey)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>31BA86BF-8FCC-4365-B5B6-89ABCAC360C2</gtr:id><gtr:impact>Discussion around poster with conference attendees

Impact Description: Discussions helped with ongoing ChIP-Seq in vitro work, and in vivo work involving rodent model of nephrotic syndrome we have developed.</gtr:impact><gtr:outcomeId>53a2c2f318a6e0.86849906</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Body Experience, Manchester Museum (James McCaffrey)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5F7986CF-54DC-4FCD-99AF-B74D24862DC3</gtr:id><gtr:impact>James McCaffrey explained how the kidney functions and what his project involves

Increased awareness of local population to research activities ongoing at University of Manchester</gtr:impact><gtr:outcomeId>53a2c60d17d4b4.52147220</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Pharmacological Society Annual Meeting (Dec 2013) (Vincent Yip)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5AA2B329-2160-4ECA-9A21-32BE3876D478</gtr:id><gtr:impact>Vincent Yip presented an overview of his MRC research

None Yet</gtr:impact><gtr:outcomeId>53ac2cd4810e76.11092262</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American College of Rheumatology Annual Conference, November 2015 (Meghna Jani) (2)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1970EA37-0DD5-4AC0-A289-67AC58022868</gtr:id><gtr:impact>Poster presentation. Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines.</gtr:impact><gtr:outcomeId>56a5edcfd3aa18.67360490</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Manchester Science Spectacular 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>30EB1648-A5C8-4E43-BBC9-D130BE285A14</gtr:id><gtr:impact>MRC Fellows, Academic Clinical Fellows and members of the British Pharmacology Society hosted an acticity stand, called 'My Marvellouse Medicine' at this event which attracts over 1000 members of the general public every year. Approximately 100 children and their families took part in the activities on the stand which sought to educate children and their parents about personalised medicine, stratification, drug trials and medicine production.

Feedback from paretns was extremely positive and children enjoyed the activities.</gtr:impact><gtr:outcomeId>5460e9e39fbfd1.09658789</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.engagement.manchester.ac.uk/highlights/manchester_science_festival/science_spectacular/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Manchester Science Fair - Psoriasis Exhibition (Amy Foulkes)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D68A9E8F-E43E-4530-8830-9B3EFF475486</gtr:id><gtr:impact>This was a well publicised, well attended event.

None</gtr:impact><gtr:outcomeId>kMjYBGk2CJV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIHR Media competition entry &quot;Imaging inflammation in rheumatoid arthritis&quot; (Sarah Skeoch)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CE460760-FABC-4A82-874B-BDB14FAE6EAF</gtr:id><gtr:impact>Sarah Skeoch entred into the NIHR media competition in March 2013 which comprised of a filmed discussion with a patient about why we were conducting research into vascular inflammation in RA that now appears on youtube.

The film has been viewed over 400 times on youtube.</gtr:impact><gtr:outcomeId>53ad6fe983f849.37219063</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=ik4NdFtV64U</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British society for Rheumatology Conference 2016, poster presentation (Sarah Skeoch)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5218B3C1-828E-47E7-AF62-A6A32236CC9F</gtr:id><gtr:impact>Sarah Skeoch presented a regional audit on the use of PET imaging in rheumatology and the development of a regional referral pathway.</gtr:impact><gtr:outcomeId>58c033fcc11075.72837157</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2013,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Liverpool-Malawi-Wellcome Conference 2013 (Sam Nightingale)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EAEDCD9D-3CE6-4306-95AB-D3127E3B4205</gtr:id><gtr:impact>Sam Nightingale presented his research data at an international conference - The Liverpool-Malawi Wellcome Conference, Blantyre, Malawi.

Sam Nightingale spoke to approx 200 people. The presentation sparked interesting dicussions. Potential for future Collaborations for work in a similar area in the developing world.</gtr:impact><gtr:outcomeId>ei5iukfDhLE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Encephalitis Society fact sheet (Sam Nightingale)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6732B1B4-8D06-4CC4-B5F8-F47CE5A8BAD8</gtr:id><gtr:impact>Dr Nightingale wrote a patient fact-sheet on HIV cognitive impairment that has been published on encephalitis society website and linked to the Terrence Higgins Trust Website

none</gtr:impact><gtr:outcomeId>BqNyrSQMeG8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>18th Annual Resistance and Antiviral Therapy Meeting, Royal College of Physicians, London. September 2014 (Sam Nightingale)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6A50A5E2-DD97-484E-8170-9EE22601CBC8</gtr:id><gtr:impact>Sam Nightingale gave a talk entitled 'The CNS has an HIV reservoir (the PARTITION study)' to scientific peers during session 3 of the 18th Annual Resistance and Antiviral Therapy Meeting, Royal College of Physicians, London. September 2014

Dissemination of PhD research.</gtr:impact><gtr:outcomeId>54525183907953.38847645</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIHR Visit to the NIHR/Wellcome Trust Clinical Research Facility 29/4/2013 (John Reynolds)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5E1DCEC6-2A79-4977-B8C0-A837F8333261</gtr:id><gtr:impact>A formal visit by senior members of the NIHR to observe the infrastructure and facilities at the NIHR Wellcome Trust clinical research facility. John demonstrated the equipment that he is using as part of his study and discussed the support network within the facility.

Demonstration of my work to senior members of the NIHR.</gtr:impact><gtr:outcomeId>or7EjsG3ws4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Community Open day- Arthritis Research UK stand (6th July 2013) (Meghna Jani)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5346BD27-E144-441F-A17D-AF9CB218889D</gtr:id><gtr:impact>6 Arthritis research UK researchers took part in this event. Meghna Jani conducted joint ultrasound on willing participants and explained how this may impact on research in Rheumatology.

The activity was popular with children and adults. Many were curious and inquisitive about the techniques used and were interested in exploring more about the imaging modality and musculoskeletal research.</gtr:impact><gtr:outcomeId>AQ4FA7QmzW6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International League Against Epilepsy UK Chapter Meeting, Glasgow September 2013 (Lauren Walker)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>602D2836-CBF1-49FC-BA3C-758FDD0B1607</gtr:id><gtr:impact>Lauren Walker submitted an abstract and gave a poster presentation of research results to date.

None yet</gtr:impact><gtr:outcomeId>Ld9WBqpo9UC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EULAR congress 2013 (Sarah Skeoch)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>420C76FA-5B9B-4AD5-8206-6F6D38548F4D</gtr:id><gtr:impact>Oral Presentation: Assessment of lupus nephritis disease activity using non-contrast MRI: A pilot study.
 S.Skeoch, M.Dobbs, P.Hubbard, J. Naish, N.Woodhouse, M. Ho, J.Waterton, G. Parker, I. Bruce.

Paper presented at the EULAR congress, Madrid, 2013

Currently writing a paper and meeting to discuss a collaberation for a larger study.</gtr:impact><gtr:outcomeId>hjnFbn1qR9c</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CSF/plasma HIV-1 RNA discordance, even at low level is associated with up -regulation of host inflammatory mediators in cerebrospinal fluid</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3AC7392F-A6E0-40D9-BFA0-BC6968FF974B</gtr:id><gtr:impact>Platform presentation to physicians and allied health professional at British HIV Association conference.</gtr:impact><gtr:outcomeId>58bec8e21775d1.08990148</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brain Awareness Week (Dr Sam Nightingale)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E328F73A-5D33-4013-A345-D7F2980D69DA</gtr:id><gtr:impact>Dr Sam Nightingale arranged 5 public events with stalls and activities to engage the public. Approximately 300 members of the public attended these events. A competition for children gained 30 entries

The events reached the attention of the media. Sam Nightingale was interviewed on local radio which allowed my message to reach a wider audience.</gtr:impact><gtr:outcomeId>bkZhNMkShF3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American College of Rheumatology (ACR) 2013 (James Bluett 2nd entry)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>55254961-1843-42D6-BF10-315AD266146D</gtr:id><gtr:impact>James Bluett presented a poster, 'Investigating a novel locus for psoriatic arthritis' at an international conference.

None Yet</gtr:impact><gtr:outcomeId>54526b3df2e269.97447753</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Junior caf? Sci, Withington Girls School (Sarah Skeoch)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>ADE2A55E-E844-437E-8389-6F77AE38E63F</gtr:id><gtr:impact>Sarah Skeoch gave a brief talk then an extended question and answer session to a group of secondary school children about a career in medical research at their junior caf&amp;eacute; Sci meeting.

Positive feedback was given by both teachers and pupils</gtr:impact><gtr:outcomeId>53ad6cf46a9192.07744611</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>North of England Dermatology Society Meeting (Amy Foulkes)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B5A0D2F1-DFD5-4D97-B0E9-BE79BC2DC568</gtr:id><gtr:impact>North of England Dermatological Society March 2012 Poster presentation

None</gtr:impact><gtr:outcomeId>SkMcypqzL4W</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Congress of Clinical Microbiology and Infectious Diseases, 2012, London, UK (Tim Felton)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>364950C5-EE47-42CB-AB19-A05990938960</gtr:id><gtr:impact>Tim Felton was present at the posters during poster rounds.

http://www.congrex.ch/eccmid2012/home.html

Felton TW, Roberts S, Brennan S, Philips A, Whiteside A, Doran H, Leonard C, Al-Aloul M, Isalska B, Yonan N, Hope WW. Isolation of Aspergillus species from the respiratory tract of lung transplant recipients is associated with increased mortality. ECCMID. London 2012. - POSTER PRESENTATION

Tim took part in discussion with many delagates about the topic.</gtr:impact><gtr:outcomeId>pjJQCvDH9dC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academy of Medical Sciences 2014 (Vincent Yip)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D23F570B-12E5-4622-9B97-AB8DD62E194F</gtr:id><gtr:impact>Vincent Yip gave a poster presentation of his MRC research work

Discussion with fellow clinical academics about research and training.</gtr:impact><gtr:outcomeId>53ac2e2de39876.60335229</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Society of Paediatric Nephrology Meeting 2015 (James McCaffrey)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0D45EF5F-BCE8-43EA-A6D1-468352950F7C</gtr:id><gtr:impact>Oral presentation at a scientific meeting. Main attendees were paediatric nephrologists from across Europe.

None yet</gtr:impact><gtr:outcomeId>5666adc8a87e87.85116041</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BPS Winter Meeting Dec 2015 (Vincent Yip)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FC6A30D5-1D13-42C7-85EE-FF6E389918E0</gtr:id><gtr:impact>Poster presentation of latest findings from PhD research</gtr:impact><gtr:outcomeId>56a0c411af0573.22377813</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meet the Scientists faculty public engagement event (2016) (Richard Myles Turner)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7EEC65D4-BB4D-4201-85B1-F844A899282E</gtr:id><gtr:impact>I was involved in a 'meet the scientists' public engagement day hosted by the faculty. Specifically, I was involved in the design and running of a stand that provided interactive games to help understand clinical trial methodology, the placebo-effect, and randomization.

This activity helped educate members of the public about clinical trials, the efficacy and safety of therapeutics, the potential of personalised medicine, and the associated ongoing research being conducted at the University of Liverpool.</gtr:impact><gtr:outcomeId>58a3298ce66085.66820409</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.liverpool.ac.uk/health-and-life-sciences/meet-the-scientists/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American Society of Nephrology Meeting (Atlanta)2013 (James McCaffrey)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>69A90308-5B45-4850-BAFE-6B0F8CA6C8EE</gtr:id><gtr:impact>International scientific meeting involveing discussion of James McCaffrey's poster with interested participants.

None yet.</gtr:impact><gtr:outcomeId>MZKfg8NikLp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Grrl (Sarah Skeoch)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C32C5FAE-2DA6-42DE-9958-8796AA743129</gtr:id><gtr:impact>A calendar was produced which portrays real female scientists carrying out work. One of the months was based on Sarah Skeoch's current research study and the calendars are on sale at various science museums around the country. Sarah Skeoch featured in the picture and attend a press launch to promote the calendar and cause and has on-going meetings with other members to discuss further fund raising and public engagement activities.

On-going promotion of STEM subjects to girls and young women.</gtr:impact><gtr:outcomeId>DqBBiwqdS5Q</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Life Sciences Careers Conference (Royal Society of Biology)  (Oct 2015) (Vincent Yip)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3B454769-92C2-4F36-AA5F-FC46263933B2</gtr:id><gtr:impact>Provide undergraduates with advice regarding careers choices and life as a clinical academic</gtr:impact><gtr:outcomeId>56a0c535219749.63121246</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:url>http://lscc.rsb.org.uk/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lupus Open Evening (as part of Lupus Awareness Month 2013) (John Reynolds)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B031F3EF-C2AA-470B-9D67-8993BD3ACDA5</gtr:id><gtr:impact>Patients and their family members attended the open evening to learn about current lupus research. John Reynolds presented the results of my research.

None yet</gtr:impact><gtr:outcomeId>53a2bdde49bf74.01620777</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Donders Neuroscience Discussion (Oct 2013) (Vincent Yip)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8FA580BF-0704-4D28-87D4-F99DC1D9183C</gtr:id><gtr:impact>Vincent Yip presented an overview of pharmacogenetics in neurology and his own MRC funded research project to other PhD students from a variety of neuroscience, neuropsychiatry and international backgrounds.

Non yet.</gtr:impact><gtr:outcomeId>oJJbVU2JcsJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.ru.nl/dondersdiscussions/about/about_the_donders/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>2nd Inflammation in Epilepsy Meeting on immunity and inflammation (Lauren Walker)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3FC5089B-2149-4F73-9D6C-4300BDFBA74C</gtr:id><gtr:impact>Lauren Walker was invited to give a platform presentation in a forum on biomarkers in epilepsy - Novel predictive biomarkers of epileptogenesis and therapy response: bedside to bench-and back.</gtr:impact><gtr:outcomeId>58ad82bedcfd04.19491314</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Participant Feedback day (Sarah Skeoch)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CF13721B-AA17-46FA-897E-18BFCDCAB988</gtr:id><gtr:impact>Sarah Skeoch arranged a feedback day for patricipants and staff who had taken part in the research study she had conducted during my PhD fellowship. She gave a presentation and then undertook and question and answer session

Feedback from participant perspective for future studies</gtr:impact><gtr:outcomeId>566847dfd9b256.21034355</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society For Rheumatology Annual Conference (Meghna Jani)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4E18A3BE-2A77-41E3-80FB-D615E2B22C38</gtr:id><gtr:impact>Poster presentation of research to scientific audience/Healthcare professionals.

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines</gtr:impact><gtr:outcomeId>53aadcd6455732.44060524</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuro-Infections Charities Network presentation (Sam Nightingale)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>12F5403C-B878-4A17-B3BF-A95D02418F05</gtr:id><gtr:impact>80 multidisciplinary professionals who work with people who have neurological infection and patients who have recovered from such infections that now offer help and support to sufferers.

none</gtr:impact><gtr:outcomeId>C5fopm6wySt</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2015. (Poster presentation, international meeting).</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>74153C8E-A286-4EAD-9F6B-F574B54786C7</gtr:id><gtr:impact>Poster Presentation: Model-based Prediction of Piperacillin Concentrations in Critically Ill Patients: A Comparison of Nine Approaches Against Clinical Data. (Farkas A, Gujadhur N, Yasin B, Felton TW, Roberts J)</gtr:impact><gtr:outcomeId>56a0c1d021eea6.65535618</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American College of Rheumatism Annual Conference (Sarah Skeoch)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4A88AFD0-408A-4244-B710-2A7ACB10F0E9</gtr:id><gtr:impact>Imaging atherosclerotic plaque inflammation in RA: methodology an initial findings in a single centre cohort
S Skeoch, P. Hubbard, H. Williams, D. Xu, S. Jie, N. Balu, W. Zhang, J. James, T. Hatsukami, C. Yuan, Y. Alexander, P.Hockings, J. Waterton, I. Bruce
Presented at the American College of Rheumatism Annual Conference, San Diego, 2013

None yet.</gtr:impact><gtr:outcomeId>Z4RXH8HwFLi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The 21st International Reid Bioanalytical Forum (2015) Dried blood spot assay development poster presentation (Richard Myles Turner)   (Richard Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1C464862-1796-4EB3-8BAF-8DF01BF4C6CA</gtr:id><gtr:impact>Richard Turner was involved in the assay development and data acquisition that was presented at this international conference by Dr Mark Bayliss within a poster entitled, 'Dried-blood spotting combined with fused core HPLC-MS/MS for the measurement of atorvastatin, simvastatin and rosuvastatin in support of PK studies in the mouse'. Authors listed are: Bayliss M, Turner R, Kitteringham N, French N, Park K, Pirmohamed M. The presentation sparked further talk regarding micro-sampling techniques, and we were informed about a potential new card material that should overcome the haematocrit limitation of current dried blood spot technologies. This activity provided publicity for our ongoing work</gtr:impact><gtr:outcomeId>56a88e42d3c665.46767292</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.bmss.org.uk/Docs/BioForum%202015%20second%20circular%20FInal2-1.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> CAP-UK Presentation (Sam Nightingale)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>10279287-3523-4941-B113-06A4EB46C8F7</gtr:id><gtr:impact>30 people from CAP-UK (a group of HIV patients who form a network of treatement advocates) attended to hear Dr Nightingale give a presentation of his research.

Dr Nightingale has been asked to train a patient representative for HIV for the Encephalitis Society.</gtr:impact><gtr:outcomeId>CdXuJC6EVGZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Cystic Fibrosis Society Conference - Poster Presentation (2014) (Stephen McWilliam)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1858D7C1-E60F-412E-A22A-AE57ABBB5089</gtr:id><gtr:impact>Poster and oral presentation at European Cystic Fibrosis Society Conference entitled 'Association of Urinary Kidney Injury Molecule-1 with Aminoglycoside Exposure in Children with Cystic Fibrosis'.

None yet</gtr:impact><gtr:outcomeId>53b6aa3e508153.47486197</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Manchester Science Spectacular 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F014D565-3B8B-4A55-B1BE-932064DDAFC2</gtr:id><gtr:impact>The Manchester Science Spectacular runs annually and is an opportunity for scientists to showcase their research work to an audience of children and families. The event is attended by approximately 1,500 people.

Interactive table top activity aimed at families and children to teach about medicine and where it comes from as well as personalised health. Several MRC Fellows took part in the event. Approximately 100 children took part in this activity.


This is the fourth year MRC Fellows have taken part in this event and the stand Marvellous Medicine has become a regular acticity stand at this event.</gtr:impact><gtr:outcomeId>5672b8917074e6.89842394</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society for Rheumatology Conference Birmingham April 2013 (John Reynolds)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EBB6BBE5-26A9-48A1-8524-5B4756C89687</gtr:id><gtr:impact>Poster Presentation of Research</gtr:impact><gtr:outcomeId>E9PwDiVx6qp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>North West Clinical Academic Training Annual Meeting Oct 2012 (Amy Foulkes)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AADE60D5-77DF-40E3-A0E6-5A08279FC04F</gtr:id><gtr:impact>North West Clinical Academic Training Annual Meeting Oct 2012 Talk on early research collaboration with industry

None</gtr:impact><gtr:outcomeId>GJq42y9bwV7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Primary School Event, St. Mary's CE Primary School, Reddish, Stockport (James McCaffrey)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E39A9177-6A37-4C58-A3DD-9154389A60E3</gtr:id><gtr:impact>James McCaffrey explained what the kidney does to primary school children

Increased enthusiasm for science and physiology among school children</gtr:impact><gtr:outcomeId>53a2c6d06036d9.17045041</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society for Rheumatology Conference Glasgow April 2016 (John Reynolds)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>23371C07-D6BE-488F-A3B9-75AB19B00A63</gtr:id><gtr:impact>Poster Presentation of Research</gtr:impact><gtr:outcomeId>58ac6bee8ba091.57890323</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Society for Antimicrobial Pharmacology, 2012, San Francisco, USA (Tim Felton)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>809EB1C9-762A-4906-AE0A-27583934050B</gtr:id><gtr:impact>Tim Felton gave a presentation to a large auditorium of doctors/scientist with an interest in this area.

http://www.isap.org/

Felton TW, Livermore J, Goodwin J, Sharp A, Gregson L, , Howard S, Warn P, Hope WW. Impact Of Intermittent Dosing Of Micafungin In Neutropenic And Non-Neutropenic Patients Using A Translation Pharmacology Approach. International Society for Antimicrobial Pharmacology. San Francisco 2012 -SPOKEN PRESENTATION

Interesting discussion after the presentation and after the session which has led to potential collaborations.</gtr:impact><gtr:outcomeId>G9B9PpvgAV8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GMANN Winter Symposium 2014 (James McCaffrey)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4D76EBF1-8351-4AC9-90E3-4F900CDD150B</gtr:id><gtr:impact>Oral presentation at scientific meeting regarding my research on this Fellowship. Main attendees were nephrologists from the North West. Triggered discussion about best ways to develop targeted therapeutics for treatment of proteinuric disease.

None yet</gtr:impact><gtr:outcomeId>5666ab9b3a5563.52737736</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://s3.extravision.com/gmann/news-and-events/2014/101214-agenda.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Immunogenicity Platform, Lisbon Feb 2014 (Meghna Jani)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B485E71C-C605-4A9E-BD96-9F48B3C8C249</gtr:id><gtr:impact>Oral- Invited speaker - The effect of DMARDs on immunogenicity of anti-TNF agents

New research contacts, publicity of work</gtr:impact><gtr:outcomeId>53aada5c0e8052.62287569</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science to go- series for the Manchester Fellowship Academy (Meghna Jani)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1836C8CE-BE7F-48DA-9275-CA6515FDA176</gtr:id><gtr:impact>Meghna Jani filmed a video regarding clinical research plans and gaining external funding

To inspire younger students on the variety of research and opportunities available with the University of Manchester</gtr:impact><gtr:outcomeId>Rv8kV1j5VKA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EACPT Summer School (July 2013) (Vincent Yip)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3C884F9F-2A20-4520-94DF-18CFFF7B23AC</gtr:id><gtr:impact>Vincent Yip gave a poster presentation of his MRC research work

Discussion with fellow clinical academics about research and training.</gtr:impact><gtr:outcomeId>H4gE2NQctTg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver 2013. (Poster presentation) (Tim Felton)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F9BEB315-3B2B-4477-BEA7-6C408C074160</gtr:id><gtr:impact>Felton TW, Roberts JA, Lodise TP, Boselli E, Van Guilder M, Neely M, Hope WW. Software for Dosage Individualisation of Piperacillin/Tazobactam for critically ill patients. Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver 2013. (Poster presentation, international meeting).</gtr:impact><gtr:outcomeId>Wqu2rzDTZDn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lupus 2013: International Congress on Systemic Lupus Erythematosus: Argentina 2013 (John Reynolds)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4EAB2452-095B-4528-8418-C742250EE343</gtr:id><gtr:impact>Presentation on John Reynolds' research in an oral abstract session

This has resulted in early discussions of collaboration between the University of Manchester and a research group in the US.</gtr:impact><gtr:outcomeId>VDjb1z6Rwxx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Meet the Scientists', Liverpool World Museum, January 2016 (Richard Turner/Programme Coordinator)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C6915BED-2542-4C43-BF8F-2AF88CA6D4BA</gtr:id><gtr:impact>A group of approx 20 PhD Students and Postdoc researchers from the Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine, including Richard Turner from the Fellowship Scheme took part in this large public engagement activity which was a callobration between the Faculty of Health and Life Science at the University of Liverpool and the Liverpool World Museum in the city centre. They hosted five activity stand exploring the development of evidence based medicine and new innovations in genetics, big data and bioinformatics that will contribute to the development of personalised medicine. This was done through a series of simple table top activities aimed at children which provided students and postdocs with the opportunity to talk to adults about personalised medicine, clinical trials, drug safety as well as talking about their own research. The vent was very popular with over 500 people visiting the five stands that were under the banner 'Marvellous Medicine'. Angela Foxcroft, the Fellowship Programme Coordinator and Kerrie McGiveron, the CDSS Research Administrator played a key role in organising this event. Richard Turner (MRC Fellow) developed the activity explaining 'Clinical Trials' and ran the stand for the whole day.</gtr:impact><gtr:outcomeId>56a88d1f12b884.39018236</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.liverpool.ac.uk/health-and-life-sciences/meet-the-scientists/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Rheumatology  2015: British Society of Rheumatology Conference  : Manchester 2015 (John Reynolds)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1A2951CB-4F49-4F8A-BF18-F3B628226F3E</gtr:id><gtr:impact>Presentation on John Reynolds' research in an oral abstract session

None yet</gtr:impact><gtr:outcomeId>5666b1763ede98.98574661</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NWE MRC Annual Showcase 2012 (All MRC CPT Research Fellows)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>27CA816A-951D-4C1A-8BA1-304A71FF84F6</gtr:id><gtr:impact>11 Clinical Research Fellows presented their ongoing MRC Research to an audience of approximately 50 academic and industry peers in Liverpool. Presentations were also made by Prof. Peter Clayton, University of Manchester and Dr Chris Chamberlain, Astra Zeneca.

An opportunity for MRC Research Fellows to network and learn more about developing research careers.</gtr:impact><gtr:outcomeId>BftA2fsmtkm</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Psoriasis and Psoriatc Arthritis Alliance Patient information leaflet Clinical trials (Amy Foulkes)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5968EC9A-0BD4-4237-A461-26C030361495</gtr:id><gtr:impact>None yet

Patient information leaflet about clinical trials, freely available online</gtr:impact><gtr:outcomeId>k2kRaPjTE85</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.papaa.org/references/clinical-trials-overview</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Manchester Science Spectacular 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>32B18974-2294-4228-87ED-80A9DD181217</gtr:id><gtr:impact>The North West England Fellowship Scheme hosted a stand at the Manchester Science Spectacular called 'Marvellouse Medicine', which introudcued children and their families to drugs and where they come from and to the idea of personalised medicine.

Approximately 80 children took part in the activities and the group received spontaneous positive feedback from several parents.</gtr:impact><gtr:outcomeId>545b96ed55c7c3.40639320</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Expert Opinion on BBC Radio Warwickshire Radio Breakfast show</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D93254DE-992E-41E0-8A93-7B2F64F5A55B</gtr:id><gtr:impact>University Press office was approached by the BBC seeking an expert opinion on the dangers of buying prescription medication via the internet (Namely Roacutane). Vincent Yip was appraoched as a dermato-pharmacologist and agreed to take part in a telephone interview to explain the danger of buying and using this drug with correct medical supervision.

Raised publi awareness regarding the dangers of obtaining prescription only medications through the internet.</gtr:impact><gtr:outcomeId>56606c63add0c0.31614110</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory attachment by an undergraduate student (July 2013) (Ricahrd Kia)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>32E296A6-9E98-4E7F-B124-74454DD6A322</gtr:id><gtr:impact>Ricahrd Kia supervised an undergraduate pharmacology student who obtained a British Pharmacology Society Summer Studentship for his attachment to the MRC CDSS. He was exposed to our research focus of assessing the utility of human-derived stem cells as a tool for drug screening.

None yet</gtr:impact><gtr:outcomeId>pp8KDbuBEAi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pan-Manchester Academic Nephrology Meeting 2012 (James McCaffrey)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1BA5B908-2E48-4CE5-A563-FD4039B94E67</gtr:id><gtr:impact>Oral presentation at a scientific meeting. Selection of clinicians and scientists from Manchester area who are involved in renal medicine. 20 minute talk, 5 mins questions.

None yet.</gtr:impact><gtr:outcomeId>SWPH8DV9467</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Thoracic Society Winter Meeting 2015 (Tim Felton)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2634A408-381F-4046-910D-8C04C1FCC808</gtr:id><gtr:impact>Poster presentation: Clinical effectiveness of non-invasive ventilation in patients with Motor Neuron Disease (Freeman D, Jothieswaran A, Mascareno M, Chaudhry N, Bokhari S, Felton TW, Bentley AM. )</gtr:impact><gtr:outcomeId>56a0bc0bee3075.33650452</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BPS Winter Meeting - 2017 (Vincent Yip)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>956F9568-E6DA-45AA-B44C-A72B4552D8A4</gtr:id><gtr:impact>Oral Presentation of latest findings from PhD research</gtr:impact><gtr:outcomeId>58ac7163de5071.52770192</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American College of Rheumatology (ACR) 2013 (James Bluett 1st entry)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>21BFEBAB-F066-4802-9EBF-F80C6AFE6C10</gtr:id><gtr:impact>James Bluett presented a poster entitled 'Impact of inadequate adherence on clinical outcomes: Results from the biologics in rheumatoid arthritis genetics and genomics study syndicate cohort'

None Yet</gtr:impact><gtr:outcomeId>53a1ae7a234275.02709457</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Pharmacogenomics in cardiovascular medicine,' given as a core component of the Genomics England Master's in Genomic Medicine course (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EECB8419-B0BB-4B91-BB6A-D965F45B4161</gtr:id><gtr:impact>This was a teaching lecture given to students (post-graduates and healthcare professionals) taking the Genomics England MSc MDSC214 course. The lecture sparked further questions, discussion, and positive feedback. The talk provided publicity for the department's on-going work.</gtr:impact><gtr:outcomeId>58be86c9e374b9.99723727</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>https://www.genomicseducation.hee.nhs.uk/taught-courses/courses/masters-in-genomic-medicine/</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Nephrotic Syndrome patient information day (James McCaffrey)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5D106232-A1DC-44D4-80DC-84904DF212BD</gtr:id><gtr:impact>Talk improved understanding of Nephrotic syndrome among sufferers.</gtr:impact><gtr:outcomeId>582b39d5d77b57.77154404</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://research.cmft.nhs.uk/news-events/manchester-event-for-patients-with-nephrotic-syndrome-and-their-families</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal College of Physicians Careers Fayre London October 2013 (Lauren Walker)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0DE68178-F2D5-43DA-AB4F-45B8C472EFDC</gtr:id><gtr:impact>Supported by the BPS, Lauren Walker attended the careers fayre at the Royal College of physicians in order to promote Clinical Pharmacology and careers in academic medicine. Approximately 500 people attended the all-day event.

Lauren Walker spoke to many medical students about fellowships and career pathways in academic medicine.</gtr:impact><gtr:outcomeId>UuokTYFL3zM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Welsh Sixth Form Conference 2014 'Discovering Genomics' (Dan Hawcutt and Vincent Yip)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>688AA5C9-AC17-42AD-934B-BC31AC7154F7</gtr:id><gtr:impact>A presentation delivered to sixth form students entitled 'Pharmacogenomics: Personalising Medicine' was delivered to an audience of Sixth From students and the Wales Gene Park sixth form conference. The presentation sparked questions and discussion from the students.

Further invitations to take part in this kind of event.</gtr:impact><gtr:outcomeId>547de74c939155.11076130</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.walesgenepark.cardiff.ac.uk/2014/10/15/sixth-form-conferences-2014/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AMS/MRS/RCP Meeting for Clinician Scientists in Training. London. March 2014 (John Reynolds)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6B3BE5BC-A34E-4B38-B9C8-DC4E361EECCF</gtr:id><gtr:impact>Poster Presentation of Research</gtr:impact><gtr:outcomeId>53a2bb10e17bb2.97202512</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2008,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Pharmacological Society Conference - Poster Presentation (2013) (Stephen McWilliam)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0FFF7DCF-918D-4494-AC46-8A6252FF0CF4</gtr:id><gtr:impact>Poster presentation at British Pharmacological Society Conference entitled 'Reference Intervals For Urinary Kidney Injury Molecule-1 And Neutrophil Gelatinase-Associated Lipocalin In Children'.

None yet</gtr:impact><gtr:outcomeId>53b6aab3ae9d61.51517686</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) - 2nd poster (Tim Felton)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>263ABC6A-7C48-4B96-AD21-FD1910DADC31</gtr:id><gtr:impact>Tim Felton presented a poster sharing his group's research work:
Box H, , Gregson L, Livermore JL, Felton TW, Whalley S, Goodwin J, McEntee L, Johnson A, Hope WW. Pharmacodynamics (PD) of Isavuconazole (ISA) For Invasive Pulmonary Aspergillosis (IPA). Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington 2014. (Poster presentation, international meeting).

Tim Felton met with conference delegates in the presentation of the poster:
Box H, , Gregson L, Livermore JL, Felton TW, Whalley S, Goodwin J, McEntee L, Johnson A, Hope WW. Pharmacodynamics (PD) of Isavuconazole (ISA) For Invasive Pulmonary Aspergillosis (IPA). Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington 2014. (Poster presentation, international meeting).</gtr:impact><gtr:outcomeId>5447788591da97.63051807</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Association for Science Education</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A42D6978-9A2E-4AF8-9261-47237807106C</gtr:id><gtr:impact>30 science teachers attended to hear of latest developments in personalised medicine

asked to go and present in shools</gtr:impact><gtr:outcomeId>PZqHaGYqvZH</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BPS The Future of Drugs Event at the Dana Centre at the Science Museum in London (Vincent Yip)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F9A03F3B-162E-448E-BE30-E522A3EF6DFA</gtr:id><gtr:impact>Presentation to the public about personalised medicines: past, present and future. Part of biology week and organised by the British Pharmacological Society

None yet</gtr:impact><gtr:outcomeId>5452670485dca9.36661811</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academic poster entitled, 'The impact of P450 oxidoreductase knock out on systemic exposure to rosuvastatin, atorvastatin and atorvastatin metabolites,' presented at the British Pharmacological Society 2016 Meeting (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F666812D-D9A4-4550-A24D-7AAA6C689DB8</gtr:id><gtr:impact>A poster presentation I presented at the British Pharmacological Society 2016 annual international meeting. The poster sparked conversations about the research presented. The talk provided publicity for my on-going research.</gtr:impact><gtr:outcomeId>58be87780b1c90.47947292</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>https://www.bps.ac.uk/pharmacology2016#Overview</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lupus UK North West AGM  (John Reynolds)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>87803E7B-F444-4393-886D-CD15F4A56004</gtr:id><gtr:impact>Patients and their family members attended regional AGM. 3 external speakers were invited to present clinical talks or their research. I presented results from the research undertaken as part of the MRC scheme.</gtr:impact><gtr:outcomeId>58ac6c97cdb095.17555650</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interactive school assembly presentation (Stephen McWilliam)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B6197708-2213-4F85-B1A8-5368A9D4F9AC</gtr:id><gtr:impact>The activity formed part of school's participation in a research study. - Around 200 children attended the assembly (in two groups). The children participated in the assembly by answering questions and voting. A large number of children asked questions at the end of the assembly.

No formal assessment of impact. Lot's of children (and parents) agreed to be healthy volunteers for study and provided urine samples.</gtr:impact><gtr:outcomeId>e4ur9gT7K11</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A Clinical Pharmacology lecture for junior doctors in the Mersey region undertaking the membership of the Royal Colleges of Physicians (MRCP) examinations (2015) (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BA676B18-0514-437C-94FD-E1C524E5F81B</gtr:id><gtr:impact>I gave a clinical pharmacology revision lecture to junior doctors from the Mersey region to help them prepare for their MRCP examinations. The talk sparked discussion and questions.

This activity helped educate junior doctors about clinical pharmacology and provided a platform to elevate the profile of Clinical Pharmacology &amp;amp; Therapeutics as an attractive and important medical specialty.</gtr:impact><gtr:outcomeId>58a32aa1ce0204.20934809</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Paediatric Clinical Pharmacology Workshop Presentation (2013) (Stephen McWilliam)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A9E2C60C-A5F2-480D-A366-AA80CB5F098C</gtr:id><gtr:impact>This event took place at the Royal Derby Hospital, and was organised by Professor Imti Choonara who is a Paediatric Clinical Pharmacologist. There were probably around 30 people there.

Non yet</gtr:impact><gtr:outcomeId>g4tHvFg5277</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2015 (invitied speaker) (Tim Felton)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>26F2414E-8237-4399-99CF-E6110C69AB82</gtr:id><gtr:impact>Tim Felton, Invited Speaker to conference. Gave a presentation entitled, &amp;quot;Clinical Pharmacokinetics/Pharmacodynamics (PK/PD) of the Lung&amp;quot;</gtr:impact><gtr:outcomeId>56a0be6c6187d3.06347140</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academy of Medical Sciences meeting, Feb 2015 (Meghna Jani)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FDCD69C5-F13F-4C02-8706-967CF18A1FD2</gtr:id><gtr:impact>Poster presentation sparked discussion

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines</gtr:impact><gtr:outcomeId>5666d1f8b0ea88.96100477</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>paper presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research mobility and drug discovery workshop attendance (2015) (Richard Myles Turner)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9AC4E5D6-5F63-4582-AB5E-64B469ABAEBE</gtr:id><gtr:impact>The Researcher mobility in drug discovery two-day workshop flagship event of the Royal Society of Chemistry, co-organised by the British Pharmacological Society and the Biochemical Society. 
Richard Turner attended this two-day residential workshop brought together researchers from across the life sciences spectrum (clinical, chemistry, biology) and from both academic and industry backgrounds, and aimed to helped engender a stronger desire for closer working ties and collaboration between disciplines and sectors, in order to improve productivity.
Richard has joined a LinkedIn forum made up of delegates at this workshop, and I hope that this will prove a useful resource for future collaborative research initiatives.</gtr:impact><gtr:outcomeId>56a89b9ac6e151.24810612</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.bps.ac.uk/news-events/future-scientific-meetings/2015/researcher-mobility-in-drug-discovery#</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HMGB1 World Congress, October 2013 New York City Feinstein Institute (Lauren Walker)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>012D545C-4776-4586-8D5B-D7693547500F</gtr:id><gtr:impact>Lauren Walker submitted an abstract (For publication in Mol Med journal) and gave a poster presentation on research results to date. Also named as a co-author and collaborator in the platform presentation of results on the development of a Meso Scale Discovery assay for detection of HMGB1.

None Yet</gtr:impact><gtr:outcomeId>SD9LFqB6uH3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society for Rheumatology Conference Glasgow April 2012 (John Reynolds)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>46F2A54B-A6A1-4AE5-A52B-154D5F0039AD</gtr:id><gtr:impact>Poster Presentation of Research</gtr:impact><gtr:outcomeId>jFSpw5B9e7B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver 2013. (Tim Felton)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>78DD7E40-B377-47EA-B861-A02E7C918BDA</gtr:id><gtr:impact>Presentation to a large auditorium of doctors/scientist with an interest in this area. Felton TW. Continuous infusions of Beta-Lactams. Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver 2013. (Invited speaker)

Interesting discussion after the presentation and after the session which has led to potential collaborations.</gtr:impact><gtr:outcomeId>jEQ26Q6m35K</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.icaac.org/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Celebrations (Vincent Yip)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>022D3C92-FC3B-4A94-8970-A2AB5FC64470</gtr:id><gtr:impact>Vincent Yip gave a 20 minute presentation about personalised medicines. How personalised medicines are used today, their benefits and how they will be incorporated into future healthcare. Brief overview of MRC CPT fellowship.

The activity was very popular with members of the local council, prospective students and the general public attending. Stimulating discussion during coffee with members of the audience.</gtr:impact><gtr:outcomeId>Crjr2WgEm56</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Statin-induced muscle toxicity: evaluating the functional effects of variability in P450 oxidoreductase (2015) (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B7C5CC4C-54A2-4B1D-A768-1C0F42E58B1F</gtr:id><gtr:impact>I gave an oral presentation at the University of Liverpool Institute of Translational Medicine Research Day covering my PhD fellowship project rationale and results to date (2015). This led to interesting and productive conversations.

This activity provided publicity for both my project and the MRC fellowship scheme that I am currently enrolled on.</gtr:impact><gtr:outcomeId>58a32723520433.76288479</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK Health Tech Conference (2015) (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9A573DD5-3DB4-458F-A604-7580F94BC174</gtr:id><gtr:impact>Richard Turner gave an oral presentation entitled, 'Developing and implementing genetic tests for personalised medicine' covering implementation of pharmacogenetic tests for personalised medicine, at the UK Health Tech Conference (2015). This led to interesting and productive conversations. This activity provided publicity for both work already undertaken by the Wolfson Centre for Personalised Medicine (University of Liverpool) and for pharmacogenetics implementation projects and initiatives that Liverpool is currently undertaking.</gtr:impact><gtr:outcomeId>56a8949502ccd8.24443094</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ukhealthtech.com/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lupus Open Evening (as part of Lupus Awareness Month) (John Reynolds)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>25FBAE2F-42B6-49CF-AB27-7C05AEC73D15</gtr:id><gtr:impact>Around 60 patients and their family members attended the open evening to learn about current lupus research. There was a discussion afterwards in which many attendees participated. The event received excellent feedback

This resulted in a number of patients contacting their physician or myself asking to take part in the research project.</gtr:impact><gtr:outcomeId>PYvitgZnrch</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NWE MRC Fellowship Annual Showcase 2011 (All MRC CPT Research Fellows)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>74CD1483-2129-4DA9-94B9-E1F9631FDE43</gtr:id><gtr:impact>8 MRC Clinical research Fellows presented their research to an audience of approx 50 academic and industry peers alongside a number of external speakers (Prof Martin Wilkins, UCL and Prof Caroline Savage, Head of Discovery Medicine at GSK) in Liverpool.

An opportunity for Clinical Research Fellows on the North West England Scheme in Clinical Pharmacology and Therapeutics to network.</gtr:impact><gtr:outcomeId>Xgf572XU4NQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interscience Conference on Antimicrobial Agents and Chemotherapy, 2012, San Francisco, USA (Tim Felton)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>21514DC4-5E78-47D0-AAD4-3EAD08F6DC9C</gtr:id><gtr:impact>Presentation to a large auditorium of doctors/scientist with an interest in this area. 

http://www.icaac.org/ 

?Felton TW, O'Connor L, Goodwin J, Sharp A, Gregson L, Livermore J, Howard S, Hope WW. Impact of Administration of Piperacillin-Tazobactam by Extended Infusion on Emergence of Resistance in an In Vitro Hollow Fiber Infection Model (HFIM). ICAAC. San Francisco 2012. - SPOKEN PRESENTATION

?Livermore JL, Sharp A, Walker C, Moser W, Gregson L, Goodwin J, Felton TW, Howard SJ, Mueller W, Perfect J, Hope WW. The Antifungal Activity of an Abbreviated Regimen of Amphotericin B Deoxycholate (DAmB) For Cryptococcal Meningitis is Due to Persistence of Drug in the Brain Rather Than T-Cell Recruitment. ICAAC. San Francisco 2012. - POSTER PRESENTATION

?O'Connor L, Livermore J, Sharp A, Goodwin J, Felton TW, Howard SJ, Hope WW. Pharmacokinetics (PK) and Pharmacodynamics (PD) of Liposomal Amphotericin B (LAmB) and Flucytosine (5FC) against Cryptococcus neoformans in a Murine Model of Cryptococcal Meningitis. ICAAC. San Francisco 2012. - POSTER PRESENTATION

?Sudan A, Livermore J, Howard S, Al-Nakeeb Z, Sharp A, Goodwin J, Gregson L, Wilkinson T, Warn PA, Felton TW, Hope WW. Pharmacokinetics and Pharmacodynamics of Fluconazole in a Murine Model of Cryptococcal Meningitis With Bridging to Humans: High Dosages are Required for Near-Maximal Antifungal Activity. ICAAC. San Francisco 2012. - POSTER PRESENTATION

?Livermore J, O'Connor L, Sharp A, Gregson L, Goodwin J, Warn PA, Felton TW, Schwartz JA, Howard SJ, Hope WW. Pharmacokinetics and Pharmacodynamics of Liposomal Amphotericin B (LAmB) for Cryptococcal Meningitis: A Single High Dose of Liposomal Amphotericin B is as Efficacious as Daily Dosing Regimens. ICAAC. San Francisco 2012. - POSTER PRESENTATION


Interesting discussion after the presentation and after the session which has led to potential collaborations.</gtr:impact><gtr:outcomeId>jUzWPZGajbV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A pharmacology lecture for physicians undertaking the membership of the Royal Colleges of Physicians (MRCP) Part I examination given on behalf of the Royal College of Physicians (2016) (Richard Myles Turner)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B2A78CAD-B987-44B8-AC12-1D35F1FD4822</gtr:id><gtr:impact>On behalf of the Royal College of Physicians, I gave a lecture covering basic and clinical pharmacology to junior doctors to help them prepare for their MRCP Part I written examination. The talk sparked significant engagement, discussion, questions, and I believe increased their understanding of pharmacology (2016).

This activity helped educate junior doctors in pharmacology and raised awareness of the specialty of Clinical Pharmacology &amp;amp; Therapeutics.</gtr:impact><gtr:outcomeId>58a32bc2cc9f01.95606027</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.rcplondon.ac.uk/events/mrcp-uk-part-1-refresher-workshop</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academy of Medical Sciences/ Royal College of Physicians - Clinician Scientists in Training Meeting (Meghna Jani)</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D53CB54A-538D-4570-A321-31DED3CD9567</gtr:id><gtr:impact>Poster presentation of research to scientific audience/Healthcare professionals.

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines</gtr:impact><gtr:outcomeId>53aadd37a12765.41943847</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School careers presentation (Stephen McWilliam)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>61917D2F-941A-40A9-90C5-C553A46254A4</gtr:id><gtr:impact>Around 100 Year 12 students attended the presentation They participated by answering questions. A number asked questions at the end of the presentation.

No formal assessment of impact</gtr:impact><gtr:outcomeId>G9jJbbW7xb5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory attachment by A Level students (July 2013) (Richard Kia)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>958CB642-25F6-4F46-B9DA-7ED557AB1283</gtr:id><gtr:impact>Ricahrd Kia supervised an A Level student who was thinking of a career in science in general and also the possibility of doing research during/after her undergraduate degree. She was exposed to what research involves and also discussed about the rigours of careers in medicine and clinical pharmacology.

None yet</gtr:impact><gtr:outcomeId>ZRxbpUMr8wC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1200</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EULAR travel bursary (2) (Meghna Jani)</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>The European League Against Rheumatism (EULAR)</gtr:fundingOrg><gtr:id>9C9AA564-EFE8-4FEA-9A69-76E451505A3F</gtr:id><gtr:outcomeId>53aae577415fc5.56570754</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>258075</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PROteKT study grant award (Stephen McWilliam)</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>J P Moulton Charitable Foundation</gtr:fundingOrg><gtr:id>3477709F-1EC6-4F7E-B074-B38248712752</gtr:id><gtr:outcomeId>53b6ae7284a0f7.83453524</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>427611</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Invention for Innovation (Tim Felton)</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>CA4DE724-E7B1-46B0-866B-DAA425617044</gtr:id><gtr:outcomeId>5441367603fbf5.42941273</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Conference attendance award - International Investigative Dermatology Meeting Edinburgh 2013 (Amy Foulkes)</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>AbbVie</gtr:fundingOrg><gtr:id>90832F4C-2C4E-46EE-8E18-3C175BC4A00A</gtr:id><gtr:outcomeId>cqcWy8FD9v7</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>52940</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proximity to Discovery award - in kind contribution (Amy Foulkes)</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>FD3D882B-4372-4B6C-A2E7-BFA04FB9EB52</gtr:id><gtr:outcomeId>58bfd658865eb3.43234954</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Trainee of the Year Third Prize (Amy Foulkes)</gtr:description><gtr:fundingOrg>Royal Society of Medicine</gtr:fundingOrg><gtr:id>EF1192FC-DFBF-4D8D-B850-7D22C00F90AD</gtr:id><gtr:outcomeId>58bfd0876c3f18.53128637</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EULAR travel bursary (Meghna Jani)</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>The European League Against Rheumatism (EULAR)</gtr:fundingOrg><gtr:id>708D804E-E16E-480D-B505-86D47A971B19</gtr:id><gtr:outcomeId>JThjwxuD5oe</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55035</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council Confidence in Concept Scheme (Sarah Skeoch)</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8488871F-90CA-4AE5-A5B2-6F40196292DA</gtr:id><gtr:outcomeId>566845ffae71a8.67512313</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Lupus Academy</gtr:department><gtr:description>Lupus Academy Travel Award (awarded to John Reynolds)</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>St. Thomas' Lupus Trust</gtr:fundingOrg><gtr:id>7B69CC42-4B99-47DD-BDB6-68542C0D43C9</gtr:id><gtr:outcomeId>ksG93ttLe6y</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Health Technology Assessment (Tim Felton)</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>20FC9164-DB71-417F-9C38-BD3C73A95978</gtr:id><gtr:outcomeId>58b585233501f4.48980544</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>550</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Liverpool internal Institute of Global Health pump priming award to set up NeuroID eLearning (Sam Nightingale)</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>University of Liverpool</gtr:fundingOrg><gtr:id>720DE47B-DC74-452D-83AA-2F8D750F5EC2</gtr:id><gtr:outcomeId>ktKB1AoiUyy</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Genetic Predisposition to clozapine agranulocytosis</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Mersey Care NHS Trust</gtr:fundingOrg><gtr:id>27999ECA-987F-4AEA-85CB-0E9AF77A4A90</gtr:id><gtr:outcomeId>56f12aea010213.86623765</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1250</gtr:amountPounds><gtr:country>Japan</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Travel award from Astellas Pharma (Awarded to Tim Felton)</gtr:description><gtr:fundingOrg>Astellas Pharma</gtr:fundingOrg><gtr:id>AB4648AC-E74B-4A57-BCC6-95D5C7FBA548</gtr:id><gtr:outcomeId>pDBDiK3hGtp0</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>348344</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research for Patient Benefit (Tim Felton)</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>A1E8E807-6BE7-40C7-A70A-2DF952C271E9</gtr:id><gtr:outcomeId>544136fb23f437.92166316</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>228</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Abbott UK</gtr:department><gtr:description>Bursery to attend British Association of Dermatologists Conference (Awarded to Amy Foulkes)</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Abbott</gtr:fundingOrg><gtr:id>51B1A1F9-9047-460C-BA5F-3B15E7B31C9F</gtr:id><gtr:outcomeId>o12sQRhCtHZ</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9810</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHIVA Research Award (Awarded to Sam Nightingale)</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>British HIV Association (BHIVA)</gtr:fundingOrg><gtr:id>BCECAD5F-0749-485A-AA42-1D99C369C0F3</gtr:id><gtr:outcomeId>mQMGwnQXfai0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Conference attendance award from Pfizer Ltd. - Gene to Clinic - 6th International Congress in Psoriasis (Awarded to Amy Foulkes)</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>9431C238-6301-494B-8493-B69ED68CD990</gtr:id><gtr:outcomeId>FLTj76Wrt9n0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Starter Grant for Clinical Lecturers (Amy Foulkes)</gtr:description><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>660BC004-95E4-4938-AA0F-36EBF88B5E3D</gtr:id><gtr:outcomeId>58bedea0733e03.61971103</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3052098</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>North West England MRC FELLOWSHIPS in Clinical Pharmacology and Therapeutics</gtr:description><gtr:end>2021-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9E86FE74-4F0C-44EC-8887-C9BB61AB924A</gtr:id><gtr:outcomeId>589865243b8976.10568661</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24593</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proximity to Discovery award (Amy Foulkes)</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F2143176-8AE4-4D64-ADEA-13CADCA3A8A9</gtr:id><gtr:outcomeId>58beddf9441577.74508488</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Society of Clinical Microbiology and Infectious Diseases travel award (awarded to Tim Felton)</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>European Society of Clinical Microbiology and Infectious Diseases (ESCMID)</gtr:fundingOrg><gtr:id>9A2505CF-C344-4E5D-AA93-249CE6BA232B</gtr:id><gtr:outcomeId>qmfuMmEb25G</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35662</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Centre for Drug Safety Science</gtr:department><gtr:description>MRC Centenary Early Career Award (Sam Nightingale)</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>University of Liverpool</gtr:fundingOrg><gtr:id>4E4CA095-5B2F-46F6-9D19-0DA5EDD7DD7C</gtr:id><gtr:outcomeId>HNLard1rTHP</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bursary to attend IQ course (awarded to Amy Foulkes)</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>2B715E87-7DE5-4893-BE4A-7FC899D29D4A</gtr:id><gtr:outcomeId>piwehiDaUBg</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Manchester Musculoskeletal Biomedical Research Unit</gtr:department><gtr:description>NIHR Manchester Musculoskeletal Biomedical Research Unit Pump Priming grant (Sarah Skeoch)</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>B58E9A0B-7065-46B0-97CF-758318C24E39</gtr:id><gtr:outcomeId>5668469cea46d3.60072780</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1074</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Direct application to the Encephalitis society (Sam Nightingale)</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>The Encephalitis Society</gtr:fundingOrg><gtr:id>D95D0A77-9BC9-4744-83FF-56FB72768C96</gtr:id><gtr:outcomeId>Ken7HuPiqRn</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Manchester Musculoskeletal Biomedical Research Unit</gtr:department><gtr:description>Award for methotrexate assay development (James Bluett)</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>1373FA5B-B84E-477B-9FEE-C286B2274C60</gtr:id><gtr:outcomeId>53a2a3b797a8f7.19341425</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9504</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The University of Liverpool Confidence in Concept Scheme (Lauren Walker)</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>359F974B-3471-4E43-8C79-1C375DE29AAB</gtr:id><gtr:outcomeId>555b18a45196d0.43317443</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EULAR Young Investigator Travel Bursary (Sarah Skeoch)</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>The European League Against Rheumatism (EULAR)</gtr:fundingOrg><gtr:id>2666CB34-2D9E-46E7-A4BD-0CACEC317A75</gtr:id><gtr:outcomeId>53b2d4d4297da1.88331141</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Cystic Fibrosis Society Travel Grant (Stephen McWilliam)</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>European Cystic Fibrosis Society (ECFS)</gtr:fundingOrg><gtr:id>F7083508-10A2-4A0D-8893-DF99682CD6DE</gtr:id><gtr:outcomeId>534bad40f14654.74035941</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Manchester Musculoskeletal Biomedical Research Unit</gtr:department><gtr:description>Manchester Biomedical Research Unit grant (Meghna Jani)</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>62675ED1-B0A1-4F5D-B60C-E3193A84FDF5</gtr:id><gtr:outcomeId>5666d075cef380.22415626</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Use of cystatin C as biomarker for acute kidney injury at Royal Manchester Children's Hospital</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>DFFB4E65-8ABC-4BEE-98E0-3D71F1326621</gtr:id><gtr:outcomeId>56a63b9bee5fb4.12434067</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.cmft.nhs.uk/15405.aspx</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Royal College of Physicians Careers Fayre London October 2013 (Lauren Walker)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EC7F6475-EC2B-4491-BB69-6030A27375AD</gtr:id><gtr:outcomeId>5672a0351451b1.66907577</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lead SpR and co-authored the Greater Manchester Medicines Management Group (GMMMG) /MAHSC guidelines on biologic use in rheumatoid arthritis (Meghna Jani)</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>A18EB90A-60FC-40E0-B227-4995EB6393A3</gtr:id><gtr:impact>-Participation in advisory committee and presentation of guidelines to GMMMG on behalf of the steering group
-The aim is to standardise prescribing practices and safety checklists of biologic treatment.
- This has allowed clinicians to use biologics outside of NICE guidelines for indications that there is scientific evidence in. It also aids recruitment to CLRN studies and clinical trials. 
- Updated and revised for use in September 2014. To be uploaded on NICE website, as evidence of good local practice</gtr:impact><gtr:outcomeId>kL8r3TaKCKr</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the EULAR task force for the management of Rheumatoid Arthritis</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>BCE3C8D4-33A4-4D04-A915-1E7502ED8569</gtr:id><gtr:impact>To influence international guidelines for management of rheumatoid arthritis</gtr:impact><gtr:outcomeId>56a5ef0ae18f10.54700535</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NeuroID eLearning: an open access online resource for clinical information on neurological infection (Sam Nightingale)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C6036F49-9864-40BF-96F7-54B57ECDA16C</gtr:id><gtr:impact>To date over 1000 people from 5 continents have accessed the site.</gtr:impact><gtr:outcomeId>Utzxr6cRsvB</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.braininfectionsuk.org/neuroid_elearning/index.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of LHP Oncology Education Group (Dr Anna Olsson-Brown)</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>5A244CF9-BC1B-4785-9A9F-16A858ECB29B</gtr:id><gtr:impact>This group has contributed to a number of training days (Regional and National) and supports an Acute Oncology Master level module at the University of Liverpool. The next educational session pertains to Oncology and Genomics.</gtr:impact><gtr:outcomeId>58c6c99bd18268.67914320</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Acting as Early Academic Career Representative on Careers Committee (Amy Foulkes)</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>1CC4C5BB-75CF-431D-BCFB-044386DA407A</gtr:id><gtr:outcomeId>58bee1759dc796.96782316</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Prevent Atrial Fibrillation Stroke: Tackling Challenges and Accelerating Improvements (Vincent Yip)</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>94439F6E-7405-4194-8F2B-E192592CB4C0</gtr:id><gtr:outcomeId>58ad666827f4b8.02325824</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Elected Member of the Trainees and Members Committee at the Royal College of Physicians in Edinburgh (Dr Anna Olsson-Brown)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D5854A25-7808-472A-AE09-6BBF80B0198F</gtr:id><gtr:impact>The committee has three main foci - Representation at National level pertaining to post-graduate training and representation; Education resulting in the composition and delivery of national lecture series &amp;quot;Evening Medical Updates&amp;quot; and a yearly symposium &amp;quot;Medical Trainees Conference&amp;quot; and Careers and Communication which is focused on the development and support of post graduate training within the medical specialties.</gtr:impact><gtr:outcomeId>58c6cac1220ea6.53458631</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NeuroAccess. A project to improve clinical neurology and the outcome of neurological infections through training links with sub-Saharan Africa (Sam Nightingale)</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>48945B78-18BC-4E2B-9B72-6BB1A86951B9</gtr:id><gtr:impact>The impact has not been formally measured, but the aim is to improve the outcome of patients with neurological illness in particular that related to neurological infection, through forming on-going connections with hospitals in sub-Saharan Africa.</gtr:impact><gtr:outcomeId>56684484e04913.11692319</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.neuroaccess.org</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of UKONS Oncology Working Group (Dr Anna Olsson-Brown)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A0CF7723-E66D-4859-A8AB-53C53B81F074</gtr:id><gtr:outcomeId>58c6c87fdf0089.43221472</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Arthritis Research UK Inflammatory Arthritis, Clinical Study Group, Steering Group member, Trainee representative (Meghna Jani)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8CC25BA6-FF88-4219-BC94-BBD6229F128C</gtr:id><gtr:impact>Aim of the ARUK CSG is to develop a national funding strategy for the charity in the field of inflammatory arthritis.
Selection into the CSG is a national competitive process</gtr:impact><gtr:outcomeId>5666fa689171c3.04074325</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Ensuring UK leadership in experimental medicine</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>369EB9F5-607C-4D02-8E63-7AB05DB357FF</gtr:id><gtr:outcomeId>56dc7e500288c6.78646577</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>https://www.bps.ac.uk/BPSMemberPortal/media/BPSWebsite/Assets/Ensuring-UK-leadership-in-experimental-medicine-Aug-2015.pdf?ext=.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Amy Foulkes: Invitation to attend Academy of Medical Sciences 'Shape of Training' review as registrar representative. Meeting to take place on 6th Dec London at AMS</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>30BE3337-86C6-4852-B409-B024BB4FCA28</gtr:id><gtr:outcomeId>B28Y4ff5AgP</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Prescribing Safety Assessment (Lauren Walker)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3FDEE95E-E4BC-46D4-B3D3-59F0F107EA6F</gtr:id><gtr:impact>Lauren Walker is currently the specialty trainee representative for the British Pharmacological Society (BPS) on both the clinical section committee and the education and training committee. Through the latter, she has been involved in the introduction of learning resources to compliment the National Prescribing Safety Assessment aimed at improving the prescribing skills of junior doctors. This has involved writing interactive electronic presentations for the online e-Learning in Clinical Pharmacology/Prescribing - www.prescribe.ac.uk.</gtr:impact><gtr:outcomeId>5666b4971adc89.50326322</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>PROteKT is a Phase IIa randomised, controlled trial of Rosuvastatin for the prevention of aminoglycoside-induced Kidney Toxicity in children with cystic fibrosis. It is an example of drug repurposing: utilising a licenced medication for a different indication. It is hoped that this intervention will lead to benefits for children with cystic fibrosis, and to other patients receiving aminoglycoside antibiotics. This is the first human study of rosuvastatin for this indication. The trial received funding from the JP Moulton Foundation, and is currently close to completion of recruitment.</gtr:description><gtr:id>A4609E5C-80E2-4DF4-A6AA-DB44D5638DBD</gtr:id><gtr:impact>This trial required a suitable, sensitive biomarker of aminoglycoside-induced kidney injury. Current clinical practice relies on change in serum creatinine which is an insensitive marker of early kidney toxicity. Through observational studies we identified a urine biomarker, kidney injury molecule-1, as a promising early marker of aminoglycoside-induced kidney toxicity. Developing and validating this biomarker has allowed us to use this as the primary outcome measure in this study.</gtr:impact><gtr:outcomeId>5461dd0aa04d02.45990452</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PROteKT Trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.protekt-trial.org.uk/</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>This database is derived from a recently completed prospective cohort study that recruited 1470 patients hospitalised with a non-ST elevation acute coronary syndrome in the UK. Clinical, demographic and biological samples were collected. I was involved in systematically and rigorously querying the data to ensure it is accurate and as complete as possible, validating the clinical endpoints, and performing statistical analysis with the clinical data.</gtr:description><gtr:id>6963FF69-A703-470C-8F8B-A459046384E4</gtr:id><gtr:impact>The research team have provided a focussed part of the database to another research group. Thus far, an oral presentation of the clinical data analysis won a conference communications prize. 
i) Publication of an analysis of clinical data within this dataset pertaining to suboptimal statin utilisation (see section 1) 
ii) An oral presentation that I gave of the above clinical data analysis won a conference communications prize (see section 14).#</gtr:impact><gtr:outcomeId>58a32fb0291e70.48131775</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Pharmacogenetics of acute coronary syndrome database (Richard Myles Turner)</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.sciencedirect.com/science/article/pii/S1933287416304548</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Database- chromatin immunoprecipitation sequencing (ChIP-Seq) for glucocorticoid receptor in kidney cell line.</gtr:description><gtr:id>51E2305E-E4D7-45B7-8F9F-3A64CFB11304</gtr:id><gtr:impact>None yet.
This dataset is likely to be made publicly available</gtr:impact><gtr:outcomeId>545ba699277a84.82140248</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Database- chromatin immunoprecipitation sequencing (ChIP-Seq) (James McCaffrey)</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Database- chromatin immunoprecipitation sequencing (ChIP-Seq) for glucocorticoid receptor in kidney cell line.</gtr:description><gtr:id>D3558A5E-131D-40D6-A960-266CC14A93EC</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:outcomeId>545ba63a26cb25.43541274</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Database- whole genome microarray (James McCaffrey)</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Mass spectrometry data on protein constituents of kidney cells and identification of glucocorticoid-regulated proteins</gtr:description><gtr:id>62F845D2-CD29-436C-8E3D-ED711F81B555</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>5666ae7c1f09c1.23510079</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Whole cell proteomic analysis of kidney cell line and discovery of Gc-regulated proteins (James McCaffrey)</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Bank of biological samples (human blood, tissue and urine) with associated clinical database.</gtr:description><gtr:id>5C5E8AB4-BD7B-4BB8-A2A0-5A5DC35528CF</gtr:id><gtr:impact>This collection, the main part of Amy Foulkes Fellowship project, has now been taken on as pilot data for the Psoriasis Stratification of Optimised Treatment Responses PSORT pilot data, granted a &amp;pound;7.2 million bid for a larger clinical study over following years.</gtr:impact><gtr:outcomeId>QPK1zTyniiG</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Bank of Biological Samples used by PSORT (Amy Foulkes)</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Richard Turner has worked alongside a bioanalytical chemist to develop a novel liquid-chromatography mass spectrometry assay that can quantify rosuvastatin and atorvastatin levels from dried blood spot samples. It has been developed for use with murine samples and so will contribute to reducing the numbers of mice involved in murine statin pharmacokinetic studies, and will be validated for use with human samples

A murine pharmacokinetic study has been undertaken, and its results will be presented at the British Pharmacology Society Annual Winter meeting, 2016.</gtr:description><gtr:id>C71B6045-B276-4122-A5FC-C61914CB094D</gtr:id><gtr:impact>A pharmacokinetic study is planned</gtr:impact><gtr:outcomeId>56a89defb97c97.28510235</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Dried blood spot statin quantification assay (Richard Myles Turner)</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>James McCaffrey is creating podocyte specific transgenic knock-out of glucocorticoid receptor in mice</gtr:description><gtr:id>247706E4-3216-4F14-BBC5-E04E723A4979</gtr:id><gtr:impact>Model being developed within lab</gtr:impact><gtr:outcomeId>muSKXpA4SuJ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mouse model development (James McCaffrey)</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Measurement of MTX and 7-OH-MTX using HPLC-SRM-MS</gtr:description><gtr:id>3483C304-F331-4A41-BBA3-9E0F7474F172</gtr:id><gtr:impact>Published a paper describing the method to measure MTX and 7-OH-MTX using HPLC-SRM-MS</gtr:impact><gtr:outcomeId>5666a3d41e7b35.54637207</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Measurement of MTX and 7-OH-MTX using HPLC-SRM-MS (James Bluett)</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Fellow:Sam Nightingale has developed an online case record form to allow secure data input from multiple sites.</gtr:description><gtr:id>B6036F83-32BC-4A97-BCF9-B1DC39B92199</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:outcomeId>LHvuWB5xKhy</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Online case record form (Sam Nightingale)</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Dr Richard Turner has worked alongside a post-doctoral colleague to develop a novel liquid-chromatography mass spectrometry assay that can simultaneously quantify the steady-state levels of atorvastatin, three major atorvastatin metabolites, bisoprolol and clopidogrel carboxylic acid from patient plasma samples. The assay has been developed, validated, and used to determine the plasma concentrations of these analytes in over 1,000 patients.</gtr:description><gtr:id>C18495E7-F477-4F8E-B58A-7FDA9B325142</gtr:id><gtr:impact>The analysis of patient samples has been conducted; statistical analysis is on-going.</gtr:impact><gtr:outcomeId>58a32e5ec64768.52037942</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Combined cardiovascular drug quantification method (Richard Myles Turner)</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Fellow: Sam Nightingale has developed 11 drug mass spect assay to measure CSF levels of antiretrovirals.</gtr:description><gtr:id>FD9AE8D0-2088-4AC9-9699-0F1F6D4F424F</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:outcomeId>HhvHnzTiVtt</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Drug mass spect assays (Sam Nightingale)</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>79DAAF1B-EBD7-4C8F-BA2E-3752A01ADE48</gtr:id><gtr:title>Pharmacogenetic Markers of Drug Efficacy and Toxicity.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af1c99024a266d26fd4cda723a9cb84"><gtr:id>1af1c99024a266d26fd4cda723a9cb84</gtr:id><gtr:otherNames>Yip VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>55362713c417b1.19514856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7BD099A-D053-4816-B2F6-D4B7497084AE</gtr:id><gtr:title>Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>Qi18j69fgCU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89FB4FDF-0738-4CA1-9BFB-C021B280B5E0</gtr:id><gtr:title>Investigation of idiopathic inflammatory myopathy for shared genetic risk factors with other autoimmune diseases: results from the European Myositis Network</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi-12583-10_1016_S0140_6736_13_60496_1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA90543C-0BB4-43A9-93CF-39AAD676BB64</gtr:id><gtr:title>Diagnostic Molecular Pathology: A Guide to Applied Molecular Testing</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/274b482f3c09d4c9e6b2dcbd3b9ff87a"><gtr:id>274b482f3c09d4c9e6b2dcbd3b9ff87a</gtr:id><gtr:otherNames>Turner R M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>9780128008867</gtr:isbn><gtr:outcomeId>58bd80bb216b82.57805274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32C66515-7786-40C5-A2AA-9914681BBAFE</gtr:id><gtr:title>The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>pm_12583_23_23946436</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>238E28A5-847D-4811-A9CA-9BE0E4612321</gtr:id><gtr:title>Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.</gtr:title><gtr:parentPublicationTitle>Rheumatology and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebb8fc6c5953024004910069e869e48"><gtr:id>7ebb8fc6c5953024004910069e869e48</gtr:id><gtr:otherNames>Bluett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2198-6576</gtr:issn><gtr:outcomeId>5a54f0a0d51840.40836843</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB901315-B664-49DB-BC63-2E92FCFB890D</gtr:id><gtr:title>What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a653a98679506c2f96be284292fd1f7"><gtr:id>2a653a98679506c2f96be284292fd1f7</gtr:id><gtr:otherNames>Foulkes AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn><gtr:outcomeId>VLJc9nD9pki</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03272809-ECCA-45FF-85ED-DD0DC79742F3</gtr:id><gtr:title>SEVERE HYPERSENSITIVITY TO ANTIEPILEPTIC DRUGS: BRITISH NEUROLOGICAL SURVEILLANCE UNIT (BNSU)</gtr:title><gtr:parentPublicationTitle>Journal of Neurology, Neurosurgery &amp; Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7240d53553db0cde41750f24a981b137"><gtr:id>7240d53553db0cde41750f24a981b137</gtr:id><gtr:otherNames>Yip V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi-12583-10_1136_jnnp_2013_306573_70</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BDE9AEA-4C1D-4645-80F2-3197D80F8758</gtr:id><gtr:title>Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3755e7ebfde21a24f46ec7aee2375d56"><gtr:id>3755e7ebfde21a24f46ec7aee2375d56</gtr:id><gtr:otherNames>Jani, M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a5ebce56f5b1.09115016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>715CCEE5-8765-438E-93BE-1911293F0BB2</gtr:id><gtr:title>Building the future of rheumatology: the role of national and international networks.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5a269705b5b3c8.16492920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB456C66-CAC9-41AF-AC68-F3189CE6C19A</gtr:id><gtr:title>Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e4cb732afe3ba40d928b43b1ea3a16b"><gtr:id>5e4cb732afe3ba40d928b43b1ea3a16b</gtr:id><gtr:otherNames>Felton TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>544679e1ce3712.24442981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CAC7B64-AE8A-48C6-B2B6-0FB546EDB505</gtr:id><gtr:title>Opioids are not just an American problem.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5a54f02eab8802.85495275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31A8495A-963D-495A-A127-68B303D0E646</gtr:id><gtr:title>Diagnostic yield of FDG-PET/CT in fever of&amp;nbsp;unknown origin: a systematic review, meta-analysis, and Delphi exercise.</gtr:title><gtr:parentPublicationTitle>Clinical radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55a42261b9f6a532b3cf5cf2959f339d"><gtr:id>55a42261b9f6a532b3cf5cf2959f339d</gtr:id><gtr:otherNames>Bharucha T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9260</gtr:issn><gtr:outcomeId>5a670f62c96781.11792446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B6DCD66-AFAF-4407-93D2-97136093403C</gtr:id><gtr:title>Oxford Textbook of Dementia and Cognitive Neurology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74ac4b3c8b77939cc0d7e41ae92c331c"><gtr:id>74ac4b3c8b77939cc0d7e41ae92c331c</gtr:id><gtr:otherNames>Nightingale S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>0199655944</gtr:isbn><gtr:outcomeId>CNHrS6B36zo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EE54608-756D-4074-AB1C-0958342DC1C1</gtr:id><gtr:title>OP0313 The Use and Impact of Social Media in Modern Rheumatology Practice Based on a Survey by the Emerging Eular Network (Emeunet)</gtr:title><gtr:parentPublicationTitle>Annals of the Rheumatic Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b3441493f8ea501dd2f642269d610b3"><gtr:id>0b3441493f8ea501dd2f642269d610b3</gtr:id><gtr:otherNames>Nikiphorou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5666c6689953d4.23435586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41FDC6C0-3951-4EEB-9347-64845AE87991</gtr:id><gtr:title>Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75d4f8c1b96b9eeaf84ebd79f404af3e"><gtr:id>75d4f8c1b96b9eeaf84ebd79f404af3e</gtr:id><gtr:otherNames>Box H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>569f7f466bc7a6.73800481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>466BDC87-C893-4AEB-B607-3BDBC352CB0B</gtr:id><gtr:title>The effect of type 1 IFN on human aortic endothelial cell function in vitro: relevance to systemic lupus erythematosus.</gtr:title><gtr:parentPublicationTitle>Journal of interferon &amp; cytokine research : the official journal of the International Society for Interferon and Cytokine Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24268c2350304b1f83d8c9cebfa73934"><gtr:id>24268c2350304b1f83d8c9cebfa73934</gtr:id><gtr:otherNames>Reynolds JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1079-9907</gtr:issn><gtr:outcomeId>pm_12583_23_24444308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1CBFFE3-31FC-4559-88BA-AF7C13C71D93</gtr:id><gtr:title>Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0c29292559a749b0887a7d83763c9bb"><gtr:id>c0c29292559a749b0887a7d83763c9bb</gtr:id><gtr:otherNames>O'Connor L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_12583_23_23599314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>892F9682-A0CB-4CEB-A158-8559D4C84278</gtr:id><gtr:title>Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach</gtr:title><gtr:parentPublicationTitle>Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8c838e93e2fe17d357f2ecec7bef348"><gtr:id>c8c838e93e2fe17d357f2ecec7bef348</gtr:id><gtr:otherNames>Fleischmann R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5671765cc77052.47110104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9209E373-E71E-4ADD-8C23-93142737AB27</gtr:id><gtr:title>High degree of patient satisfaction and exceptional feedback in a specialist dermatology and rheumatology clinic</gtr:title><gtr:parentPublicationTitle>British Association of Dermatologists' Annual Meeting</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3a887648c31ba7b68fc6a149d610197"><gtr:id>a3a887648c31ba7b68fc6a149d610197</gtr:id><gtr:otherNames>Foulkes, Amy, C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>QQjtVfTw8vi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50FD787B-D369-41FD-9EFE-9B3D91D9057B</gtr:id><gtr:title>The safety of biologic therapies in RA-associated interstitial lung disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4790</gtr:issn><gtr:outcomeId>apvrGiXdnqy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFBE341A-E14C-4A61-A6AB-D33FD7315925</gtr:id><gtr:title>Inflammation and epilepsy: the foundations for a new therapeutic approach in epilepsy?</gtr:title><gtr:parentPublicationTitle>Epilepsy currents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b84e3efddf91ce32c4275d8e133ebf2a"><gtr:id>b84e3efddf91ce32c4275d8e133ebf2a</gtr:id><gtr:otherNames>Walker L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1535-7511</gtr:issn><gtr:outcomeId>pm_12583_23_22368518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8011C2F5-5CEC-46C6-B12F-85D80885A24B</gtr:id><gtr:title>Aspergillus bronchitis without significant immunocompromise.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a06557d762730b01c962226401ba355f"><gtr:id>a06557d762730b01c962226401ba355f</gtr:id><gtr:otherNames>Chrdle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>pm_12583_23_23231717</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05ACFDF8-8962-488F-A2C7-79612004C87C</gtr:id><gtr:title>Epilepsy and the inflammasome: Targeting inflammation as a novel therapeutic strategy for seizure disorders</gtr:title><gtr:parentPublicationTitle>Inflammasome</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99fa54c5f3689349ca5d4738646277e3"><gtr:id>99fa54c5f3689349ca5d4738646277e3</gtr:id><gtr:otherNames>Edye M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545cec0501cf72.65360449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25298A4B-A5BB-46DA-A35D-659E1FAEA6D6</gtr:id><gtr:title>A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease.</gtr:title><gtr:parentPublicationTitle>Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2589e0b69b8887580c88c7f00026c23d"><gtr:id>2589e0b69b8887580c88c7f00026c23d</gtr:id><gtr:otherNames>Walker LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1354-750X</gtr:issn><gtr:outcomeId>58458364e143e1.15491658</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A97A342F-DB37-4BEE-82EE-D538DC4F8386</gtr:id><gtr:title>Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a653a98679506c2f96be284292fd1f7"><gtr:id>2a653a98679506c2f96be284292fd1f7</gtr:id><gtr:otherNames>Foulkes AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>pm_12583_23_23909440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83141707-768B-4E98-B63A-53ACD04EB2C1</gtr:id><gtr:title>O55. Prevalence of Autoantibodies to Hmgcr in Myositis Patients</gtr:title><gtr:parentPublicationTitle>Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd1186908396fd2867d94658b08a6148"><gtr:id>cd1186908396fd2867d94658b08a6148</gtr:id><gtr:otherNames>Betteridge Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56715a27e3d048.53680888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46EC5772-C5B9-47AB-BA10-F50387EC1C10</gtr:id><gtr:title>Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet?</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f8b5adafdd370252c7fc6d85d8b907"><gtr:id>e8f8b5adafdd370252c7fc6d85d8b907</gtr:id><gtr:otherNames>Kia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>pm_12583_23_22703588</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1FF5D7B-1F1A-4C5C-8AC0-4B66C9A43D97</gtr:id><gtr:title>'Twitterland': a brave new world?</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b3441493f8ea501dd2f642269d610b3"><gtr:id>0b3441493f8ea501dd2f642269d610b3</gtr:id><gtr:otherNames>Nikiphorou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a54f068f02d16.97485308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D559161D-5E59-4CD2-8F77-A91F7D2DB840</gtr:id><gtr:title>Progress in understanding the pathogenesis and management of psoriasis.</gtr:title><gtr:parentPublicationTitle>Advanced Medicine Conference 2011: Rheumatology and Dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63045ac5800974efc81e31e5043d87ff"><gtr:id>63045ac5800974efc81e31e5043d87ff</gtr:id><gtr:otherNames>Foulkes, Amy C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>NwmPfUpXkkG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBCC99AD-1F3A-4AA5-BAC7-02D7EA25C186</gtr:id><gtr:title>89. Influence of Immunogenicity on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab: A UK-Based Prospective Study</gtr:title><gtr:parentPublicationTitle>Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>567179532ac8a0.39704981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F6CBC3C-1D26-451A-8632-8A515FA10522</gtr:id><gtr:title>OP0235 Genetic Risk Factors in Idiopathic Inflammatory Myopathies Are Shared with Other Autoimmune Disorders in European Populations</gtr:title><gtr:parentPublicationTitle>Annals of the Rheumatic Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56717a6a0cf5d1.33653938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BE3E582-44A1-433C-AC9C-F21EE77CDB7F</gtr:id><gtr:title>Vitamin D treatment for connective tissue diseases: hope beyond the hype?</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24268c2350304b1f83d8c9cebfa73934"><gtr:id>24268c2350304b1f83d8c9cebfa73934</gtr:id><gtr:otherNames>Reynolds JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>58ac63612212e4.96231178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7590980C-BC23-4087-A65B-9B95F518D1FF</gtr:id><gtr:title>Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2436b505841d1fe76d0f50b168e3aa3f"><gtr:id>2436b505841d1fe76d0f50b168e3aa3f</gtr:id><gtr:otherNames>McWilliam SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12583_23_22937100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4B41D03-69A2-496F-907F-481A91FE12F7</gtr:id><gtr:title>The Association of Baseline and Longitudinal Change in Endothelial Microparticle Count with Mortality in Chronic Kidney Disease.</gtr:title><gtr:parentPublicationTitle>Nephron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d16702ece233c9b0bf893ed83dbc388"><gtr:id>5d16702ece233c9b0bf893ed83dbc388</gtr:id><gtr:otherNames>Green D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1660-8151</gtr:issn><gtr:outcomeId>58ad84ea12bb89.07082269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4834CF24-D539-49EA-8490-63494961525C</gtr:id><gtr:title>Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.</gtr:title><gtr:parentPublicationTitle>The pharmacogenomics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebb8fc6c5953024004910069e869e48"><gtr:id>7ebb8fc6c5953024004910069e869e48</gtr:id><gtr:otherNames>Bluett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-269X</gtr:issn><gtr:outcomeId>pm_12583_23_23856853</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08FA8419-7DDC-40E1-9F5A-0C279BD30C33</gtr:id><gtr:title>Imaging atherosclerosis in rheumatoid arthritis: evidence for increased prevalence, altered phenotype and a link between systemic and localised plaque inflammation.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c540d11f3bc9e407e4c30ba3160fc3c5"><gtr:id>c540d11f3bc9e407e4c30ba3160fc3c5</gtr:id><gtr:otherNames>Skeoch S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a671020cf3c90.59798309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE75B949-93B1-4B4B-9175-D94C3ADFE192</gtr:id><gtr:title>Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile.</gtr:title><gtr:parentPublicationTitle>Archives of toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d53a3afd301c96535e58f4eb19ac9f4c"><gtr:id>d53a3afd301c96535e58f4eb19ac9f4c</gtr:id><gtr:otherNames>Heslop JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0340-5761</gtr:issn><gtr:outcomeId>58a315c6cdc322.28108949</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EE2888E-6FCC-44E6-9C48-1A9ED6402719</gtr:id><gtr:title>Pulmonary penetration of piperacillin and tazobactam in critically ill patients.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e4cb732afe3ba40d928b43b1ea3a16b"><gtr:id>5e4cb732afe3ba40d928b43b1ea3a16b</gtr:id><gtr:otherNames>Felton TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>5446796a85e7b7.37858727</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A76A074C-5097-4AE7-A6B8-B59E61386675</gtr:id><gtr:title>Recent developments in the detection and management of acute kidney injury.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93557e9a9bccc915e7d9dc9f044309b4"><gtr:id>93557e9a9bccc915e7d9dc9f044309b4</gtr:id><gtr:otherNames>McCaffrey J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>582ae63ced2f28.02781208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6D8381D-DB49-4308-B384-5E4ACDAB6E3E</gtr:id><gtr:title>Overview of the management of systemic lupus erythematosus.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d1d999a1e2e8482a987e52d50ecf8df"><gtr:id>5d1d999a1e2e8482a987e52d50ecf8df</gtr:id><gtr:otherNames>Reynolds, John A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>ogSYz7akPKR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F69AA4CA-517C-4234-8050-F0B1903DA395</gtr:id><gtr:title>Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f54b4d10725610bc2a73fc02bf9cf770"><gtr:id>f54b4d10725610bc2a73fc02bf9cf770</gtr:id><gtr:otherNames>Sudan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12583_23_23571544</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4869B4D-9EE2-4AE2-8465-4A0B27D547FB</gtr:id><gtr:title>Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome.</gtr:title><gtr:parentPublicationTitle>Journal of clinical lipidology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4469eb28365ff976201c153df829a59"><gtr:id>b4469eb28365ff976201c153df829a59</gtr:id><gtr:otherNames>Turner RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1876-4789</gtr:issn><gtr:outcomeId>58b711ce950236.39071085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7286D1D9-BCB8-4CDA-AA0A-5E12EE07483C</gtr:id><gtr:title>NeuroID eLearning</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbb2cf1e530dc0ce4acb74017d411f58"><gtr:id>cbb2cf1e530dc0ce4acb74017d411f58</gtr:id><gtr:otherNames>Sam Nightingale</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>53d8d34c42f409.82872887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F980950F-FB9C-4685-92DF-3A6EFFF33A35</gtr:id><gtr:title>Pharmacogenetics in Epilepsy</gtr:title><gtr:parentPublicationTitle>Epilepsy Professional Magazine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3865bc97338d609da554259e372f8a5b"><gtr:id>3865bc97338d609da554259e372f8a5b</gtr:id><gtr:otherNames>Yip, Vincent</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>p9UrqEg49Gc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DD878E2-ADD7-497D-A942-636E7913CE6B</gtr:id><gtr:title>WONOEP appraisal: Molecular and cellular biomarkers for epilepsy.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2589e0b69b8887580c88c7f00026c23d"><gtr:id>2589e0b69b8887580c88c7f00026c23d</gtr:id><gtr:otherNames>Walker LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>568f8caa757644.99387737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C676E95-7158-4784-977B-02D8E68E4126</gtr:id><gtr:title>Clinicians approaches to management of background therapy in Systemic Lupus Erythematosus patients in clinical remission: Results of an international observational survey</gtr:title><gtr:parentPublicationTitle>Lupus Science and Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0266e886cf78a83730dd8b01a35eb1a2"><gtr:id>0266e886cf78a83730dd8b01a35eb1a2</gtr:id><gtr:otherNames>McCarthy E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58c01a95831ad9.03084560</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69AF0279-1866-4330-ACF5-B21C77634AD8</gtr:id><gtr:title>Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f03de4e3dc4a0fe6de23f8cf9979730"><gtr:id>8f03de4e3dc4a0fe6de23f8cf9979730</gtr:id><gtr:otherNames>Ramos-Mart?n V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>569f7fbc59b327.39288696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BEC4CDD-19A8-4E06-8472-AB65C518D89F</gtr:id><gtr:title>Intratracheal Administration of Antimicrobial Agents in Mechanically Ventilated Adults: An International Survey on Delivery Practices and Safety.</gtr:title><gtr:parentPublicationTitle>Respiratory care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bc1bf6464842a5f0b28ce269af785a2"><gtr:id>7bc1bf6464842a5f0b28ce269af785a2</gtr:id><gtr:otherNames>Sol?-Lleonart C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0020-1324</gtr:issn><gtr:outcomeId>56a0c99ede9f84.77544429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACC066A2-CB75-49D8-B611-C617DAF710D4</gtr:id><gtr:title>The non-immunosuppressive management of childhood nephrotic syndrome.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93557e9a9bccc915e7d9dc9f044309b4"><gtr:id>93557e9a9bccc915e7d9dc9f044309b4</gtr:id><gtr:otherNames>McCaffrey J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>56a5e3bae5c6f5.80178120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB3DEA0F-E482-494E-B0AF-E1811339181B</gtr:id><gtr:title>Drug-specific risk, and associated factors, of vasculitis-like events in patients exposed to tumour necrosis factor alpha inhibitor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>56a5ea6e386560.83389330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A6B46D1-8E8E-4A96-99C2-B12BC58101B1</gtr:id><gtr:title>Effect of immunogenicity on efficacy of long-term treatment of rheumatoid arthritis with adalimumab</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>doi_12583_14_60323_8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F3E97D0-0BC5-4F9F-9708-2B17F3A1395E</gtr:id><gtr:title>High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a26981c672f47.42058101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D1A49FF-25B8-4FFC-9A3A-D6F509F9E717</gtr:id><gtr:title>Theallele: influence on carbamazepine treatment.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics and personalized medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af1c99024a266d26fd4cda723a9cb84"><gtr:id>1af1c99024a266d26fd4cda723a9cb84</gtr:id><gtr:otherNames>Yip VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1178-7066</gtr:issn><gtr:outcomeId>58a1b3be16b0b0.38478704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C936CE1-C76B-4F47-AF13-1951EDEB411D</gtr:id><gtr:title>Pharmacogenetics of Acute Coronary Syndrome</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d069a637bdf2c98c852e81bcfa6bd55"><gtr:id>5d069a637bdf2c98c852e81bcfa6bd55</gtr:id><gtr:otherNames>Yin Peng</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a887d09c4894.17726252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10D48FFF-574B-465F-ACB0-A561A7038373</gtr:id><gtr:title>Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_12583_23_24812289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5642A072-7321-4954-AA76-79295E6F564E</gtr:id><gtr:title>How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?</gtr:title><gtr:parentPublicationTitle>Diagnostic microbiology and infectious disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e4cb732afe3ba40d928b43b1ea3a16b"><gtr:id>5e4cb732afe3ba40d928b43b1ea3a16b</gtr:id><gtr:otherNames>Felton TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0732-8893</gtr:issn><gtr:outcomeId>54467a8e7c42e3.54610971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44F1963E-B01A-41AE-BEE2-CC3BFF07A24F</gtr:id><gtr:title>039 Systems biology approach to the analysis of pharmacogenomic data in psoriasis</gtr:title><gtr:parentPublicationTitle>Journal of Investigative Dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3719fef87f465edfdb493c6725b959eb"><gtr:id>3719fef87f465edfdb493c6725b959eb</gtr:id><gtr:otherNames>Foulkes A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58beda44dbc228.82149939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB0F2A52-D061-4B0F-90C0-57573AF6749F</gtr:id><gtr:title>Parsing interindividual drug variability: an emerging role for systems pharmacology.</gtr:title><gtr:parentPublicationTitle>Wiley interdisciplinary reviews. Systems biology and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4469eb28365ff976201c153df829a59"><gtr:id>b4469eb28365ff976201c153df829a59</gtr:id><gtr:otherNames>Turner RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1939-005X</gtr:issn><gtr:outcomeId>5555c6f8148782.18568646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28FE22EB-73FA-4285-BE89-0C8362FFE2D6</gtr:id><gtr:title>Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d388427d71e2e932d1f9c396c8c06a1"><gtr:id>7d388427d71e2e932d1f9c396c8c06a1</gtr:id><gtr:otherNames>van der Wouden CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>586a23fab4d0c2.87493199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAC0B830-5B5C-47A7-92AB-0D856B7CAA04</gtr:id><gtr:title>The Effects of Extensive Glomerular Filtration of Thin Graphene Oxide Sheets on Kidney Physiology.</gtr:title><gtr:parentPublicationTitle>ACS nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d7442ac04c536901d1b8a3a62596474"><gtr:id>0d7442ac04c536901d1b8a3a62596474</gtr:id><gtr:otherNames>Jasim DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1936-0851</gtr:issn><gtr:outcomeId>5a66168894a0f8.68681155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AB5B277-8D08-4866-AFBE-985FBD87F478</gtr:id><gtr:title>Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey.</gtr:title><gtr:parentPublicationTitle>Lupus science &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf57fae4cbec80ff384257cf45a657dd"><gtr:id>cf57fae4cbec80ff384257cf45a657dd</gtr:id><gtr:otherNames>Ngamjanyaporn P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2053-8790</gtr:issn><gtr:outcomeId>5a3943ddecdf59.00994547</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C913103-340B-4B7C-AD83-42E50FE9BB02</gtr:id><gtr:title>The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic Approaches</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e656ec2c7e85ab1ca6a504bd9b0a0805"><gtr:id>e656ec2c7e85ab1ca6a504bd9b0a0805</gtr:id><gtr:otherNames>Dimitroulas T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:isbn>978-0128032671</gtr:isbn><gtr:outcomeId>58c01fcdf0f8b5.95081624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>519B5815-4631-42BA-B3FF-D6B78AB3FF52</gtr:id><gtr:title>HIV-associated neurocognitive disease: case studies and suggestions for diagnosis and management in different patient subgroups.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fae4a236fc71b0c3e2ebde012fd2cf24"><gtr:id>fae4a236fc71b0c3e2ebde012fd2cf24</gtr:id><gtr:otherNames>Pozniak A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_12583_23_23519006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79463948-2C0E-4F48-98B1-9B3030FBE760</gtr:id><gtr:title>Design for Health (Design for Social Responsibility)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/454f83358f2e9d1eb912fb0edf3b4275"><gtr:id>454f83358f2e9d1eb912fb0edf3b4275</gtr:id><gtr:otherNames>Black A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:isbn>1472457420</gtr:isbn><gtr:outcomeId>58c683bc99af70.19389007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B208DE0C-7E4A-4301-8436-80301A1ED75C</gtr:id><gtr:title>Repurposing Statins for Renal Protection: Is It a Class Effect?</gtr:title><gtr:parentPublicationTitle>Clinical and translational science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2436b505841d1fe76d0f50b168e3aa3f"><gtr:id>2436b505841d1fe76d0f50b168e3aa3f</gtr:id><gtr:otherNames>McWilliam SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1752-8054</gtr:issn><gtr:outcomeId>5a14224f693e42.38456784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8F0CB97-937D-4930-AE15-44C72AD853E2</gtr:id><gtr:title>Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>5666b53931f4c2.51523217</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3740F78A-CEE2-4B72-8B49-965428F2E87D</gtr:id><gtr:title>Improving cardiovascular outcomes in rheumatic diseases: therapeutic potential of circulating endothelial progenitor cells.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24268c2350304b1f83d8c9cebfa73934"><gtr:id>24268c2350304b1f83d8c9cebfa73934</gtr:id><gtr:otherNames>Reynolds JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>56685b22e88577.57008277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C36CA46-2BE6-4409-9144-1ED13C2FC0F8</gtr:id><gtr:title>Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis.</gtr:title><gtr:parentPublicationTitle>The Journal of dermatological treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a653a98679506c2f96be284292fd1f7"><gtr:id>2a653a98679506c2f96be284292fd1f7</gtr:id><gtr:otherNames>Foulkes AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0954-6634</gtr:issn><gtr:outcomeId>pm_12583_23_22812533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9A9ED7F-723B-463B-9D5D-327D8E23022A</gtr:id><gtr:title>Measuring and managing cognitive impairment in HIV.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74ac4b3c8b77939cc0d7e41ae92c331c"><gtr:id>74ac4b3c8b77939cc0d7e41ae92c331c</gtr:id><gtr:otherNames>Nightingale S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a6f04e58943d6.07581464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAC517A2-DB96-445A-A962-302DF0874DDA</gtr:id><gtr:title>Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G?T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74ac4b3c8b77939cc0d7e41ae92c331c"><gtr:id>74ac4b3c8b77939cc0d7e41ae92c331c</gtr:id><gtr:otherNames>Nightingale S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>57359bfd6df279.75805821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57FF8C7F-E571-4B33-A511-F16FBB970770</gtr:id><gtr:title>Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions</gtr:title><gtr:parentPublicationTitle>Mycoses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e4a3112408be2691abd3fd662e6472b"><gtr:id>5e4a3112408be2691abd3fd662e6472b</gtr:id><gtr:otherNames>Hope W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>545c8575186386.45392942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77C92433-FE4E-4187-B1CD-FFB3069D3F42</gtr:id><gtr:title>THU0165 High rate of cardiovascular events in lupus patients at 5 year follow up and association of classical and lupus related risk factors</gtr:title><gtr:parentPublicationTitle>Annals of the Rheumatic Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c540d11f3bc9e407e4c30ba3160fc3c5"><gtr:id>c540d11f3bc9e407e4c30ba3160fc3c5</gtr:id><gtr:otherNames>Skeoch S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>hCR5NZVjKvk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3409AE53-144F-4955-A1EA-2FF4F9F4C481</gtr:id><gtr:title>Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa4a253f264cb393a790819f7c98e9cb"><gtr:id>fa4a253f264cb393a790819f7c98e9cb</gtr:id><gtr:otherNames>Warn PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12583_23_22123680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA12B406-AC17-4AF6-B466-12843F6B2275</gtr:id><gtr:title>Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84f10854808a3f43f06f2fd28f286b45"><gtr:id>84f10854808a3f43f06f2fd28f286b45</gtr:id><gtr:otherNames>Al-Nakeeb Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12583_23_22615280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>793E6A8A-D840-41F2-A334-949186E256E6</gtr:id><gtr:title>Brief Report: Vitamin D Deficiency Is Associated With Endothelial Dysfunction and Increases Type I Interferon Gene Expression in a Murine Model of Systemic Lupus Erythematosus.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24268c2350304b1f83d8c9cebfa73934"><gtr:id>24268c2350304b1f83d8c9cebfa73934</gtr:id><gtr:otherNames>Reynolds JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>58ac6184cf1fc0.57225128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72D6E41B-C9CC-46B2-8EB4-73A31F69908E</gtr:id><gtr:title>SAT0355 Risk and Characteristics of Drug Induced Vasculitis in Patients Exposed to Tumour Necrosis Factor a Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis</gtr:title><gtr:parentPublicationTitle>Annals of the Rheumatic Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5666c5ec17acf1.80914688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22C3D5AD-24A8-4A88-BD4E-3921F07D7D6B</gtr:id><gtr:title>Response to &amp;quot;HLA allelic variants and carbamazepine-induced hypersensitivity&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af1c99024a266d26fd4cda723a9cb84"><gtr:id>1af1c99024a266d26fd4cda723a9cb84</gtr:id><gtr:otherNames>Yip VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>doi_12583_lpt_2013_5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA7D9563-9DC6-44C6-A929-12AD1741BB17</gtr:id><gtr:title>Precision Medicine in Rheumatoid Arthritis.</gtr:title><gtr:parentPublicationTitle>Rheumatic diseases clinics of North America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebb8fc6c5953024004910069e869e48"><gtr:id>7ebb8fc6c5953024004910069e869e48</gtr:id><gtr:otherNames>Bluett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0889-857X</gtr:issn><gtr:outcomeId>5a62095d667505.59402380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D548DFB8-D436-4110-ACB1-05A8608D9C12</gtr:id><gtr:title>Investigating the prevalence, predictors and prognosis of suboptimal statin therapy early after a non-ST elevation acute coronary syndrome</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65cab07e70bd5a24ef901bb3e8cad914"><gtr:id>65cab07e70bd5a24ef901bb3e8cad914</gtr:id><gtr:otherNames>Turner Richard M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a8870f7ae078.64301632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71FD0CC1-9E2F-487B-A6F1-FF0180EC7B4F</gtr:id><gtr:title>Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebb8fc6c5953024004910069e869e48"><gtr:id>7ebb8fc6c5953024004910069e869e48</gtr:id><gtr:otherNames>Bluett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5452699dc18580.85942732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFD1A07A-A133-4580-807C-6ABEB0483BAE</gtr:id><gtr:title>Towards a biomarker panel for the assessment of AKI in children receiving intensive care.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93557e9a9bccc915e7d9dc9f044309b4"><gtr:id>93557e9a9bccc915e7d9dc9f044309b4</gtr:id><gtr:otherNames>McCaffrey J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>5666a94dec6451.00293374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44901051-CDBF-464A-B50A-9396FF49072F</gtr:id><gtr:title>Handbook of Pharmacogenomics and Stratified Medicine</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52e3aaaafa4de8ac1a8bcd10748fba4c"><gtr:id>52e3aaaafa4de8ac1a8bcd10748fba4c</gtr:id><gtr:otherNames>Walker LE, Yip V and Pirmohamed M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-0-12-386882-4</gtr:isbn><gtr:outcomeId>X1enqDMVA8T</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D66A887-419E-4802-9902-DBC00D296B38</gtr:id><gtr:title>Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children.</gtr:title><gtr:parentPublicationTitle>Biomarkers in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2436b505841d1fe76d0f50b168e3aa3f"><gtr:id>2436b505841d1fe76d0f50b168e3aa3f</gtr:id><gtr:otherNames>McWilliam SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1752-0363</gtr:issn><gtr:outcomeId>pm_12583_23_24661102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17D4A8A1-6711-41FC-86C4-32A9960B39E5</gtr:id><gtr:title>A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5a269886c31537.55910377</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64E26732-FB7F-4B9C-950D-E7D5B320C4FC</gtr:id><gtr:title>Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2589e0b69b8887580c88c7f00026c23d"><gtr:id>2589e0b69b8887580c88c7f00026c23d</gtr:id><gtr:otherNames>Walker LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>5922c99aa59a96.84892041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13D6F421-F133-4A5D-8531-9E075841E10A</gtr:id><gtr:title>Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.</gtr:title><gtr:parentPublicationTitle>mBio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c9ea96d4f291ca5d38d0b793fa18406"><gtr:id>7c9ea96d4f291ca5d38d0b793fa18406</gtr:id><gtr:otherNames>Livermore J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>XDefVDUbG3v</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BDE67AD-95EE-444A-AB76-F519DA1AE35D</gtr:id><gtr:title>Landmark Papers in Rheumatology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/343f6a50ddba37a270cef9c4a09a3fcb"><gtr:id>343f6a50ddba37a270cef9c4a09a3fcb</gtr:id><gtr:otherNames>James Bluett, Suzanne Verstappen, and Deborah Symmons</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>9780199688371</gtr:isbn><gtr:outcomeId>56607405e80940.53150520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6949F1D8-83F7-43F0-B869-A88DC97851CB</gtr:id><gtr:title>HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebb8fc6c5953024004910069e869e48"><gtr:id>7ebb8fc6c5953024004910069e869e48</gtr:id><gtr:otherNames>Bluett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>59199f0557c566.82914470</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5C97BC4-1B1B-40CC-9811-1856ED766146</gtr:id><gtr:title>FRI0358 Risk and Characteristics of Drug Induced Lupus in Patients Exposed to Tumour Necrosis Factor-a Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis</gtr:title><gtr:parentPublicationTitle>Annals of the Rheumatic Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5666c6285454d8.06662645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E923D3D-9EB2-48EB-AD3D-B4E19C53910E</gtr:id><gtr:title>Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e4cb732afe3ba40d928b43b1ea3a16b"><gtr:id>5e4cb732afe3ba40d928b43b1ea3a16b</gtr:id><gtr:otherNames>Felton TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12583_23_22585219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41D36B12-B313-4A5C-8291-2861022A73A4</gtr:id><gtr:title>Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e92a9763579596a92adbc06125785e0"><gtr:id>4e92a9763579596a92adbc06125785e0</gtr:id><gtr:otherNames>Hope WW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12583_23_22869566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10BC0FD3-EE4C-41E2-AB96-6570CB47040E</gtr:id><gtr:title>HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af1c99024a266d26fd4cda723a9cb84"><gtr:id>1af1c99024a266d26fd4cda723a9cb84</gtr:id><gtr:otherNames>Yip VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>pm_12583_23_23132554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9BA73BC-52E0-4DF8-B01A-CBD645918842</gtr:id><gtr:title>Stroke Genetics</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00408717ce71ca785527413789bb5b01"><gtr:id>00408717ce71ca785527413789bb5b01</gtr:id><gtr:otherNames>Walker LE, Stewart A and Pirmohamed M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>Bmx7egbQjuh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8747CA7-DD1F-4704-85CB-C83428CA9DDC</gtr:id><gtr:title>Patients' narratives.</gtr:title><gtr:parentPublicationTitle>Current problems in dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a653a98679506c2f96be284292fd1f7"><gtr:id>2a653a98679506c2f96be284292fd1f7</gtr:id><gtr:otherNames>Foulkes AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1421-5721</gtr:issn><gtr:outcomeId>pm_12583_23_23796819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D297BCC-6513-4857-A887-AD576F641609</gtr:id><gtr:title>CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF.</gtr:title><gtr:parentPublicationTitle>Cytokine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74ac4b3c8b77939cc0d7e41ae92c331c"><gtr:id>74ac4b3c8b77939cc0d7e41ae92c331c</gtr:id><gtr:otherNames>Nightingale S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1043-4666</gtr:issn><gtr:outcomeId>572b34d06ad1e5.33143388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4AADB59-8980-41F3-B53E-35BE56086907</gtr:id><gtr:title>Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/251e8f80dc64f3415ad91ed03022c666"><gtr:id>251e8f80dc64f3415ad91ed03022c666</gtr:id><gtr:otherNames>Plumpton CO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>5577e0e1b6dd63.30628310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01505D0D-4E4C-45CD-9844-A22283A0B5B6</gtr:id><gtr:title>Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56cf0727935f9c02b371ebd47a7256aa"><gtr:id>56cf0727935f9c02b371ebd47a7256aa</gtr:id><gtr:otherNames>Bowes J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>566070b4a1de72.67520825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C7597CE-3FBF-4249-9126-7DD7B5298806</gtr:id><gtr:title>Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5a2698afacff85.06918980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6ED6DAED-E710-4E19-BC2A-81CEA1FCF2B6</gtr:id><gtr:title>Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1cf7d7a5043d3f6cdc681efd839a3ab"><gtr:id>b1cf7d7a5043d3f6cdc681efd839a3ab</gtr:id><gtr:otherNames>Roberts JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>54467b6e3bc8a7.78222387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B16A319C-C368-4C5D-BDD2-21A9C68A12D4</gtr:id><gtr:title>Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74ac4b3c8b77939cc0d7e41ae92c331c"><gtr:id>74ac4b3c8b77939cc0d7e41ae92c331c</gtr:id><gtr:otherNames>Nightingale S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>QvfRs1eVjpF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93CF19A1-19B7-406B-A7E2-941CEA4B2CCB</gtr:id><gtr:title>Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.</gtr:title><gtr:parentPublicationTitle>RMD open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2056-5933</gtr:issn><gtr:outcomeId>5a269747aec792.30217521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAD48AD2-ADD7-48A7-8736-1E4A09609E45</gtr:id><gtr:title>Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature.</gtr:title><gtr:parentPublicationTitle>Dermatology and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33656c72a7737b5df3cbdee83735efe8"><gtr:id>33656c72a7737b5df3cbdee83735efe8</gtr:id><gtr:otherNames>Weidmann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>pm_12583_23_24942326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B484973C-0EAF-499B-BE8C-10AC8AF2A20E</gtr:id><gtr:title>Posaconazole: the case for therapeutic drug monitoring.</gtr:title><gtr:parentPublicationTitle>Therapeutic drug monitoring</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cd97331f6fcc5d9f193c7353c33f628"><gtr:id>6cd97331f6fcc5d9f193c7353c33f628</gtr:id><gtr:otherNames>Howard SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0163-4356</gtr:issn><gtr:outcomeId>pm_12583_23_22215487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACD7251F-E01B-4DF3-B98E-2C716F6522CF</gtr:id><gtr:title>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bcbc7527d40f3e94f7ec647d54bc5dd"><gtr:id>6bcbc7527d40f3e94f7ec647d54bc5dd</gtr:id><gtr:otherNames>Smolen JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a269691c62657.45221323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49403F17-3E5B-444F-B475-62E193D6710E</gtr:id><gtr:title>Atherosclerosis in rheumatoid arthritis: is it all about inflammation?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c540d11f3bc9e407e4c30ba3160fc3c5"><gtr:id>c540d11f3bc9e407e4c30ba3160fc3c5</gtr:id><gtr:otherNames>Skeoch S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1759-4790</gtr:issn><gtr:outcomeId>56684519efbaa1.93815477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3C55CF8-5DF6-414C-B96D-5CFC404B20E9</gtr:id><gtr:title>Cell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLE.</gtr:title><gtr:parentPublicationTitle>Lupus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c540d11f3bc9e407e4c30ba3160fc3c5"><gtr:id>c540d11f3bc9e407e4c30ba3160fc3c5</gtr:id><gtr:otherNames>Skeoch S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0961-2033</gtr:issn><gtr:outcomeId>pm_12583_23_24647443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ECC3EEF-E231-418B-BA5A-14C81739DFF5</gtr:id><gtr:title>Optimising the use of medicines to reduce acute kidney injury in children and babies.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c59e7c89cf935ba8559cf2dfe38b2bef"><gtr:id>c59e7c89cf935ba8559cf2dfe38b2bef</gtr:id><gtr:otherNames>Oni L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>5a65c5457557b7.51123811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BD63BDC-94B6-4CCB-A979-F68762CDC39C</gtr:id><gtr:title>Expanding role of pharmacogenomics in the management of cardiovascular disorders.</gtr:title><gtr:parentPublicationTitle>American journal of cardiovascular drugs : drugs, devices, and other interventions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af1c99024a266d26fd4cda723a9cb84"><gtr:id>1af1c99024a266d26fd4cda723a9cb84</gtr:id><gtr:otherNames>Yip VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1175-3277</gtr:issn><gtr:outcomeId>doi_12583_013_0024_5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99A4F3ED-55A2-433E-A9E3-670724A6E582</gtr:id><gtr:title>Quantitative Online Liquid Chromatography-Surface-Enhanced Raman Scattering (LC-SERS) of Methotrexate and its Major Metabolites.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/159439c6d1398913ad2d03b2e935e010"><gtr:id>159439c6d1398913ad2d03b2e935e010</gtr:id><gtr:otherNames>Subaihi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>5a620a6abb2fe9.30815036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C98A5B1-DD24-434E-8183-BE275DD3A381</gtr:id><gtr:title>SAT0189 Use of Anti-200/100 Antibody in the Evaluation of Statin Induced Myositis: Experience of a UK Based Tertiary Myositis-Referral Centre</gtr:title><gtr:parentPublicationTitle>Annals of the Rheumatic Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>CMUTSy4cg4L</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FC1B2CD-920B-4C72-A6D5-E029C50F66EC</gtr:id><gtr:title>Palmoplantar contractures in childhood: a rare complication of vascular Ehlers-Danlos syndrome.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a653a98679506c2f96be284292fd1f7"><gtr:id>2a653a98679506c2f96be284292fd1f7</gtr:id><gtr:otherNames>Foulkes AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn><gtr:outcomeId>L8kTEnFywEz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DF4CEFB-CD5D-4C83-8365-EADC0CEE80E1</gtr:id><gtr:title>Controversies in HIV-associated neurocognitive disorders.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74ac4b3c8b77939cc0d7e41ae92c331c"><gtr:id>74ac4b3c8b77939cc0d7e41ae92c331c</gtr:id><gtr:otherNames>Nightingale S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>54524f19c8cc45.84871519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E64DC79-4B80-4A7E-B874-BD96D0AEA950</gtr:id><gtr:title>Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bc1bf6464842a5f0b28ce269af785a2"><gtr:id>7bc1bf6464842a5f0b28ce269af785a2</gtr:id><gtr:otherNames>Sol?-Lleonart C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn><gtr:outcomeId>569f7e8dca6869.38505819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA9B2671-CE40-42C6-B0C8-A95EAB276F98</gtr:id><gtr:title>Oxford Handbook of Tropical Medicine</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9baf0d76eafd8f7133fa2e9b6e86df9"><gtr:id>e9baf0d76eafd8f7133fa2e9b6e86df9</gtr:id><gtr:otherNames>Nightingale, Sam and Solomon, Tom</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>eReFemwdNcf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>834E2BB1-0AB5-42C1-B14A-812F25C63B72</gtr:id><gtr:title>Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43b4c27a4baeb16a3592942587ff0d36"><gtr:id>43b4c27a4baeb16a3592942587ff0d36</gtr:id><gtr:otherNames>Livermore JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12583_23_23114778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>688CACBE-9091-43FF-BF05-B715303B8E10</gtr:id><gtr:title>642 Phenotypic Comparison of Hepatocyte-Like Cells Differentiated From Human Induced Pluripotent Stem Cells Derived by Cellular Reprogramming of Primary Hepatocytes and Dermal Fibroblasts Obtained From the Same Donor</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f8b5adafdd370252c7fc6d85d8b907"><gtr:id>e8f8b5adafdd370252c7fc6d85d8b907</gtr:id><gtr:otherNames>Kia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>doi_12583_14_63338_2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CFCF92F-AEBA-44BD-8F25-7855B9FBB6C0</gtr:id><gtr:title>OP0150 Long-Term Persistence with Oral Methotrexate in Patients with Early Inflammatory Arthritis</gtr:title><gtr:parentPublicationTitle>Annals of the Rheumatic Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebb8fc6c5953024004910069e869e48"><gtr:id>7ebb8fc6c5953024004910069e869e48</gtr:id><gtr:otherNames>Bluett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>566071e9754b26.24589272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>669F8D44-892F-4AD2-83A2-1B2FD15156B7</gtr:id><gtr:title>MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f8b5adafdd370252c7fc6d85d8b907"><gtr:id>e8f8b5adafdd370252c7fc6d85d8b907</gtr:id><gtr:otherNames>Kia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn><gtr:outcomeId>566701f1d14fb3.39244016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35FE41EA-0F90-4FB2-863C-52FB4AA4B3A4</gtr:id><gtr:title>Oxford Handbook of Tropical Medicine</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9baf0d76eafd8f7133fa2e9b6e86df9"><gtr:id>e9baf0d76eafd8f7133fa2e9b6e86df9</gtr:id><gtr:otherNames>Nightingale, Sam and Solomon, Tom</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-0-19-969256-9</gtr:isbn><gtr:outcomeId>53d8b881180ec4.32361762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFA6E2E4-12E7-4BF7-A88E-3837A88C7087</gtr:id><gtr:title>Population pharmacokinetics of teicoplanin in children.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f03de4e3dc4a0fe6de23f8cf9979730"><gtr:id>8f03de4e3dc4a0fe6de23f8cf9979730</gtr:id><gtr:otherNames>Ramos-Mart?n V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>544678d4105ad3.51887162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD237303-CB98-4B24-ABEA-B9B467F20070</gtr:id><gtr:title>Podocyte-specific glucocorticoid effects in childhood nephrotic syndrome</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55bda152d8cc703fdeba76620e163384"><gtr:id>55bda152d8cc703fdeba76620e163384</gtr:id><gtr:otherNames>Mccaffrey James</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>582b14380f09c5.30058468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61C410F8-3F21-4EB4-93E5-98918A60F013</gtr:id><gtr:title>Tissue penetration of antifungal agents.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/891b9c472d7ac102b135d2ddc9fa808e"><gtr:id>891b9c472d7ac102b135d2ddc9fa808e</gtr:id><gtr:otherNames>Felton T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0893-8512</gtr:issn><gtr:outcomeId>54467cd2c947b4.64903471</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1856C897-DC27-4B35-9100-C55D0F506583</gtr:id><gtr:title>Donor-Dependent and Other Nondefined Factors have Greater Influence on the Hepatic Phenotype than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells.</gtr:title><gtr:parentPublicationTitle>Stem cells translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d53a3afd301c96535e58f4eb19ac9f4c"><gtr:id>d53a3afd301c96535e58f4eb19ac9f4c</gtr:id><gtr:otherNames>Heslop JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2157-6564</gtr:issn><gtr:outcomeId>5a54ec4b386be5.74905662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B695111E-9E1D-4860-8BF4-77A09E56C077</gtr:id><gtr:title>Case Studies in Neurological Infection</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56f85d617311d95591da55cdeba6c0ce"><gtr:id>56f85d617311d95591da55cdeba6c0ce</gtr:id><gtr:otherNames>Nightingale, Sam</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>XTcSBGg4fUo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C7BA969-7D3C-499D-AEEE-654FE66F14A0</gtr:id><gtr:title>Review of NeuroPACES, the Walton Centre for Neurology and Neurosurgery</gtr:title><gtr:parentPublicationTitle>Advances in Clinical Neurosciences and Rehabilitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3865bc97338d609da554259e372f8a5b"><gtr:id>3865bc97338d609da554259e372f8a5b</gtr:id><gtr:otherNames>Yip, Vincent</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>BCaG3nzv9DB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CA75710-DF9F-4F1A-8906-BC1A803148C6</gtr:id><gtr:title>Social media use among young rheumatologists and basic scientists: results of an international survey by the Emerging EULAR Network (EMEUNET).</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b3441493f8ea501dd2f642269d610b3"><gtr:id>0b3441493f8ea501dd2f642269d610b3</gtr:id><gtr:otherNames>Nikiphorou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a2698518b21d4.46847339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86169603-DE17-4131-8EDB-66523FE50E02</gtr:id><gtr:title>Psoriasis: Advances in Knowledge and Care, An Issue of Dermatologic Clinics</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b62aae174950057392375c4d78d40719"><gtr:id>b62aae174950057392375c4d78d40719</gtr:id><gtr:otherNames>Menter Alan</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>9780323341745</gtr:isbn><gtr:outcomeId>545ceb6d818375.89512876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F266491-C4D9-426D-880A-1506A417E91D</gtr:id><gtr:title>Age-related impairment of endothelial progenitor cell migration correlates with structural alterations of heparan sulfate proteoglycans.</gtr:title><gtr:parentPublicationTitle>Aging cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8b057f36c63e21093af1f9fe1543281"><gtr:id>e8b057f36c63e21093af1f9fe1543281</gtr:id><gtr:otherNames>Williamson KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-9718</gtr:issn><gtr:outcomeId>eerKmGYv8MR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>318FBAE1-2715-4B0D-8E9E-45B09C5A02D7</gtr:id><gtr:title>SAT0052 Influence of Immunogenicity and Drug Levels on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A Uk-Based Prospective Study</gtr:title><gtr:parentPublicationTitle>Annals of the Rheumatic Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545b9b1170b5b3.30656005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBD15A9C-441E-4A63-9C14-81B970393770</gtr:id><gtr:title>Prospective clinical trials to investigate clinical and molecular biomarkers.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f7ac18670ca187d7d05e556e1d69356"><gtr:id>3f7ac18670ca187d7d05e556e1d69356</gtr:id><gtr:otherNames>Auvin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>5a6f1003f2ad98.15602912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72770D45-DA14-44E5-85D5-4007F0FAD2D1</gtr:id><gtr:title>Covalent adduction of carbamazepine 10, 11-epoxide with human serum albumin and glutathione S-transferase pi: implications for carbamazepine hypersensitivity</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7240d53553db0cde41750f24a981b137"><gtr:id>7240d53553db0cde41750f24a981b137</gtr:id><gtr:otherNames>Yip V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54526475239634.05663661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D6E4A11-CD5B-456D-8536-5B1156D33415</gtr:id><gtr:title>Quantification of urinary mevalonic acid as a biomarker of HMG-CoA reductase activity by a novel translational LC-MS/MS method.</gtr:title><gtr:parentPublicationTitle>Bioanalysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7c3fe5d8ec9f343325d0281d8282f13"><gtr:id>c7c3fe5d8ec9f343325d0281d8282f13</gtr:id><gtr:otherNames>Rodrigues AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1757-6180</gtr:issn><gtr:outcomeId>545216f6dd96c4.86131032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EE09456-B8C6-4D14-8D80-73C17CA8792F</gtr:id><gtr:title>Glucocorticoid therapy regulates podocyte motility by inhibition of Rac1.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec1a96c0bd54455855f22500a0126aff"><gtr:id>ec1a96c0bd54455855f22500a0126aff</gtr:id><gtr:otherNames>McCaffrey JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a6616b7b17052.97510448</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C16F8B6-AC9A-46FA-9EB2-95F9F534B649</gtr:id><gtr:title>Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review.</gtr:title><gtr:parentPublicationTitle>Clinical reviews in allergy &amp; immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af1c99024a266d26fd4cda723a9cb84"><gtr:id>1af1c99024a266d26fd4cda723a9cb84</gtr:id><gtr:otherNames>Yip VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1080-0549</gtr:issn><gtr:outcomeId>545217cbc9d843.68148575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80E413D5-096A-4889-A9F2-0290DF80A4DE</gtr:id><gtr:title>FRI0415 Effectiveness of sequential biologic use in psoriatic arthritis: results of a large uk-based retrospective survey</gtr:title><gtr:parentPublicationTitle>Annals of the Rheumatic Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>A7W2FTSPNYh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1D078FF-570A-4BB3-81E3-2C26BC1EAB78</gtr:id><gtr:title>Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e4cb732afe3ba40d928b43b1ea3a16b"><gtr:id>5e4cb732afe3ba40d928b43b1ea3a16b</gtr:id><gtr:otherNames>Felton TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12583_23_24002098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B6F6865-C496-4A41-AA76-050E168501BF</gtr:id><gtr:title>Immunomodulatory interventions for focal epilepsy syndromes.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b84e3efddf91ce32c4275d8e133ebf2a"><gtr:id>b84e3efddf91ce32c4275d8e133ebf2a</gtr:id><gtr:otherNames>Walker L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>pm_12583_23_23803963</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>132E83CC-97A5-4FE7-9C74-7A90F5B9758A</gtr:id><gtr:title>Oxford Textbook of Rheumatology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9bda19246157ab90a66d45818cd505f"><gtr:id>c9bda19246157ab90a66d45818cd505f</gtr:id><gtr:otherNames>Foulkes AC, Griffiths CEM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>978-0198509486</gtr:isbn><gtr:outcomeId>oL89NGdZ9ag</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B34C1F6-99C7-403D-95BD-286311B43295</gtr:id><gtr:title>Cervical spine calcinosis in systemic sclerosis.</gtr:title><gtr:parentPublicationTitle>The Journal of rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebb8fc6c5953024004910069e869e48"><gtr:id>7ebb8fc6c5953024004910069e869e48</gtr:id><gtr:otherNames>Bluett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0315-162X</gtr:issn><gtr:outcomeId>pm_12583_23_23996996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04FB6067-A321-4856-910A-19EEF92E85DE</gtr:id><gtr:title>Evaluation of non-contrast MRI biomarkers in lupus nephritis.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c540d11f3bc9e407e4c30ba3160fc3c5"><gtr:id>c540d11f3bc9e407e4c30ba3160fc3c5</gtr:id><gtr:otherNames>Skeoch S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0392-856X</gtr:issn><gtr:outcomeId>5a670e1f9fb970.35764920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>674CA7F1-526E-4012-8BA7-C860811AB171</gtr:id><gtr:title>Personalized medicine approaches in epilepsy.</gtr:title><gtr:parentPublicationTitle>Journal of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2589e0b69b8887580c88c7f00026c23d"><gtr:id>2589e0b69b8887580c88c7f00026c23d</gtr:id><gtr:otherNames>Walker LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0954-6820</gtr:issn><gtr:outcomeId>5450d1d72221f2.23177688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>446CEA22-5905-4926-AAC5-900D1A773B6F</gtr:id><gtr:title>A HPLC-SRM-MS based method for the detection and quantification of methotrexate in urine at doses used in clinical practice for patients with rheumatological disease: a potential measure of adherence.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebb8fc6c5953024004910069e869e48"><gtr:id>7ebb8fc6c5953024004910069e869e48</gtr:id><gtr:otherNames>Bluett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>56607118e46e43.58817599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5195AE7D-8F10-48CE-AE3D-FD4587BB460E</gtr:id><gtr:title>Towards corticosteroid-free immunosuppression in children</gtr:title><gtr:parentPublicationTitle>The British Journal of Renal Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de0c2f92577f3115608034257997b9ec"><gtr:id>de0c2f92577f3115608034257997b9ec</gtr:id><gtr:otherNames>McCaffrey, James</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>JvU9wTMEfzy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31545129-A6B5-4332-A0DD-3C89B4F0DD8F</gtr:id><gtr:title>Pharmacogenetics of treatment response in psoriatic arthritis.</gtr:title><gtr:parentPublicationTitle>Current rheumatology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1523-3774</gtr:issn><gtr:outcomeId>5666b589137045.85640294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F5B1135-42E6-4FA6-BB83-56F3A86F4C10</gtr:id><gtr:title>Isolation of Aspergillus species from the airway of lung transplant recipients is associated with excess mortality.</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e4cb732afe3ba40d928b43b1ea3a16b"><gtr:id>5e4cb732afe3ba40d928b43b1ea3a16b</gtr:id><gtr:otherNames>Felton TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>pm_12583_23_22863902</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DC70CC4-F1D1-4662-A42B-6768DA73FE99</gtr:id><gtr:title>Mass Spectrometric Characterization of Circulating Covalent Protein Adducts Derived from Epoxide Metabolites of Carbamazepine in Patients.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b730eed49605806c487d7cf4dae71450"><gtr:id>b730eed49605806c487d7cf4dae71450</gtr:id><gtr:otherNames>Yip VLM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>592fe026b91644.99926185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6AA8EC7-A7C0-4D9C-B119-206E664D84FC</gtr:id><gtr:title>The glomerulonephritides</gtr:title><gtr:parentPublicationTitle>Paediatrics and Child Health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/253100fe99b76effb70975c42caf50cd"><gtr:id>253100fe99b76effb70975c42caf50cd</gtr:id><gtr:otherNames>O'Hagan E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>582ae339b6e5f0.01139124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8792E0FA-E141-4496-A554-6AE45E9BDFA5</gtr:id><gtr:title>Endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ded30288962db187b9f663921e75e45"><gtr:id>0ded30288962db187b9f663921e75e45</gtr:id><gtr:otherNames>Mohan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>5666b061711322.52807069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6A14B4C-8EDB-43DC-8C50-53F7D79D028C</gtr:id><gtr:title>PENETRATION OF ANTIRETROVIRAL THERAPY INTO THE NERVOUS SYSTEM; COGNITIVE IMPAIRMENT IN HIV AND THE ROLE OF THE CNS AS A SANCTUARY SITE. A PROGRESS REPORT ON THE PARTITION STUDY</gtr:title><gtr:parentPublicationTitle>Journal of Neurology, Neurosurgery &amp; Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74ac4b3c8b77939cc0d7e41ae92c331c"><gtr:id>74ac4b3c8b77939cc0d7e41ae92c331c</gtr:id><gtr:otherNames>Nightingale S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>56713777e47631.23615619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E44359A-0ADA-4FEF-BFF7-3C8AEE74ED7E</gtr:id><gtr:title>Aminoglycoside-induced nephrotoxicity in children.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2436b505841d1fe76d0f50b168e3aa3f"><gtr:id>2436b505841d1fe76d0f50b168e3aa3f</gtr:id><gtr:otherNames>McWilliam SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>583409f36aa7d3.66965489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DC457FE-496E-4E89-A2A6-24DA99EBBEFE</gtr:id><gtr:title>Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia.</gtr:title><gtr:parentPublicationTitle>Journal of neurovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74ac4b3c8b77939cc0d7e41ae92c331c"><gtr:id>74ac4b3c8b77939cc0d7e41ae92c331c</gtr:id><gtr:otherNames>Nightingale S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1355-0284</gtr:issn><gtr:outcomeId>5742d4fb138c17.63579853</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DD80305-BF5E-4A17-BD3A-684F7EE3ACBE</gtr:id><gtr:title>Human pluripotent stem cells for modeling toxicity.</gtr:title><gtr:parentPublicationTitle>Advances in pharmacology (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89cbc9f170ee302729639b71bf20ab47"><gtr:id>89cbc9f170ee302729639b71bf20ab47</gtr:id><gtr:otherNames>Sison-Young RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1054-3589</gtr:issn><gtr:outcomeId>pm_12583_23_22776643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A7919AB-68A2-49A2-ADF8-951EFD70CD8D</gtr:id><gtr:title>Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58fc8298a6aeafc2d5c812c2490ca4dc"><gtr:id>58fc8298a6aeafc2d5c812c2490ca4dc</gtr:id><gtr:otherNames>Satia I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58b5567b722cd0.06839512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34BB50E2-C31E-49DB-8461-B2E5468856E0</gtr:id><gtr:title>Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes.</gtr:title><gtr:parentPublicationTitle>RMD open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d0deba9490215c586e569769245769a"><gtr:id>5d0deba9490215c586e569769245769a</gtr:id><gtr:otherNames>Hope HF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2056-5933</gtr:issn><gtr:outcomeId>5a6209152687f4.60014314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBA619EC-05A4-4241-B94F-07D08558583B</gtr:id><gtr:title>Global analysis of glucocorticoid action in podocytes</gtr:title><gtr:parentPublicationTitle>Joint congress of the British Transplantation Society &amp; Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df06bae874471d21e2665a6d5a677158"><gtr:id>df06bae874471d21e2665a6d5a677158</gtr:id><gtr:otherNames>McCaffrey, J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>BKBmQa7WKbr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56E34783-B90A-4F9C-BB6C-7C9E80BBB8E6</gtr:id><gtr:title>WONOEP appraisal: Molecular and cellular biomarkers for epilepsy.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2589e0b69b8887580c88c7f00026c23d"><gtr:id>2589e0b69b8887580c88c7f00026c23d</gtr:id><gtr:otherNames>Walker LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>585d3985a15655.31599403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA02106D-EF6F-4729-98DB-BB4A0F12806D</gtr:id><gtr:title>Pharmacokinetics: Concepts and Applications in Drug Discovery and Development</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5e2104aba94226b85736e6ad3869a51"><gtr:id>b5e2104aba94226b85736e6ad3869a51</gtr:id><gtr:otherNames>Carr D, Walker LE and Pirmohamed M.</gtr:otherNames></gtr:author></gtr:authors><gtr:isbn>978-0470582121</gtr:isbn><gtr:outcomeId>Wj4cDGkEaMr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7334A78-BBA8-46F1-83E5-A2F3D663ECC2</gtr:id><gtr:title>Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9947425478818f3f056819b465ff20bf"><gtr:id>9947425478818f3f056819b465ff20bf</gtr:id><gtr:otherNames>Jani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5666c50a7b7042.97842089</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000417</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>